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1.1 The human karyotype 
 
During the first 40 years of the previous century, scientists tended to dismiss the 
possibility that DNA could carry the genetic information in chromosomes, partly because 
nucleic acids were wrongly believed to contain only a simple repeating nucleotide sequence 
consisting of four different nucleotides, i.e., adenine (A), cytosine (C), thymine (T) and 
guanine (G). However, we now know that DNA is a long, linear molecule that contains 
millions of these four nucleotides arranged in an irregular but non-random order, providing 
a blueprint for the formation and maintenance of an organism. This blueprint represents 
the genome of an organism. 
 
The DNA molecule constitutes a double helix, which is coiled and folded into a 
chromosome structure. Chromosomes can be visualized during cell division using light 
microscopy. In 1956, cytogenetics, the study of chromosome sets and their genetic 
properties, revealed that the human cell contains 46 chromosomes, consisting of 22 pairs 
of autosomes, and a single pair of sex chromosomes (Tjio & Levan 1956). The subsequent 
development of chromosome banding techniques such as Giemsa-, Quinacrine 
Hydrochloride- and Reverse banding, has enabled a very precise recognition of individual 
chromosomes (Caspersson et al. 1968; Caspersson et al. 1970; Rooney 2001; Trask 
2002; Smeets 2004). Ordering the chromosomes according to their size and position of 
the centromere, in conjunction with their banding pattern, is referred to as karyotyping. A 
normal female karyotype is designated as 46,XX whereas a normal male karyotype is 
designated as 46,XY. 
 
Chromosomal landmarks, such as size, position of the centromere and banding pattern, 
are not only useful for the identification of normal chromosomes, but also for the 
characterization of structural abnormalities in them which, next to numerical 
abnormalities, may seriously hamper the processes of normal growth and development. 
 
 
1.2 Microscopically visible chromosome abnormalities 
 
Numerical abnormalities result from loss or gain of individual chromosomes and/or sets of 
chromosomes. Loss of one chromosome copy gives rise to a monosomy for that particular 
chromosome, whereas gain of a chromosome copy results in a trisomy. A monosomy is 
almost always incompatible with embryonic development, with the exception of monosomy 
X which causes Turner’s syndrome. Trisomies for the autosomes 13, 18 or 21 are 
compatible with survival to pregnancy term, but trisomy 13 and trisomy 18 result in 
severe conditions that convey a poor prognosis. Consequently, most affected newborns die 
during the first few weeks of life. Individuals with trisomy 21, better known as Down’s 
syndrome, have a better prognosis and their current life expectancy is 50 to 60 years 
(Mueller & Young 2001). 
 
Structural abnormalities result from chromosome breakage and subsequent joining in an 
altered configuration. This altered configuration can lead to loss or gain of genetic 
material, in which case the abnormality is unbalanced. Alternatively, all genetic material 
may be retained. In this latter case the abnormality is balanced. Structural chromosome 
abnormalities include (i) deletions, (ii) duplications, (iii) isochromosomes, (iv) ring 
chromosomes, (v) inversions and (vi) translocations (Figure 1.1). By definition, deletions, 
isochromosomes, duplications and ring chromosomes are unbalanced in nature. 
     Chapter 1      
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Translocations and inversions can either be balanced or unbalanced. The clinical 
consequences of unbalanced structural rearrangements depend on the size of the 
rearrangement and the genetic information affected. For example, a deletion of a single 
dosage-sensitive gene can cause a clinically recognizable syndrome (paragraph 1.6). 
However, a balanced rearrangement may give rise to a similar clinical phenotype if it 
disrupts the function of such an important gene and/ or results in the formation of a new 
fusion gene. 
 
Both numerical and structural chromosome abnormalities can be present in all cells of the 
body or, alternatively, in only a subset of them. Constitutional abnormalities that are 
present in all cells most likely result from a gamete containing the abnormality, whereas 
abnormalities that are present in only a subset of cells may have been acquired during a 
later stage of development. As a consequence, acquired abnormalities are present in a 
mosaic configuration, introducing a second cell line with a different chromosomal 
constitution. The clinical consequences of acquired chromosome abnormalities depend on 
the developmental stage and the cell type in which these abnormalities occur. For 
example, if the abnormality occurs during early embryogenesis affecting a progenitor cell, 
this may lead to a severe congenital defect. Alternatively, if the abnormality occurs later in 
life, this somatic event may lead to the aberrant proliferation of a cell that normally would 
no longer replicate. The clone of mutant cells generated in this way may eventually 
progress towards cancer. 
 
Gross chromosomal rearrangements can be detected by karyotyping. However, this 
approach has its limitations. First, karyotyping requires mitotic cells in order to obtain 
chromosomes in their optimal configuration for visualization (i.e. metaphase 
chromosomes). Second, karyotyping has a limited resolution, i.e., structural chromosome 
rearrangements need to be of sufficient size in order to be detectable (involving at least 5-
10 million base pairs, Mb). Third, the detection of abnormalities may be difficult, in 
particular in cases where only a small percentage of cells contains the abnormality. 
 
 
1.3 Detection of submicroscopic chromosome rearrangements 
 
The resolution of chromosome analysis has greatly benefited from the introduction of 
fluorescent in situ hybridization (FISH) techniques (van Prooijen-Knegt et al. 1982). FISH 
allows the detection of rearrangements beyond the detection limit of conventional 
karyotyping. The technology relies on the unique ability of single stranded fluorescently 
labeled DNA, known as probe, to anneal to its complementary sequence in chromosomes. 
Next, the location of the annealed (or hybridized) probe can be visualized by use of a 
fluorescent microscope. Depending on the application, different types of FISH probes can 
be used, including telomere-specific probes, whole-chromosome painting probes and/or 
locus-specific probes. The latter probe type can be used to e.g. specifically analyse 
chromosomal regions based on clinical suspicion. 
 
The resolution of chromosome analysis was further enhanced by the possibility to 
simultaneously hybridize a multitude of probes. By doing so, the staining of all human 
chromosomes in different colours has become possible, and various techniques to do so 
are currently available such as multicolour FISH (M-FISH) and spectral karyotyping (SKY) 
(Liehr et al. 2004). These latter FISH-based technologies have the advantage of studying
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Figure 1.1 
Schematic representation of structural rearrangements. (a) Deletion. Loss of genetic material. (b) 
Duplication. Insertion of genetic material (grey). (c) Isochromosome of the p arm. Loss of one 
chromosome arm with duplication of the other arm (duplication in grey). (d) Ring chromosome. Joining 
of two ‘sticky’ chromosome ends caused by deletion of genetic material on both chromosome arms. (e) 
Inversion. Reversion of genetic material on a single chromosome. (f) Translocation. Transfer of genetic 
material from one chromosome to another chromosome. In this case a translocation of the 
chromosomes 4 (in black) and 7 (in grey). Part of the 4q arm is exchanged with material originating 
from the 7q arm. 
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the constitution of all human chromosomes in a single experiment, and thus, are 
particularly useful for the analysis of (complex) chromosome rearrangements without prior 
knowledge of the chromosomal regions involved. 
 
In subsequent years, these genome-wide FISH technologies were further modified, 
resulting in the introduction of a method that has been denoted comparative genomic 
hybridization (CGH) (Kallioniemi et al. 1992; Lichter et al. 2000). CGH is based on the 
comparison of two genomic DNA populations, one derived from a test (patient) sample, 
and one derived from a normal reference sample. Equal amounts of DNA are differentially 
labeled and simultaneously hybridized onto normal human metaphase chromosomes, thus 
competing for the same targets on the chromosomes. Variation in fluorescence intensities 
of test and reference DNA along each chromosome target reveals the genomic locations of 
chromosome rearrangements in the test DNA. The advantage of CGH over M-FISH or SKY 
is its independence of actively dividing cells from the test sample as a source for 
metaphase spreads. As such, CGH can be performed on virtually all samples from which 
DNA can be extracted. CGH has proven particularly useful in cancer research. In general, 
tumour samples are difficult to culture and harvest for preparing metaphase spreads. In 
addition, these spreads are difficult to analyse by conventional karyotyping because of the 
abundance and complexity of the rearrangements present. The resolution of CGH, 
however, still depends on the resolution of the target metaphase chromosomes, i.e., it 
remains difficult to detect rearrangements below the level of 5-10 Mb (Forozan et al. 
1997). 
 
 
1.4 Clinical consequence of submicroscopic chromosome rearrangements 
 
Over the last decades various FISH studies have revealed that submicroscopic 
subtelomeric rearrangements account for approximately 6% of all previously unexplained 
cases of mental retardation (MR) (Flint et al. 1995; Knight et al. 1999; Knight & Flint 
2000; de Vries et al. 2003). Similarly, it was found that interstitial submicroscopic 
chromosome rearrangements account for a vast proportion of contiguous gene syndromes 
(paragraph 1.6; Osborne et al. 2001; Shaikh et al. 2001). However, in cases where the 
clinical phenotype has not previously been associated with a known genomic 
rearrangement, there is no a priori knowledge of the region to be tested and, hence, FISH 
is no longer the method of choice. In order to detect such submicroscopic rearrangements 
on a genome-wide scale, novel technologies were needed that combine the resolution of 
targeted FISH technologies with the genome-wide approach of CGH. One such technology 
is array-based comparative genomic hybridization (array CGH). 
 
 
1.5 Array-based comparative genomic hybridization  
 
Through the development of novel technologies such as array CGH the resolving power of 
conventional chromosome analysis techniques has increased from the megabase to the 
kilobase level (Solinas-Toldo et al. 1997; Pinkel et al. 1998). Tools that have facilitated the 
development of these technologies include (i) genome-wide clone resources integrated 
into the finished human genome sequence, (ii) high-throughput microarray platforms, and 
(iii) optimized CGH protocols and data analysis systems. Together, these microarray-based  
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Figure 1.2 
Schematic overview of the array CGH procedure. Genomic DNA samples from a test (patient; left) and 
reference (normal control; right) are differentially labeled with different fluorochromes, usually Cy3 and 
Cy5 (for green and red, respectively). The two DNA samples are mixed in equal amounts and hybridized 
to the microarray, onto which large-insert clone DNAs (e.g. BAC clones) have been robotically spotted 
as targets. Subsequent computer imaging assesses the relative fluorescence levels of each labeled DNA 
for each array target. Clones to which equal amounts of patient DNA and reference DNA have been 
hybridized, will appear in yellow, clones deleted in the patient DNA compared to the reference DNA will 
appear in red, and clones that are duplicated in the patient DNA compared to the reference DNA will 
appear in green. The ratio between the test and reference DNA for each clone on the array can be 
plotted to visualize chromosome imbalances, marked by a deviation from the normal log2 T/R ratio. 
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technological developments have accumulated into a so-called ‘molecular karyotyping’ 
approach that allows for the sensitive and specific detection of submicroscopic single copy 
number changes throughout the entire human genome. Array CGH builds upon 
conventional CGH procedures (paragraph 1.3), in such a way that the target metaphase 
spreads are replaced by genomic fragments with known physical locations in a microarray 
format. In comparison with conventional CGH, the microarray format provides a higher 
resolution, a higher dynamic range and a better possibility for automation. In addition, it 
allows for direct linking of (submicroscopic) chromosome rearrangements to known 
genomic sequences and, thus, to genes which may be involved in the disease under 
investigation. 
 
The array CGH procedure that employs BAC clones as targets includes the following steps. 
First, the large DNA insert BAC clones are amplified by either degenerate oligonucleotide-
primed (DOP) PCR (Telenius et al. 1992) or ligation-mediated PCR (Klein et al. 1999) in 
order to obtain sufficient quantities needed for spotting. Next, these PCR products are 
spotted onto glass slides coated with substrates such as aminosilane using microarray 
robots equipped with high-precision printing pins. Depending on the amount of clones to 
be spotted and the space available on the microarray slide, clones can either be spotted 
once per array or in replicate. Test (patient) and reference (normal control) DNAs are 
usually labeled with either Cy3- or Cy5-dUTP using random priming and, subsequently, co-
hybridized onto the microarray in a solution containing an excess of Cot1-DNA to block 
repetitive sequences. During co-hybridization, test and reference DNA compete for the 
same targets on the microarray. Subsequently, the hybridized DNAs are detected by the 
different fluorochromes using scanning equipment with either a confocal laser or a charge 
coupled device (CCD) camera-based reader, followed by spot identification. The presence 
and location of chromosomal imbalances can be detected and quantified by calculating the 
ratio of the test-over-reference fluorescent intensities along the targets on the microarray. 
These T/R ratios show which chromosomal regions in the test genome are overrepresented 
(duplicated) or underrespresented (deleted) relative to the reference genome. As the ratio 
profiles can be ordered based on the physical location of the target BAC clones, an 
overview of the (submicroscopic) chromosomal imbalances throughout the entire genome 
can be generated, thereby providing a ‘molecular karyotype’ (Figure 1.2).  
 
The increase in data obtained through high-density microarrays requires standardized 
storage systems as well as thorough statistical tools, similar to those required for 
microarray-based gene expression profiling (Quackenbush 2002; Stoeckert et al. 2002). 
Owing to the complicated process of producing and hybridizing spotted microarrays, a 
certain degree of systematic variation does exist in the data produced. Normalization of 
microarray data is used to eliminate such systematic variation and, therefore, represents 
an important pre-processing step in the analysis of almost all microarray data. One of the 
most frequently applied normalization procedures in microarray-based expression studies 
is the locally weighted scatterplot smoothing (LOWESS). After this data normalization, 
automated statistical procedures are required for the reliable detection of genomic copy 
number changes. One such algorithm uses the Hidden Markov Model (HMM) (Rabiner 
1989) which is not only suited for distinguishing genuine copy number changes from 
random microarray noise, but also for precisely localizing the start- and end-points of each 
copy number alteration. Independent validation of chromosome rearrangements may be 
obtained either via FISH using probe sequences targeted to the region involved, or via 
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Figure 1.3  
Putative effects of mutations that alter the quantity of a gene product (protein). The solid vertical lines 
mark the thresholds for clinical effects, whereas the dotted vertical lines mark the levels of protein 
present. (a) In case of a heterozygous mutation, the clinical effect may become apparent when the 
protein level is below 20% of normal. (b) In case of haploinsuffiency, the clinical effect may become 
apparent when the protein level is below 60% of normal. (c) In case of a gain-of-function mutation, the 
clinical effect may become apparent when the level of product is above 100% of normal. 
 
 
 
multiplex ligation-dependent probe amplification (MLPA), a semi-quantitative PCR assay 
using primers specifically designed to the region of interest (Schouten et al. 2002). This 
comprehensive array CGH technique, once established and validated, allows the high-
throughput genome-wide screening for chromosomal imbalances with a resolution limited 
only by the size and distribution of the target BAC clones used. 
 
 
1.6 Monogenic disease, contiguous gene syndromes and genomic disorders 
 
In single gene disorders, or monogenic diseases, the phenotypic spectrum observed can 
be attributed to the malfunctioning of a single gene. Such malfunctioning can be achieved 
by physical deletion or duplication of (parts of) a genomic copy of the gene or by more 
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subtle intragenic mutations. The ultimate effect of a deletion or mutation that e.g. leads to 
a premature stop in the reading frame of the affected gene is haploinsufficiency, a state by 
which a decrease in the level of the corresponding protein gives rise to the phenotype. 
Such genes are dosage-sensitive (Figure 1.3). In reverse, duplications or gain-of-function 
mutations create proteins that exhibit an increase in constitutive activity, even in the 
absence of a physiological activator, or that create insensitivity to negative regulators 
(Figure 1.3). To date, over 10,000 single gene disorders are known and listed in the 
database of Online Mendelian Inheritance in Man (OMIM). 
 
In contrast to single gene disorders, it has been shown that several conditions, including 
mental retardation and additional congenital/developmental abnormalities, may be due to 
submicroscopic chromosome rearrangements encompassing several genes. In 1986, 
Schmickel (1986) coined the term contiguous gene syndrome for these disorders. Since 
the introduction of this term many alternatives have been suggested including 
‘microdeletion/ microduplication syndrome’ and ‘segmental aneusomy syndrome’. All these 
terms intend to imply that the phenotype of the disorder results from an inappropriate 
dosage of more than one critical gene located within the genomic region affected, i.e., 
individual genes located in such genomic regions contribute to distinct clinical features of 
the syndrome. It has, therefore, been suggested that the extent of the chromosomal 
region involved in each case would correlate with the ultimate phenotype, and that 
individual clinical features might be inherited in isolation (Budarf & Emanuel 1997). 
 
Interestingly, for many ‘microdeletion/microduplication syndromes’, the submicroscopic 
deletion or duplication identified appeared to be of virtual identical size in all patients. In- 
depth molecular analyses have shown that local genomic architectural features, such as 
low-copy repeat (LCR) structures, play an important role in the formation of these 
recurrent microdeletions and microduplications. LCRs, also termed segmental duplications 
or duplicons, encompass apparently normal stretches of genomic DNA and often contain 
genes. LCRs are present in more than one copy in the genome and are defined by a ≥ 1 kb 
size and a >90% sequence identity (Bailey et al. 2001; Eichler 2001; Bailey et al. 2002). 
LCRs can mediate recurrent DNA rearrangements such as deletions, duplications and 
inversions through chromosome or chromatid misalignment followed by nonallelic 
homologous recombination (NAHR) (Figure 1.4). In fact, the majority of the currently 
known ‘microdeletion/duplication syndromes’ result from NAHR between large (usually 
>10 kb), highly identical (>95%) LCRs and are, therefore, also termed genomic disorders 
(Lupski 1998; Stankiewicz & Lupski 2002; Lupski & Stankiewicz 2006). 
 
 
1.7 Disease-gene identification in monogenic disease and contiguous gene 
syndromes 
 
Microscopically visible and submicroscopic chromosome rearrangements have significantly 
contributed to the delineation of single gene disorders. For instance, translocations of 
Xp21 suggested for the first time that the Duchenne muscular dystrophy gene might map 
to this chromosomal region (Jacobs et al. 1981). While de novo translocations have been 
most widely used for the mapping and identification of disease genes, deletions have also 
been instrumental for the positional cloning of a variety of disease genes, including those 
for familial adenomatous polyposis (Herrera et al. 1986), retinoblastoma (Lele et al. 
1963), WAGR syndrome (Riccardi et al. 1978), and a number of contiguous gene
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Table 1.1: Monogenic diseases with frequent occurrence of deletions or duplications >50 kb. 
a :mutation/deletion detection dependent on ethnic background 
 
 
 
 
 
syndromes (Schmickel 1986). One particularly successful application of systematic deletion 
analysis has been the identification of a number of genes for holoprosencephaly, including 
SHH, ZIC2, SIX3 and TGIF (Munke 1989; Roessler et al. 1996; Brown et al. 1998; Wallis 
et al. 1999; Gripp et al. 2000). 
 
As outlined above, it is becoming increasingly clear that many ‘microdeletion syndromes’ 
can largely or completely be attributed to the phenotypic effects of haploinsufficiencies for 
single genes (paragraph 1.6). Pertinent examples are the RAI1 gene in Smith-Magenis 
syndrome (Slager et al. 2003), the UBE3A gene in Angelman syndrome (Kishino et al. 
1997), and the TBX1 gene in deletion 22q11 syndrome (Lindsay et al. 2001). For the LIS1 
gene in Miller-Dieker syndrome, however, the situation is more complex. While deletion of 
this gene is responsible for lissencephaly (Dobyns et al. 1993), it was found that the 
concomitant deletion of the 14-3-3 epsilon gene also contributes to this brain phenotype 
(Cardoso et al. 2003; Toyo-Oka et al. 2003). The reason that such clinical conditions are 
usually caused by microdeletions and rarely by intragenic mutations reflects their local 
genomic architecture rather than the intrinsic features of the causative gene(s) itself 
(Stankiewicz & Lupski 2002; paragraph 1.6). In fact, the only real requirement for a 
candidate microdeletion syndrome gene is that it should be dosage-sensitive. In case of 
microduplications, the effect of having a complete extra copy of a gene may result in a 
phenotype that is not mirrored by other mutations in this gene. For example, PMP22 gene 
duplications result in Charcot-Marie-Tooth Type 1A whereas point mutations in this gene 
may lead to hereditary liability to pressure palsies (Valentijn et al. 1992; Chance et al. 
1993). However, this does not hold for all cases, since both duplications and deletions of 
the PLP gene are common causes of Pelizaeus-Merzbacher disease (Woodward & Malcolm 
1999). Also, deletions and duplications of the SOX3 gene appear to yield a similar 
phenotype, i.e., infundibular hypoplasia and hypopituitarism (Woods et al. 2005). 
 
Syndrome Location 
Dosage-
sensitive 
gene 
Frequency of 
deletion/ 
duplication  
Reference 
Sotos syndrome 5q35 NSD1 6-49 %a Kurotaki et al. 2003 
Neurofibromatosis Type 1 17q11.2 NF1 7 % Cnossen et al. 1997 
Alagille syndrome 20p12 JAG1 7 % Krantz et al. 1997 
Rubinstein-Taybi syndrome 16p13.3 CREBBP 10 % Petrij et al. 2000 
Congenital 21-alpha  
              hydroxylase deficiency 
6p21.3 CYP21A2 28 % Olney et al. 2002 
Transient neonatal diabetes 6q24  36 % Temple et al. 1996 
Cystinosis syndrome 17p13 CTNS 44 % Shotelersuk et al. 1998 
Pelizaeus-Merzbacher Xq22 PLP1 62 % Mimault et al. 1999 
Smith-Magenis syndrome 17p11.2 RAI1 >90 % Juyal et al. 1996  
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The frequencies at which microdeletions or microduplications are encountered in 
monogenic diseases differ markedly. For example, there are monogenic diseases that are 
mostly caused by gene mutations and rarely by deletions or duplications, such as von 
Recklinghausen Neurofibromatosis, Rubinstein-Taybi syndrome and Alagille syndrome 
(Table 1.1). In other monogenic diseases, however, large deletions or duplications 
involving a dosage-sensitive gene are responsible for the majority of the cases (Table 
1.1). A more complex situation is encountered in Sotos syndrome. This syndrome is 
caused predominantly by heterozygous NSD1 point mutations in the Caucasian population 
(Douglas et al. 2003), whereas microdeletions containing the NSD1 gene prevail in the 
Japanese population (Kurotaki et al. 2003). This difference in mutation spectrum may 
reflect differences in genomic architecture between Japanese and Caucasians. Thus, 
microdeletions and microduplications occur at various frequencies in many monogenic 
diseases with a known genetic cause, and the difference between a microdeletion 
syndrome with rare mutations and a single gene disorder with occasional large deletions 
may be gradual rather than absolute. The availability of novel, highly sensitive methods, 
such as array CGH (paragraph 1.5), may further enhance the possibilities for a 
straightforward mapping of the genes underlying these disorders.  
Figure 1.4 
Model for nonallelic homologous recombination (NAHR) involving region-specific low-copy repeats 
(gray blocks). (a) Normal situation in which the appropriate LCRs align and recombine. (b) 
Interchromosomal NAHR of LCRs on two misaligned homologous chromosomes, resulting in a 
(submicroscopic) duplication and a reciprocal deletion of the intervening DNA segment. (c) 
Intrachromosomal NAHR of LCRs forming an intrachromatidal loop, resulting in the excision of the 
intervening segment. Arrows indicate the relative orientation of LCRs to each other. 
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1.8 Aim and outline of this thesis 
 
The work described in this thesis was initiated in September 2002, five years after the first 
hybridization of patient-derived DNA to nucleic acids from different genomic loci spotted on 
a microarray was reported (array CGH; Solinas-Toldo et al. 1997). In those five years, the 
application of array CGH remained mainly restricted to cancer research (Pinkel et al. 1998; 
Pollack et al. 1999; Albertson et al. 2000; Snijders et al. 2001; Wilhelm et al. 2002). 
Based on this experience, it was anticipated that array CGH-based genome-wide copy 
number screening might also be applicable to the detection of submicroscopic chromosome 
rearrangements in patients with mental retardation and/or malformation syndromes. 
Within this context, it was of particular relevance that the potency of this technique for the 
identification of chromosome rearrangements without any prior knowledge of the genomic 
regions involved would reach far beyond that of the existing chromosome analysis 
techniques. In addition, the integration of large collections of BAC clones into genome 
browsers like those from Ensembl and UCSC would allow for a direct inspection of 
candidate genes affected by the copy number imbalances detected which, in turn, should 
be of major help in explaining the clinical phenotypes. Therefore, the general aim of this 
thesis was to explore the feasibilities of the array CGH technology for its application in 
both clinical genetic and genome research. 
 
Specifically, we aimed at the following objectives: 
 
I. The generation of a microarray for genome-wide copy number assessment and 
optimization of protocols for the detection of single copy chromosome imbalances. 
 
The detection of submicroscopic chromosome deletions and duplications might enhance 
the mapping of genes underlying monogenic diseases and, simultaneously, facilitate the 
identification of novel contiguous gene syndromes. In Chapter 2 we describe the 
generation of a microarray containing ~3,500 FISH-verified BAC clones selected to cover 
the human genome with an average spacing of one clone per megabase. After 
optimisation, we used this array for the identification of submicroscopic chromosome 
rearrangements in 20 patients with unexplained mental retardation. In this series, three 
microdeletions and two microduplications were uncovered. 
 
II. The application of array CGH for resolving the genetic causes of well-characterized 
clinical syndromes  
 
For several well-recognized clinical syndromes, the genetic cause remains elusive. The 
identification of recurrent microdeletions and microduplications may resolve the genetic 
cause for such syndromes. In addition, microdeletions encompassing causative genes have 
been reported to occur at low frequencies in single gene disorders. In Chapter 3 we show 
that high-resolution genome-wide screening by array CGH can be used as an effective new 
approach for this purpose through the identification of the gene underlying CHARGE 
syndrome. 
 
III. The application of array CGH for the identification of novel ‘microdeletion/ 
microduplication syndromes’. 
 
The identification of overlapping submicroscopic deletions or duplications in patients who 
display similar phenotypic characteristics, might reflect new microdeletion syndromes or 
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genomic disorders. In Chapter 4 we describe the identification of three overlapping 
interstitial submicroscopic deletions on 17q21.31 in patients with a previously unknown 
clinically recognizable syndrome. Interestingly, the microdeletions are directly related to 
the local genomic architecture of 17q21.31, thereby classifying this new syndrome as a 
genuine genomic disorder. 
 
IV. The assessment of large-scale DNA copy number variations within the human 
genome. 
 
By using array CGH, a new class of genomic variations has been uncovered (Iafrate et al. 
2004; Sebat et al. 2004). These variations may encompass genomic segments ranging in 
size from ~100 kb to ~2.5 Mb, and are commonly referred to as copy number variations 
(CNVs). The full nature and extent of CNV and its frequency in different ethnic populations 
is, however, largely unknown. In Chapter 5 we describe a detailed analysis of 12 CNV loci 
in >300 healthy individuals of five different ethnic populations. From this analysis we 
conclude that several of these CNV loci differ between populations, not only in frequencies 
between populations, but also in absolute DNA copy numbers within populations. Our data 
suggest that insight into absolute DNA copy numbers for loci exhibiting CNV is a 
prerequisite for assessing their putative role in health and disease. 
 
V. The role of genomic architecture in mediating non-recurrent submicroscopic 
chromosome rearrangements. 
 
Nonallelic homologous recombination between region-specific genomic architectural 
features is a major mechanism underlying the occurrence of recurrent chromosomal 
rearrangements associated with many genomic disorders. However, the question whether 
such architectural features also mediate non-recurrent chromosomal rearrangements has 
largely remained elusive. In Chapter 6 we describe a detailed molecular analysis of two 
individuals with non-recurrent complex chromosome rearrangements (CCR) involving the 
short arm of chromosome 17. In total, we identified and characterized 17 breakpoints by 
high-resolution array CGH and dual-color FISH analysis. Of these 17 breakpoints, four 
were located within low copy repeats (LCRs), suggesting that these genomic architectural 
features may indeed mediate the formation of these non-recurrent chromosomal 
rearrangements. 
 
In Chapter 7 the objectives explored in the preceding chapters are discussed and an 
outline for future research is presented. Finally, a summary of this thesis is provided in 
Chapter 8. 
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Abstract 
 
Microdeletions and microduplications, not visible by routine chromosome analysis, are a 
major cause of human malformation and mental retardation. Novel high-resolution, whole-
genome technologies can improve the diagnostic detection rate of these small 
chromosomal abnormalities. Array-based comparative genomic hybridization allows such a 
high-resolution screening by hybridizing differentially labeled test and reference DNAs to 
arrays consisting of thousands of genomic clones. In this study, we tested the diagnostic 
capacity of this technology using ~3,500 fluorescent in situ hybridization–verified clones 
selected to cover the genome with an average of 1 clone per megabase (Mb). The 
sensitivity and specificity of the technology were tested in normal-versus-normal control 
experiments and through the screening of patients with known microdeletion syndromes. 
Subsequently, a series of 20 cytogenetically normal patients with mental retardation and 
dysmorphisms suggestive of a chromosomal abnormality were analyzed. In this series, 
three microdeletions and two microduplications were identified and validated. Two of these 
genomic changes were identified also in one of the parents, indicating that these are large-
scale genomic polymorphisms. Deletions and duplications as small as 1 Mb could be 
reliably detected by our approach. The percentage of false-positive results was reduced to 
a minimum by use of a dye-swap-replicate analysis, all but eliminating the need for 
laborious validation experiments and facilitating implementation in a routine diagnostic 
setting. This high- resolution assay will facilitate the identification of novel genes involved 
in human mental retardation and/or malformation syndromes and will provide insight into 
the flexibility and plasticity of the human genome.  
 
 
Introduction 
 
Mental retardation, with or without additional malformations, occurs in 2–3% of the 
general population. Although a considerable number of cases can be explained by the 
presence of gross chromosomal abnormalities or other factors, such as metabolic and/or 
neurological anomalies, the etiology of mental retardation remains unexplained for ~50% 
of patients (Anderson et al. 1996; de Vries et al. 1997). Submicroscopic, subtelomeric 
chromosome rearrangements contribute significantly to mental retardation and 
malformation, comprising up to 6% of the previously unexplained cases (Flint et al. 1995; 
Knight et al. 1999; Biesecker 2002; de Vries et al. 2003). These findings underscore the 
potential importance of submicroscopic chromosomal anomalies as a major cause of 
human mental retardation and malformation. To routinely detect these changes in a 
diagnostic setting, an efficient and robust technology is needed that screens the entire 
genome for copy number abnormalities with a resolution beyond the level of a light 
microscope (5–10 Mb). Array-based comparative genomic hybridization (array CGH) 
technology measures submicroscopic DNA copy number changes and allows the 
simultaneous high-resolution mapping of these changes onto the genome sequence 
(Solinas-Toldo et al. 1997; Pinkel et al. 1998; Snijders et al. 2001). We previously 
developed an array-based subtelomeric assay that screens all human subtelomeric regions 
in a single hybridization reaction (Veltman et al. 2002). Here we report the construction 
and application of a genome-wide microarray for the identification of known and novel 
microdeletions and duplications in patients with mental retardation and malformations. 
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Patients and Methods 
 
Patients 
Genomic DNAs, isolated from blood lymphocytes of four cytogenetically normal, healthy 
individuals (two males and two females), were used for array validation and as normal 
reference DNAs. Additional genomic DNAs were isolated from three patients with FISH-
verified known microdeletion syndromes (Prader-Willi syndrome [PWS; MIM 176270] on 
chromosome 15q11-15q12, Smith-Magenis syndrome [SMS; MIM 182290] on 
chromosome 17p11.2, and Trichorhinophalangeal syndrome [TRPS; MIM 190350] on 
chromosome 8q23.1–q24.11), as well as from 20 patients with mental retardation and 
additional dysmorphisms of unknown etiology. The latter patients were all seen by a 
clinical geneticist and had undergone extensive diagnostic work-up, including routine 
chromosome analysis without a diagnosis. They all had a phenotype suggestive of a 
chromosomal abnormality, and all scored three points or higher on the checklist developed 
by de Vries et al. (2001). Genomic DNAs from patients and controls were isolated and 
purified using a QIAamp kit (Qiagen), according to the instructions of the manufacturer.  
 
Array-Based comparative genomic hybridization 
Clone set 
A total of 3,569 well characterized, colony-purified, and FISH-verified BAC clones were 
used for array construction. Most of the BACs were derived from the RPCI-11 BAC library 
used as the main intermediate substrate for the sequencing and mapping of the human 
genome (Osoegawa et al. 2001). The set includes ~3,200 clones selected through a 
collaboration of the Children’s Hospital Oakland Research Institute, BACPAC Resources 
Center, and several other groups to cover the genome with a 1-Mb resolution (Cheung et 
al. 2001). Information on this clone set and its availability can be obtained at the BACPAC 
Resources Center Web site. Additional clones were added to the array, resulting in an even 
higher-resolution coverage of genomic regions known to be involved in human 
malformation and mental retardation, including the subtelomeric regions of all human 
chromosomes (77 clones) (Knight et al. 2000) and regions associated with known 
microdeletion syndromes (30 clones). Finally, chromosome 12 and chromosome 18 were 
covered with a higher density through the addition of clones used in previous studies 
(Veltman et al. 2003a; Zafarana et al. 2003).  
 
Array preparation 
Genomic target DNAs were isolated from 12-ml bacterial cultures using Qiagen R.E.A.L. 
Prep 96 BioRobot kits on a Qiagen BioRobot 9600 (Qiagen), following the instructions of 
the manufacturer. Degenerate oligonucleotide-primed (DOP) PCR was performed on 
isolated DNA from all clones, essentially as described elsewhere (Telenius et al. 1992), 
with minor modifications (Veltman et al. 2002). Taq2000 (Stratagene) was used as a 
thermostable polymerase. DOP-PCR products were dissolved at a concentration of 1 µg/µl 
in a 50% DMSO solution and robotically spotted in triplicate onto CMT-GAPS coated glass 
slides (Corning, UltraGaps) using an OmniGrid 100 arrayer (Genomic Solutions). The array 
consisted of 48 subgrids, and replicates were printed in different subgrids across the array.  
 
Labeling and hybridization 
Labeling and hybridization were performed essentially as described elsewhere (Veltman et 
al. 2002). In brief, genomic DNA was labelled by random priming with Cy3-dUTP or Cy5-
dUTP (Amersham Biosciences). Test and reference samples were mixed with 120 µg Cot-1 
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DNA (Roche), coprecipitated, and resuspended in 130 µl of a hybridization solution 
containing 50% formamide, 10% dextran sulfate, 2  SSC, 4% SDS, and 10 µg/µl yeast 
tRNA (Invitrogen). After denaturation of probe and target DNA, hybridization and 
posthybridization washing procedures were performed using a GeneTAC Hybridization 
Station (Genomic Solutions), according to the manufacturer’s instructions. In brief, an   
18-h hybridization with active circulation of the probe was performed, followed by five 
posthybridization wash cycles in 50% formamide/2  SSC at 45ºC and five wash cycles in 
phosphate-buffered saline at 20ºC. Slides were dried by centrifugation after a brief wash 
in water.  
 
Image analysis and processing 
Slides were scanned and imaged on an Affymetrix 428 scanner (Affymetrix) using the 
Affymetrix 428 scanner software package (version 1.0). The acquired microarray images 
were analyzed using GenePix Pro 4.0 (Axon Instruments), as described elsewhere 
(Veltman et al. 2002). For all further analyses, the median of the pixel intensities minus 
the median local background was used for every spot on the array (Cy3 and Cy5, 
calculated separately). Data normalization was performed in the software package SAS 
version 8.0 (SAS Institute) for each array subgrid, by applying Lowess curve fitting with a 
smoothing factor of 0.1 to predict the log2-transformed test-over-reference (T/R) value on 
the basis of the average logarithmic fluorescent intensities (Cleveland 1979). This 
smoothing factor was shown to result in the lowest percentage of false-positive results 
while not increasing the amount of false-negative results in the validation experiments. A 
consequence of this smoothing procedure is that the ratios of the clones with a copy 
number gain or loss are closer to the normal range of log2 ratios than in normalization 
procedures without this smoothing. 
 
Quality control 
Clones with an SD of the triplicates >0.3 were excluded in individual experiments, as well 
as clones with fewer than two replicates remaining after this analysis. Excluded from all 
experiments were 63 clones that did not show reliable hybridization results in at least four 
of the five normal-versus-normal control experiments. Clones that mapped to the sex 
chromosomes (n=163) were not analyzed in detail. The array contains a final set of 3,343 
autosomal clones with a coverage of at least 1 clone per Mb. From this final set, 3% of the 
clones, on average, were excluded per experiment on the basis of the quality criteria. 
Thresholds for copy number gain and loss were determined by examining the results of the 
control experiments and of previously published work and were set at log2 T/R values of 
0.3 and -0.3, respectively. Experiments were excluded when >5% of the clones showed 
intensity ratios outside of these regions. Of the 40 experiments performed in this study, 5 
experiments did not meet these quality criteria. These experiments were successfully 
repeated. The final data set is available as a downloadable electronic supplement via the 
online version of this article. 
 
Analysis of replicate experiments 
In this study, we performed a dye-swap experiment for each case (patient or control). For 
statistical analysis of these two experiments, we developed a two-dimensional assay in the 
software package SAS version 8.0 (SAS Institute) in which reference regions were 
calculated containing 99.999% of the data points (P=.99999), assuming that the pairs of 
normalized ratios follow a bivariate normal distribution (Figure 2.1b and Figure 2.1d). 
Under the assumption of no deleted or duplicated regions, the number of data points 
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outside the resulting ellipse is expected to be 1/100,000  the number of clones on the 
array— in our case, 1/100,000  3,343=0.03. Clones represented by data points outside 
this reference region in the scatterplot are candidates for a microduplication or deletion 
event. However, since a dye-swap experiment was performed for each case, the data 
points also have to be located in the correct quadrant of the scatterplot (i.e., a positive 
sign for experiment 1 [patient 1 vs. control 1] and a negative sign for experiment 2 
[control 1 vs. patient 1] indicates a potentially duplicated clone, whereas a deleted clone 
shows opposite signs in both experiments). The a priori thresholds for copy number gain 
(log2 T/R value 0.3) or loss (log2 T/R value -0.3) are therefore integrated into the 
scatterplot to indicate the candidate clones for microdeletion or duplication events. 
 
FISH validation experiments 
FISH validation experiments were performed on metaphase spreads prepared from 
patient-derived lymphoblast cell lines using routine procedures. Probe labeling, slide 
preparation, and hybridization were carried out essentially as described elsewhere (de 
Bruijn et al. 2001). A Zeiss epifluorescence microscope, equipped with appropriate filters, 
was used for visual examination of the slides. Digital images were captured using a high-
performance cooled CCD camera (Photometrics) coupled to a Macintosh Quadra 950 
computer. The Image FISH software package (Intergen) was used for analysis of the FISH 
images. Inverted images of DAPI-stained slides were used for chromosome identification. 
 
 
 
Figure 2.1 
Array CGH genomic profiles of validation experiments. Arrays contained 3,343 human autosomal clones 
(indicated by small circles representing the mean log2-transformed and Lowess-normalized T/R 
intensity ratios), ordered in a and c from 1pter to 22qter on the basis of the physical mapping positions 
obtained from the November 2002 freeze of the UCSC genome browser. In panels a and c, 
chromosome boundaries are indicated by vertical lines. Panel a shows the result of a normal-versus-
normal hybridization (control 3 vs. control 1). Nearly all clones fall within the a priori thresholds for 
copy number gain (log2 T/R value 0.3) and copy number loss (log2 T/R value -0.3) indicated by the 
horizontal lines. One clone on chromosome 2 shows an intensity ratio outside these thresholds and 
might represent a false-positive result. Panel b shows the result of the combined analysis of the two 
hybridizations performed with control 1 (x axis: control 1 vs. control 2; y axis: control 3 vs. control 1). 
The ellipse represents the border of the reference regions containing 99.999% of the data points; the 
thresholds for copy number gain and loss are also integrated into this figure (see the “Patients and 
Methods” section for details). As can be seen, there is only one clone outside the reference region; 
however, this clone does not pass the thresholds for copy number loss in both experiments and can 
therefore be discarded from further analyses. The clone on chromosome 2 that fell outside the 
threshold for copy number loss in panel a is clearly within the normal reference region and can 
therefore also be discarded for further analyses. Panel c shows the result of the hybridization of DNA 
from a patient with TRPS against DNA from a patient with PWS. A total of four clones, spanning 2.7 Mb 
of genomic sequence on 8q23.3-q24.11, showed log2 TRPS-over-PWS intensity ratios below the 
threshold for copy number loss, confirming the presence of a deletion of this genomic region in the 
TRPS patient. In addition, five clones, spanning 2.9 Mb of sequence on 15q11.2, show log2 intensity 
ratios above the (reverse) threshold for copy number gain, indicating a deletion of this genomic region 
in the PWS patient. No clones outside these target genomic regions show potential false-positive 
results. The combined results of two experiments involving the PWS patient are shown in panel d. The 
five target clones on 15q11.2 are reproducibly deleted in both experiments and fall outside the bivariate 
normal distribution reference region (P=.99999) and within the copy number loss quadrant indicated in 
the upper left quadrant. 
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Results 
 
Validation experiments 
To test the specificity and sensitivity of the whole genome BAC array, we performed a 
series of five normal-versus-normal control hybridizations using four normal healthy blood 
donors (including a dye-swap experiment for each control). Figure 2.1a shows a 
representative genomic profile resulting from such an experiment. Nearly all clones show 
log2 intensity ratios in between the a priori thresholds for copy number gain (0.3) or loss  
(-0.3). In the five normal-versus-normal experiments, an average of six clones (0.18%) 
passed these thresholds. Although very low, this level of background noise would still 
require a substantial number of FISH experiments to distinguish true microdeletions and 
microduplications from false-positive results. Therefore, the combination of two 
experiments (with dye swap) was analyzed for each control case, using stringent criteria 
for the presence of copy number gain or loss (see the “Patients and Methods section” and 
Figure 2.1b). The added value of combining data of two separate (T/R) experiments was 
clearly shown by the fact that the number of false positives was reduced to zero in all four 
cases tested. 
 
Next, we tested the sensitivity of the technology by hybridizing DNA from three patients 
with known, FISH-confirmed microdeletion syndromes (i.e., one patient with PWS, one 
patient with SMS, and one patient with TRPS) to the genome-wide array. Similar to the 
normal-versus-normal experiments, DNA samples were hybridized not only against each 
other but also against one of the normal controls. Figure 2.1c shows the result of a 
hybridization of DNA from the patient with TRPS against DNA from the patient with PWS. A 
total of four clones, representing 2.7 Mb of consensus genomic sequence on 8q23.3-
q24.11, showed TRPS-over-PWS intensity ratios below the threshold for copy number loss, 
thus confirming the presence of a deletion of this genomic region in the TRPS patient. In 
addition, five clones, spanning 2.9 Mb of sequence on 15q11.2, showed log2 intensity 
ratios above the (reverse) threshold for copy number gain, indicating a deletion of this 
genomic interval encompassing the genes SNRPN and UBE3A in the patient with PWS. The 
combined results of two experiments involving the patient with PWS are shown in Figure 
2.1d. The five target clones on 15q11.2 are reproducibly deleted in both experiments and 
fall outside the bivariate normal distribution reference region (P=.99999) and within the 
upper left quadrant, indicating copy number loss. Detailed analysis of the DNA from these 
two patients and the patient with SMS (containing a deletion of two genomic clones 
spanning a 1.5-Mb region on 17p11.2) showed that the target microdeletion region could 
be readily identified in each individual experiment with the target clones present on the 
array. Individual hybridizations showed an average of seven clones (0.21%) with log2 
intensity ratios outside the thresholds for copy number gain or loss, very similar to the 
percentage of false positives obtained in the normal-versus-normal control experiments 
described above. Statistical analysis of the duplicate experiments for each case failed to 
reproduce any of these aberrant ratios, strongly indicating that these were indeed false-
positive results.  
 
In conclusion, the sensitivity to detect submicroscopic (1.5–2.9 Mb) deletions was 
reproducibly validated, and the specificity of the technology was assured by performing 
two hybridizations for each case and applying a stringent statistical analysis. 
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Table 2.1: Phenotypes and Detected Microdeletions/-duplications 
a: MR=mental retardation. b: Detailed clinical information is given in the text. 
 
 
 
Detection of novel deletions and duplications in patients with unexplained mental 
retardation and dysmorphisms 
We selected a test series of 20 patients with mental retardation of unknown etiology to 
investigate whether the high-resolution, genome-wide, microarray-based, copy number 
screening would allow the identification of small genomic changes not detectable by 
routine karyotyping. In concordance with the validation experiments, each case was 
hybridized once against a normal control sample and once against another patient with a 
different clinical phenotype. This procedure was chosen to minimize the costs and, at the 
same time, the risks of hybridizing cases with identical genetic abnormalities against each 
other, which would result in masking of the abnormality. In 7 of the 20 patients, copy 
number alterations were reproducibly detected by array CGH on our genome-wide 
microarray. In five of these cases, the results could be confirmed by FISH on metaphase 
spreads of the patients. These included three microdeletions and two microduplications 
(Table 2.1; Figure 2.2). De novo occurrence was checked by investigating DNA samples 
from the parents. As expected, the microduplications proved difficult to validate by FISH. 
We therefore repeated the array CGH procedure in the two cases with microduplications on 
a small, high density array containing only the regions of interest and confirmed the 
presence of a microduplication in both cases (data not shown). The largest deletion 
identified in patient 1 was verified by FISH (Figure 2.2a and Figure 2.2f) and targeted 
17 clones on the array, spanning a total region of 8.6 Mb on 7q11.21-q11.23. The 
karyotype of this case was re-examined because of the relatively large size of this 
deletion, but no abnormalities were identified. It is interesting that this genomic region 
Patient Sex 
Age 
(years) 
Degree of 
MRa 
Phenotypeb Array CGH result 
1 Male 2 Severe 
Microcephaly, facial 
dysmorphism, pulmonary 
arterial and valve stenosis 
del(7)(q11.21q11.23), 
17 clones, 
8 Mb, de novo 
      
2 Female 12 Severe 
Microcephaly, facial 
dysmorphism, short 
stature 
del(2)(q22.3q23.2), 
3 clones, 
2 Mb, de novo 
      
3 Female 23 Moderate 
Facial dysmorphism, 
short stature, ventricular 
septum defect 
del(1)(p21p21), 
1 clone, 
<1 Mb, also detected in 
father 
      
4 Male 2 Severe 
Microcephaly, facial 
dysmorphism 
dup(2)(q21.2q21.2), 
1 clone, 
<1 Mb, also detected in 
father 
      
5 Male 19 Mild 
Facial dysmorphism, 
polydactyly, polycystic 
kidney (familial) 
dup(6)(q25.3q26), 
1 clone, 
<1 Mb, parents not 
available 
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contains the complete common deletion segment for the Williams-Beuren syndrome 
(Bayes et al. 2003). The other deletions and duplications were considerably smaller. In 
patient 2, the deletion on 2q22.3-q23.2 was encompassed by three clones mapping in a 2-
Mb genomic interval, whereas, in the other three cases, only one clone was involved, 
indicating the presence of abnormalities <1Mb in size. In one patient (patient 3) with a 
deletion on 1p21, the deletion was identified by FISH in the father of the patient as well, 
indicating that this might be a novel genomic polymorphism. Similarly, the duplication of a 
single clone on 2q21.2 in patient 4 was identified by FISH in the father. Unfortunately, the 
parents of patient 5, whose DNA contained a duplication of a single clone on 6q25.3-q26, 
were not available for checking de novo occurrence. 
 
 
Discussion  
 
Array CGH provides a high spatial genomic resolution and allows a fully automated 
evaluation of thousands of genomic loci. Previous applications have been mainly directed 
at genomic abnormalities in cancer (Snijders et al. 2001; Veltman et al. 2003b; 
Wessendorf et al. 2003). In this study, we demonstrate the application of array CGH in 
detecting known and novel submicroscopic abnormalities. The specificity and sensitivity of 
this approach was tested and validated in cytogenetically normal and healthy individuals, 
as well as in patients with known microdeletion syndromes. Deletions and duplications 
were detected reliably in a single overnight hybridization experiment without a priori 
knowledge of the genomic region involved. Individual experiments were performed with a 
low level of false-positive results that was reduced further by performing a replicate dye-
swap experiment followed by a thorough statistical analysis. From our data, we conclude 
that such replicate experiments are essential for implementation in a diagnostic setting, 
since they considerably reduce the need for laborious confirmation experiments while 
greatly improving the validity of the results. Application of this approach in a pilot study of 
20 patients with unexplained mental retardation and additional malformations resulted in 
 
 
 
Figure 2.2  
Detailed genomic profiles and FISH validation of copy number abnormalities identified in five cases with 
unexplained mental retardation. Panels a–e represent individual profiles of the affected chromosomes 
for each case, with clones ordered, for each chromosome, from pter to qter, on the basis of the physical 
mapping positions obtained from the November 2002 freeze of the UCSC genome browser. The 
centromeric region is indicated by a vertical gray dash, the thresholds for copy number gain (log2 T/R 
value 0.3) and copy number loss (log2 T/R value -0.3) are indicated by horizontal lines. Panels f-j 
represent the FISH validation using (one of) the target clone(s) identified by array CGH. Affected 
chromosomes are indicated by an asterisk (*). Panel a shows the deletion on 7q11 in patient 1, with 14 
clones in this region showing an average log2 intensity ratio of -0.5. FISH validation of this case is 
shown in the adjacent panel f, in which one of the deleted clones on 7q11 is shown in red and an 
undeleted control probe is shown in green. Panel b shows the microdeletion on 2q22 in patient 2 with a 
total of three clones crossing the threshold for copy number loss, with FISH validation in the adjacent 
panel g. Deletion of a single clone on 1p21 is shown in panel c for patient 3; this clone was confirmed 
by FISH to be deleted not only in the patient (panel h) but also in the father of the patient. Copy 
number gain detected in a single clone is shown in panels d and e for patients 4 and 5, with FISH 
confirmation in panels i and j. 
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the detection of five copy number abnormalities, three deletions, and two duplications, all 
beyond the microscopic resolution (~10 Mb). The patient with the largest deletion (8.6 Mb 
on 7q11.21-q11.23) was a 2-year-old boy (patient 1) with severe mental retardation, 
plagio- and microcephaly, postnatal growth retardation, facial dysmorphism (downward-
slanting palpebral fissures, periorbital fullness, epicanthus and telecanthus, broad mouth 
with full lips, and sagging cheeks), short neck, unilateral simian crease, and a peripheral 
and valvular pulmonary stenosis. The deletion completely overlaps with the common 1.6 
Mb region deleted in patients with Williams syndrome (Bayes et al. 2003). Although this 
boy had some facial features fitting the diagnosis of Williams syndrome, his clinical 
presentation was more severe than is commonly observed in patients with Williams 
syndrome, most notably the severe retardation. Moreover, a pulmonary valve stenosis is 
less often observed in this syndrome (Eronen et al. 2002). It seems likely that the severity 
of the phenotype is related to the large size of the deletion, a finding that has also been 
observed in four cases with even larger deletions, three of which also showed 
characteristics typical of the Williams syndrome (Valentine & Sergovich 1977; Frydman et 
al. 1986; Mizugishi et al. 1998; Wu et al. 1999).  
 
A 2-Mb deletion on 2q22.3-q23.2 was identified in a 12-year-old girl (patient 2) who had 
severe mental retardation, short stature (height 3 SDs below normal), microcephaly (head 
circumference 2.5 SDs below normal), obesitas, facial dysmorphism (coarse facies, 
upward- slanting palpebral fissures, hypotelorism, abnormally shaped ears, high nasal 
bridge, small, carp-shaped mouth with downward-turned corners, narrow, flat palate, and 
broad chin), and long, narrow hands with short digiti V. The deletion was just distal to a 
more common deletion on 2q22 and did not include the SIP1 gene, which is associated 
with Mowat-Wilson syndrome (Mowat et al. 2003). The clinical presentation of this girl 
differs also from the phenotype seen in this relatively new syndrome. The deletion is de 
novo, so haploinsufficiency of one or more genes within the deleted region could be 
causative for the phenotype. So far, no obvious candidate gene appears to be present in 
this genomic region.  
 
In a 23-year-old female (patient 3) with moderate mental retardation, autism, short 
stature, minor facial dysmorphism (upward-slanting palpebral fissures, deepset eyes, short 
philtrum), short broad feet, a small ventricular septum defect, and childhood absences, we 
detected a deletion of a single clone on 1p21. This deletion was present in her healthy 
father, as well. Although familial occurrence of this small deletion (<1 Mb) does not rule 
out a causative role, it may very well be a novel genomic polymorphism. It is known that 
similar polymorphisms (either deletions or duplications) without any clinical significance 
are present in the genome, but, at present, they are underrecognized. Examples of known 
normal genomic variations include a 2.5-Mb duplication of 8p23.1 (Barber et al. 1998; 
Engelen et al. 2000) and a number of subtelomeric polymorphisms (Ballif et al. 2000; 
Linardopoulou et al. 2001; Der-Sarkissian et al. 2002). 
 
It is interesting that two microduplications were also detected using this comparative 
microarray technology. One duplication on 2q21.2 (<1 Mb) occurred in a 2-year-old boy 
(patient 4) with severe mental retardation, microcephaly, and facial dysmorphism 
(metopic ridge, synophrys, arched eyebrows, long eyelashes, upwardslanting palpebral 
fissures, low-set, posteriorly rotated malformed ears, and high nasal bridge). This 
duplication was detected also in his father, indicating the presence of another genomic 
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polymorphism. The other duplication was found to be present on 6q25.3-q26 (<1 Mb) in a 
19-year-old male (patient 5) with mild mental retardation, postaxial polydactyly of hands 
and feet, facial dysmorphism (upward-slanting palpebral fissures, high, narrow nasal 
bridge, short philtrum, retrognathia, and irregular teething), and medullary polycystic 
kidneys. The kidney abnormality was also present in his two mentally normal sisters. It is 
interesting to note that, in a series of 36 patients with a larger duplication, including the 
6q25.3-q26 region, four cases have been reported with a polydactyly (Schinzel 2001). 
Unfortunately, the parents of this patient were unavailable for checking de novo 
occurrence. However, a common copy-number variation affecting a single BAC at 6q26 
was recently reported by Albertson and Pinkel (2003). In this publication, the observed 
copy-number differences between individuals were explained by variation in the length of 
the apolipoprotein (a) gene, which is highly polymorphic in the human genome because of 
variation in the number of copies of a 5.5-kb sequence encoding kringle repeats (Kamboh 
et al. 1991; Lackner et al. 1993). Indeed, this gene is located within the BAC affected in 
this patient (RP11-43B19), and therefore it is highly likely that this copy-number change 
also represents a genomic polymorphism.  
 
The detection of five microdeletions/-duplications in a series of 20 patients with mental 
retardation of unknown etiology in this pilot study underscores the strength of the array 
CGH technique. It should be mentioned that the patients in this study were selected on the 
basis of a phenotype suggestive of a chromosomal abnormality (de Vries et al. 2001). 
Therefore, this cohort may not be representative of the population of individuals with 
mental retardation as a whole. Also, two of the genomic abnormalities were identified in 
one of the parents as well, reducing the chance that these abnormalities are underlying 
the disorder. On the other hand, the resolution of the current microarray is, on average, 1 
Mb, and, therefore, cases with more subtle anomalies may have been missed. To this end, 
we and other groups are in the process of constructing microarrays completely covering 
the genome with an average resolution of ~50 kb (for more information, see the BACPAC 
Resources Center’s Human BAC Minimal Tiling Set Website).  
 
There are three main applications for using array CGH in patients with mental retardation 
and malformations. First, it is to be expected that the number of interstitial 
microdeletions/-duplications will be comparable or may even exceed the ~5% 
submicroscopic, subtelomeric rearrangements currently reported among individuals with 
mental retardation (de Vries et al. 2003). For this reason, this 1-Mb–resolution array is 
currently being evaluated in a diagnostic setting in our department. Ultimately, this array-
based copy number screening may partially replace karyotyping in this patient group. 
Second, these studies will facilitate the detection of genes involved in physical and mental 
development. Several such genes have already been identified as a result of systematic 
deletion mapping using microscopic chromosomal abnormalities (Romeo et al. 1994; 
Belloni et al. 1996; Robinson et al. 2003). The high resolution of the array CGH method 
allows for rapid and precise mapping of candidate genes for specific malformations. Third, 
a systematic analysis of genomic polymorphisms will give more insight into the flexibility 
and plasticity of the human genome. This latter may prove to be a fruitful field of study, 
given the fact that such large rearrangements will often involve multiple genes and may 
therefore serve as predisposing factors for multifactorial disorders. 
 
     Chapter 2      
   
 
            
38 
Acknowledgements 
 
We thank Yvonne Jonkers, Martin Elferink, and Monique Kersten-Niessen, for expert 
technical assistance; Ben Hamel, for referring cases; and Rolph Pfundt, for useful 
discussions. B.B.A.d.V. was supported by a grant from the Netherlands Organization for 
Health Research and Development (ZonMW). 
   
 
            
39      Chapter 2      
   
 
            
40 
 
 
   
 
            
41 
 
 
 
 
 
Chapter 3 
 
 
 
 
 
 
Mutations in a novel member  
of the chromodomain gene family 
cause CHARGE syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lisenka ELM Vissers, Conny MA van Ravenswaaij, Ronald Admiraal, Jane A Hurst, Bert BA de Vries, 
Irene M Janssen, Walter A van der Vliet, Erik HLPG Huys, Pieter J de Jong, Ben CJ Hamel, Eric FPM 
Schoenmakers, Han G Brunner, Joris A Veltman & Ad Geurts van Kessel 
 
Nature Genetics 36: 955-957, 2004 
   
 
            
42 
   
 
            
43 
Abstract  
 
CHARGE syndrome is a common cause of congenital anomalies affecting several tissues in 
a nonrandom fashion. We report a 2.3 Mb de novo overlapping microdeletion on 
chromosome 8q12 identified by array comparative genomic hybridization in two individuals 
with CHARGE syndrome. Sequence analysis of genes located in this region, detected 
mutations in the gene CHD7 in 10 of 17 individuals with CHARGE syndrome without 
microdeletions, accounting for the disease in most affected individuals. 
 
 
Introduction 
 
CHARGE syndrome denotes a nonrandom pattern of congenital anomalies including 
choanal atresia, malformations of the heart, inner ear and retina (Pagon et al. 1981). With 
an estimated birth incidence of 1:12,000 CHARGE syndrome is a common cause of 
congenital anomalies (Kallen et al. 1999). Most cases of CHARGE syndrome are sporadic, 
but several aspects of this condition, including the existence of rare familial cases and a 
high concordance rate in monozygotic twins, support the involvement of a genetic factor. 
Cytogenetic abnormalities have been described previously, but no specific locus has been 
identified (Lalani et al. 2003). Systematic genome scans by conventional comparative 
genomic hybridization (CGH) (Sanlaville et al. 2002) or microsatellite analysis (Lalani et al. 
2003) did not identify a common genetic anomaly; neither did sequencing of candidate 
genes PAX2 (Tellier et al. 2000) and PITX2 (Martin et al. 2002). 
 
 
Material and Methods 
 
Individuals with CHARGE syndrome 
Eighteen individuals with CHARGE syndrome and normal karyotypes upon routine 
cytogenetic investigation were selected based on the presence of at least 4 of the following 
7 features: coloboma of the eye, heart malformation, choanal atresia, psychomotor and/or 
growth retardation, urogenital abnormalities, dysmorphic ears and/or deafness, and 
anomalies of the os petrosum (agenesis of the semicircular canals) on a CT-scan. Based on 
the initial array CGH results an additional, previously published individual with CHARGE 
syndrome and a de novo t(6;8) was included in this study (individual 2 in Table 3.1) 
(Hurst et al. 1991). 
 
Array-based comparative genomic hybridization 
Array CGH was performed essentially as described previously (Veltman et al. 2002; Vissers 
et al. 2003). Our genome-wide array contains 3569 BAC clones with an approximate 
average spacing of 1 clone per megabase (Vissers et al. 2003). The chromosome 8 array 
was composed of 918 BACs resulting in an average of 1 clone per 159 kb. These clones 
are part of a tiling resolution clone set (Ishkanian et al. 2004). Clones were spotted in 
triplicate onto UltraGAPS slides (Corning) using an Omnigrid 100 arrayer (Genomic 
Solutions). The array CGH profiles were established through co-hybridization of 500 ng 
Cy3-dUTP and Cy5-dUTP (Amersham Biosciences) labeled test and reference DNA, using a 
GeneTac Hybridization station (Genomic Solutions). After scanning, test-over-reference 
ratios (T/R values) were determined for each clone, log2-transformed and normalized per 
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array subgrid by Lowess curve fitting (Cleveland 1979; Vissers et al. 2003) Thresholds for 
copy number gain and loss were set at log2 T/R values of 0.3 and –0.3, respectively.  
 
Mutation analysis 
All coding sequences and flanking intronic sequences of the genes (MGC39325, SDCBP, 
AL831990, CYP7A1, NSMAF, TOX, CA8, RAB2 and CHD7) located in the critical 8q12 
interval were amplified and subsequently sequenced using oligonucleotides annealing 100-
200 bp from the intron-exon boundaries. Primer sequences and PCR conditions are 
available upon request. All mutations were confirmed by bi-directional sequencing and 
checked for their de novo occurrence through mutation analysis of parental DNAs, if 
available. 
 
FISH validations 
FISH validation experiments were performed on metaphase and interphase cells prepared 
from individual-derived and normal control-derived lymphoblastoid cell lines, respectively, 
using routine procedures. Probe labeling, slide preparation, hybridization and analysis were 
carried out according to routine procedures (Vissers et al. 2003).  
 
Expression profiling by semiquantitative RT-PCR 
For semiquantitative RT-PCR (Luijendijk et al. 2003), primers spanning intronic sequences 
were used. The expression profile of the CHD7 gene was determined in 12 fetal tissues 
(eye, cochlea, brain, central nervous system, stomach, intestine, skeleton, heart, tongue, 
kidney, lung and liver) and 7 adult tissues (retina, cornea, brain, skeletal muscle, heart, 
kidney and lung). RT-PCR was performed in a volume of 35 µl. Samples of 8 µl were taken 
from the PCRs after 25, 30 and 35 cycles. Primer sequences and PCR conditions are 
available upon request. 
 
 
 
Figure 3.1 
Array CGH profiles of two individuals with CHARGE syndrome and FISH validation. (a) Array CGH 
genome-wide profile of the index individual with a copy number deletion of three adjacent clones on 
8q12 (arrow). This profile represents the result of a single hybridization experiment; analysis of the 
replicate experiment identified only the 8q12 clones as being reproducibly deleted. Vertical lines 
indicate chromosome boundaries. (b) Profile of the same individual (brown squares) on the tiling 
chromosome 8 BAC array with 31 clones characterizing the deletion, and the chromosome 8 profile of 
an individual (black circles) with an apparently balanced t(6;8) translocation that overlaps with the 
deletion of the index individual. (a, b) Clones are ordered on the x axis according to physical mapping 
positions; log2 transformed test-over-reference ratios for each clone are given on the y axis. (c-g) FISH 
validation of the deletion in individual 1 (c) and testing for de novo occurrence in the accompanying 
parents (d-e) with clone RP11-91I20. (f) Determination of proximal deletion boundary (RP11-310L18 in 
red is normal; RP11-44D19 in green is deleted) and (g) determination of distal deletion boundary; 
RP11-274C23 in green is deleted whereas RP11-252M13 in red is normal. (h-k) FISH validation of the 
two distinct deletions in individual 2 and determination of the deletion boundaries. (h) The proximal 
deletion contains RP11-44D19 (green) on the centromeric site but not RP11-310L18 (red), and on the 
telomeric site (i) RP11-696A12 (red) but not RP11-630K16 (green). (j) Normal region between the two 
deletions is indicated by RP11-360N16 (red), whereas RP11-91I20 (green) marks the distal deletion. 
(k) This distal deletion contains RP11-265K14 (red) on the telomeric site, but not RP11-317H6 (green). 
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Results and Discussion 
 
We recently optimized array CGH (Pinkel et al. 1998) for high-resolution genome-wide 
screening of submicroscopic copy number changes (Vissers et al. 2003), and used this 
approach to identify microdeletions or duplications underlying CHARGE syndrome. We co-
hybridized genomic DNA from two individuals with CHARGE syndrome with normal 
reference DNA onto a genome-wide BAC array with 1 Mb resolution. The genome-wide 
array CGH profile from one of these individuals is shown in Figure 3.1a. The only clones 
reproducibly deleted in this individual map to chromosomal band 8q12 and encompass a 
genomic interval of ~5 Mb. We confirmed the deletion by fluorescent in situ hybridization 
(FISH) analysis and proved that it occurred de novo (Figure 3.1c-e). The second 
individual with CHARGE syndrome included in this pilot study had no microdeletion or 
microduplication. 
 
To further characterize the deletion in the index individual and to screen additional 
individuals for abnormalities of chromosome 8, we established a tiling resolution 
chromosome 8 array containing 918 overlapping BAC clones. After hybridizing DNA from 
the index individual onto this array (Figure 3.1b), we detected a deletion of 31 
overlapping clones spanning a region of 4.8 Mb on 8q12, extending from RP11-44D19 to 
RP11-274C23 (Figure 3.1f-g). Notably, an individual with CHARGE syndrome with an 
apparently balanced chromosome 8 translocation was previously reported (Hurst et al. 
1991). Hybridization of genomic DNA from this person onto the chromosome 8 BAC array 
detected two microdeletions overlapping with the one that we identified in the index 
individual (Figure 3.1b): one encompassing 6 overlapping clones (from RP11-44D19 to 
RP11-661A3, ~0.8 Mb) and one encompassing 11 overlapping clones (from RP11-51L11 to 
RP11-113D4, ~1.5 Mb). Between these two deleted regions, 6 clones (~0.9 Mb) showed 
normal test-over-reference ratios. We used metaphase FISH analysis to confirm the 
presence of and to determine the boundaries of the two distinct microdeletions in this 
person (Figure 3.1h-k). Although we could not verify de novo occurrence of the 
microdeletions in this case, the translocation was previously shown to be de novo (Hurst et 
al. 1991). Using data from these two individuals, we defined a shortest region of deletion 
overlap encompassing 2.3 Mb of genomic sequence on 8q12 (Figure 3.2a). We then 
screened 17 additional individuals with CHARGE syndrome using the chromosome 8 tiling 
array and detected no additional chromosome 8 copy number changes. Next, we 
sequenced the coding regions and the intron-exon boundaries of all nine annotated or 
predicted genes located in or just outside the shortest region of deletion overlap (Figure 
3.2a). We identified ten heterozygous mutations in the gene CHD7, including seven stop-
codon mutations, two missense mutations and one mutation at an intron-exon boundary 
(Figure 3.2b-c, Table 3.1). CHD7 consists of 38 exons and has a genomic size of 188 kb. 
The stop-codon mutations were scattered throughout the gene: two in exon 2, one in exon 
3, one in exon 26, two in exon 30 and one in exon 35. The two de novo missense 
mutations are predicted to lead to the amino acid substitutions I1028V (in exon 12), and 
L1257R (in exon 15). We observed one de novo mutation 7 bp upstream of exon 26 that 
could possibly affect splicing (IVS26-7GA). 
 
cDNA clone KIAA1416 (Nagase et al. 2000), encompassing the last 34 exons of CHD7, is a 
member of the chromodomain helicase DNA-binding (CHD) genes. CHD proteins belong to 
a superfamily of proteins that have a unique combination of functional domains, including 
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Figure 3.2  
Detailed genomic view of 8q12, organization of the CHD7 gene and mutations detected. (a) Transcript 
map of the deleted 8q12 genomic region. The shortest region of deletion overlap in the two individuals 
is shown. Genes in green were screened for mutations. Cen, centromeric; Tel, telomeric. (b) Genomic 
structure of CHD7 indicating the positions of seven nonsense mutations (circles), two missense 
mutations (squares) and one intron-exon boundary mutation (triangle). The corresponding functional 
CHD7 domains are marked (colored bars). (c) Partial electropherograms obtained by direct sequencing 
of PCR products showing two nonsense mutations in individual 5 (1714C>T) and individual 8 
(5418C>G) and one missense mutation in individual 7 (3770T>G).  
 
 
 
two N-terminal chromodomains, a SNF2-like ATPase/helicase domain and a DNA-binding 
domain (Woodage et al. 1997) (Figure 3.2b). This class of proteins is thought to have 
pivotal roles in early embryonic development by affecting chromatin structure and gene 
expression (Cavalli et al. 1998). The congenital malformations found in CHARGE syndrome 
have their origin in early embryonic development. CHD7 has ubiquitous expression in 
several fetal and adult tissues (Figure 3.3), including those affected in CHARGE 
syndrome. 
 
The identification of seven heterozygous CHD7 stop-codon mutations and two single copy 
8q12 deletions of CHD7 indicate that haploinsufficiency of this gene could account for most 
cases of CHARGE syndrome. Two amino acid changes are located in one of the functional 
domains of the CHD7, the SNF2 domain, and both affect a conserved amino acid (Figure 
3.4). We did not observe any overt phenotypic difference between individuals with 8q12 
deletions and those with nonsense or missense mutations in CHD7 (Table 3.1). The index 
individual, with a 4.8 Mb deletion, has relatively severe mental retardation, which may be 
due to the presence of intronic or promoter mutations or to whole exon deletions. CHARGE
a  
b  
c  
     Chapter 3      
   
 
            
48 
Table 3.1: Clinical characteristics of individuals with CHARGE syndrome and mutations in 
CHD7 
 a: anomalies on CT-scan of inner ear (semicircular canal agenesis); b: Hurst et al. 1991; F: female. M: 
male. U: unknown. *: Only one parent available for testing, no mutation identified. 
 
 
syndrome might also have a genetically heterogeneous etiology, as different genomic 
abnormalities have been identified in affected individuals (Sanlaville et al. 2002; Lalani et 
al. 2003). Notably, monosomy with respect to 22q11.2 has been reported to occur in 
individuals with features of both DiGeorge syndrome and CHARGE syndrome (de Lonlay-
Debeney et al. 1997). Deletion of 22q11.2 was excluded in the individuals in this study 
who did not have CHD7 deletions or mutations. Microdeletions encompassing the 
underlying gene have been reported to occur at low frequencies in single gene disorders 
(de Kok et al. 1995a; Johnson et al. 1998). We show that high-resolution genome-wide 
screening by array CGH is an effective new approach to localize such underlying genes. 
This approach is of particular interest for sporadic malformation syndromes that cannot be 
tackled by other mapping approaches because of reproductive lethality. 
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1 F + + - + - +  + - - del 8q12    yes 
2b F + + - + - +  U + - del 8q12    U 
3 F + + - + - +  U - + 469 C>T 2 R157X U 
4 F - + + + - +  U - - 1078 G>T 2 G360X U* 
5 M - - - + + +  + + + 1714 C>T 3 Q572X yes 
6 F + - - + - +  + - - 3082 A>G 12 I1028V yes 
7 F + - - + + +  + - - 3770 T>G 15 L1257R yes 
8 F - + + + + +  + - - 5418 C>G 26 Y1806X yes 
9 M + - - + + +  U - + 6051 T>A 30 C2017X U 
10 F + + - + - +  + + - 6070 C>T 30 R2024X U* 
11 F - + + + - +  + - - 7824 T>A 35 Y2608X yes 
12 M + + - + + +  + - + IVS26-7G>A 26 Splice site yes 
13 F + + + + + +  + - +     
14 F + - + + - +  U - +     
15 M + - - + - +  + - -     
16 F + + - + + +  + - +     
17 F - + - + + +  + + -     
18 M + + - + + +  U + +     
19 M + + + + + +  + - -     
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Figure 3.3 
Expression profile analysis by semiquantitative RT-PCR analysis of CHD7. (a) RT-PRC specific for the 
transcript encoding the CHD7 gene. Samples were taken after 25, 30 and 35 cycles. The RNA used for 
the RT-PCR was derived from the following tissues: fetal (1) eye, (2) cochlea, (3) brain, (4) central 
nervous system, (5) stomach, (6) intestine, (7) skeleton, (8) heart, (9) tongue, (10) kidney, (11) lung 
and (12) liver; adult (1) retina, (2) cornea, (3) brain, (4) skeletal muscle, (5) heart, (6) kidney and (7) 
lung. Expression was detected in all tissues at equal levels. 
 
 
 
Figure 3.4  
Conservation of mutated amino acids between CHD7 protein family in human and between different 
species. The affected residues are conserved within different proteins of the CHD protein family and 
between different species. (a) Mutation I1028V of individual 6 in exon 12 affecting the SNF2 domain. 
(b) Mutation L1257R of individual 7 in exon 15 also affecting the SNF2 domain. Black background: high 
conservation; Gray background: mild conservation; White background: no conservation. 
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Abstract 
 
Submicroscopic genomic copy number changes have been identified only recently as an 
important cause of mental retardation. We describe the detection of three interstitial, 
overlapping 17q21.31 microdeletions in a cohort of 1,200 mentally retarded individuals 
associated with a clearly recognizable clinical phenotype of mental retardation, hypotonia 
and a characteristic face. The deletions encompass the MAPT and CRHR1 genes and are 
associated with a common inversion polymorphism. 
 
 
Introduction 
 
Mental retardation is the most common developmental disorder, affecting intellectual and 
adaptive functions with a frequency of approximately 2–3% in the general population. 
Whole-genome scanning technologies such as array-based comparative genomic 
hybridization (array CGH) (Pinkel et al. 1998) have enabled the detection of interstitial 
submicroscopic copy number alterations in ~10% of individuals with mental retardation of 
unknown etiology (de Vries et al. 2005).  
 
 
Material and Methods 
 
Individuals 
We tested 360 mentally retarded individuals for copy number changes using our genome-
wide tiling path resolution microarray in a diagnostic setting (de Vries et al. 2005). 
Previous routine chromosome analysis was normal and subtelomeric MLPA failed to reveal 
any anomalies (SALSA MLPA kit P036, MRC Holland, Amsterdam, the Netherlands) in all 
individuals. In addition, we tested a cohort of 840 mentally retarded individuals for copy 
number changes in the 17q21.31 region by MLPA. DNA samples of these individuals were 
collected from centres in Oxford, UK (n=130), Antwerp, Belgium (n=130), Zurich, 
Switzerland (n=100), Troina, Italy (n=130), Stockholm, Sweden (n=70) and Nijmegen, 
The Netherlands (n=280). We obtained informed consent from the parents, including 
consent to publish photographs of all subjects described in this study. 
 
Clinical description of individuals with the 17q21.31 deletion 
Individual 1 
The chromosomes of this 3 year-old-girl were analyzed prenatally and found to be normal. 
She was born at 35 2/7 weeks gestation with a birth weight of 2078 g (10th centile) and 
head circumference of 30.4 cm (5th centile). She was severely hypotonic and her 
development was considerable delayed: sitting at 3 years and no words at 3 years and 1 
month. Magnetic Resonance Imaging (MRI) of the brain at 1 year of age showed widened 
ventricles and periventricular white matter changes. Electromyography (EMG) was normal, 
but Brainstem Evoked Response Audiometry (BERA) was abnormal. At 3 months she was 
treated for a congenital hip dysplasia. Diagnostic testing including DNA analysis for 
myotonic dystrophy, Spinal Muscular Atrophy (SMA), Prader-Willi syndrome, metabolic 
screening in blood and urine revealed no abnormalities. 
 
On physical examination at the age of 3 years and 1 month, a height of 95 cm (40th 
centile), and a head circumference of 49.5 cm (50th centile) was noted. She had a long 
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hypotonic face with frontal bossing and bitemporal narrowing, ptosis, blepharophimosis, 
upward slanting palpebral fissures, epicanthal folds, large low set ears with hypoplastic 
crus superior, low nasal bridge, bulbous nasal tip, long columella, triangular nostrils, high 
palate with broad gums and a broad chin (Figure 4.1a). Her broad thorax had wide-space 
nipples and a mild pectus excavatum. She had long fingers, narrow long feet with long 
toes and hyperlaxity of the joints (Beighton score of 6/8). She was good-natured with 
normal eye contact. 
 
Individual 2 
This 17-year-old, moderately mentally retarded woman was born at 38 weeks gestation in 
breech position with a caesarian section and she had a birth weight of 1980 g (<3rd 
centile). In the first 3 weeks she received nasal catheter feeding because of low glucose 
levels and phototherapy because of hyperbilirubinaemia. She was hypotonic and started 
walking and speaking after the age of 2 years. She had an IQ of 48 points and attended 
special schooling. From the age of 1.5 to 3.5 years she had epileptic insults for which 
antiepileptic drugs were used. An MRI of the cerebrum showed wide ventricles, especially 
of the temporal horn of the lateral ventricles. In addition, routine chromosome analysis, 
metabolic screening in blood and urine and EMG, revealed no abnormalities. She 
developed a scoliosis at 13 years of age. She had normal hearing but mildly impaired 
vision (+4/+4). 
 
On physical examination at the age of 17 years, low-normal height of 160.8 cm (10th 
centile), head circumference of 53 cm (10th centile) and weight 51.2 kg (50th centile for 
height) was noted. She had a long hypotonic face with ptosis, blepharophimosis, upward 
slanting palpebral fissures, large ears with hypoplastic crus superior, tubular pear-shaped 
nose with high nasal bridge and long columella, short philtrum, two missing upper teeth, 
everted lower lip and broad chin (Figure 4.1b). She had a thoracal scoliosis with a lumbar 
hyperlordosis. Her hands and fingers were long and slender with a simian crease in the left 
palm. Her feet had high arches with hallux valgus bilaterally and mild hammer toes. The 
lower part of the limbs was slender and there was a mild general decrease of strength. In 
addition, she had mild hyperlaxity of the finger joints (Beighton score of 2/9), and 
numerous moles on the skin. She had nasal speech and an amiable nature. 
 
Individual 3  
This 26-year-old, moderately mentally retarded male was born after an uneventful 
pregnancy at term with a normal birth weight of 3120 g (50th centile) but a large head 
circumference of 37.5 cm (>97th centile). He was notably hypotonic and computed 
tomography imaging of the brain at 4 months of age showed a communicating 
hydrocephaly without increased intracranial pressure. Both Somatosensory Sensory 
Evoked Potentials (SSEP) and BERA studies were abnormal at 6 months but normalized 
later in life. His development was retarded, walking at 3 years of age and he attended 
special school. He was operated on inguinal hernia and cryptorchidism. A scoliosis 
developed at 13 years of age. Diagnostic test including routine chromosome, FMR1 
analysis and metabolic screening in blood and urine revealed no abnormalities.  
 
On physical examination at the age of 26 years, low-normal height of 173 cm (10th 
centile), and a large head circumference of 63 cm (>97th centile) was noted. He had a 
long narrow face with a high, broad forehead, blepharophimosis, strabismus divergence, 
large ears with hypoplastic crus superior and large lobules, tubular pear-shaped nose with 
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Figure 4.1 
Clinical characteristics of the 17q21.31 deletion syndrome. (a) Patient 1, at 3 years of age. (b) patient 
2, at 17 years of age, and (c) patient 3, at 26 years of age. Note the characteristic facial features, a 
hypotonic face with ptosis, blepharophimosis, large low set ears, bulbous nasal tip, long collumella with 
hypoplasic alae nasi, and a broad chin. 
 
 
 
bulbous tip and long columella, high palate with broad gums and diastemia frontal upper 
teeth, and a large broad chin (Figure 4.1c). The thorax was flat and broad with wide-
spaced nipples and a scoliosis. His hands and fingers were long and hyperlax (Beighton 
score of 4/9). His feet had high arches with hallux valgus bilaterally and his skin revealed 
numerous moles. He had nasal speech and a friendly nature. 
 
Array-based comparative genomic hybridization 
Microarray preparation, hybridization, and data analysis were performed as described 
previously (de Vries et al. 2005). In brief, the array contains 32,447 BAC clones resulting 
in a complete coverage of the human genome (Ishkanian et al. 2004). The array CGH 
profiles were established through co-hybridization of 500 ng Cy3-dUTP labeled patient DNA 
and 500 ng sex-mismatched Cy5-dUTP labeled (Amersham Biosciences) reference DNA. 
After scanning, test-over-reference ratios were determined for each clone, log2-
transformed and normalized by subtracting its local mean log2 test-over-reference ratio 
obtained by a weighted median filter. The normalized ratios were analyzed for loss and 
gain regions by a standard hidden Markov model (HMM). 
 
Copy number screening of the 17q21.31 region by MLPA 
We used MLPA (Schouten et al. 2002) to screen for copy number changes at 17q21.31 in 
the cohort of 840 mentally retarded individuals. A set of uniquely sized MLPA probes, 
hybridizing to exons 3 and 13 of CRHR1, and to exon 2 of MAPT was used. The probes 
were designed according to a protocol provided by MRC-Holland 
(http://www.mlpa.com/index.htm). The three MLPA probes were combined in one MLPA 
assay in conjunction with three standard control probes (VIPR2, MRPL41, and KIAA0056). 
Probe sequences are provided in Table 4.1. Hybridization, ligation and amplification of the 
MLPA probes were performed as described before (Schouten et al. 2002). Amplification  
products were identified and quantified by capillary electrophoresis on a genetic analyzer 
(ABI 3730 or 3100), using GeneMapper software (Applied Biosystems). 
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Data were normalised by dividing each probe’s signal strength by the average control 
probe signal strength of the sample. This normalised peak pattern was divided by the 
average peak height of all the samples in the same experiment. Copy number change 
detection was based on thresholds for gains and losses of 1.30 and 0.70 respectively (±3 
SD). The MLPA analysis was repeated for all samples in which an aberration was identified. 
For these confirmation experiments, DNA samples of healthy controls were used for the 
normalization. 
 
FISH validation studies and de novo occurrence 
The 17q21.31 deletions identified by array CGH and MLPA were validated and tested for de 
novo occurrence by FISH analysis on fixed metaphase spreads from the respective 
patients and their parents as described before (de Vries et al. 2005). BAC clones in the 
aberrant 17q21.31 region were selected and used as probes in the FISH validation assay. 
In addition, parental DNA samples were tested using the same synthetic MLPA probe set 
described above. 
 
Genotyping for H1 and H2, and parent-of-origin analysis 
The presence of an intronic 238-bp deletion in intron 9 of the MAPT gene, characteristic for 
the H2 background (Baker et al. 1999), was used to genotype individuals with the 
17q21.31 deletion and the accompanying parental DNA samples. The 238-bp deletion, if 
present, was determined by visualizing PCR product on an agarose gel. PCR reactions were 
performed using primer sequences GGAAGACGTTCTCACTGATCTG (sense) and 
AGGAGTCTGGCTTCAGTCTCTC (antisense) as described previously (Baker et al. 1999) in a 
25 µl reaction mixture containing 50 ng of template DNA, 10 pmol of each primer, 0.4 mM 
dNTPs, 1.6 mM MgCl2, and 1.25 U Amplitaq Gold Polymerase (Invitrogen). PCR conditions 
were as follows: 3 min 94°C followed by 5 cycles 94°C for 30s, 60°C for 30s, 72°C for 45 
sec. Subsequently, a 10 cycle touchdown from 60°C to 50°C was performed, followed by 
20 cycles 94°C for 30s, 50°C for 30s, 72°C for 45s, with a final extension 72°C for 10 min. 
The dinucleotide marker, DG17S142 in intron 9 of the MAPT gene, was used for 
independent validation of the H1/H2 genotyping Two additional markers, D17S810 and 
D17S920, were used to study the parental origin of the deletions according to standard 
procedures. 
 
Computational analysis 
The chromosome 17 H1 lineage sequence map, was reconstructed for the region of 
interest (40.5 Mb – 42.0 Mb) based on the finished human chromosome 17 sequence. 
Interspersed repeat sequences within the reconstructed DNA sequence were eliminated by 
RepeatMasker (http://genome.ucsc.edu) and the repeat masked genomic sequence was 
analyzed using NCBI BLAST2 for the identification of LCRs (http://www. 
ncbi.nlm.nih.gov/blast/bl2seq/bl2.html). All LCRs identified on H1 were in concordance 
with the previous study of Stefansson et al. (2005). LCR structures for the H2 lineage were 
adapted from Stefansson et al. (2005). The H2 lineage differs from the H1 lineage by a 
common 900-kb inversion polymorphism, the presence of a 32-kb DNA sequence 
(LCR17qE) that is present in two copies on the H2 lineage whereas only once on the H1 
lineage (Stefansson et al. 2005), and the absence of LCR17qC. 
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Results and Discussion 
 
After obtaining informed consent, we tested 360 mentally retarded individuals within a 
diagnostic setting for copy number changes using our genome-wide tiling resolution 
microarray containing 32,477 BAC clones. In one individual, we identified a copy number 
loss with an approximate size of 600 kb at 17q21.31, encompassing eight BAC clones 
(Figure 4.2a). Subsequently, we screened a cohort of 840 mentally retarded individuals 
for deletions in the 17q21.31 region using multiplex ligation-dependent probe amplification 
(Schouten et al. 2002) with probes hybridizing to unique sequences in two genes located 
within this region, MAPT and CRHR1. By doing so, we identified two additional individuals 
with microdeletions in 17q21.31 (Figure 4.2b), with identical genomic sizes and deletion 
breakpoints at the BAC clone level. One of these breakpoints was identical to that of the 
index individual, whereas the other breakpoint was located ~100 kb distal to the first 
(Figure 4.4). For all individuals, we confirmed the presence of the 17q21.31 deletion by 
fluorescent in situ hybridization and showed that it arose de novo (Figure 4.2c-k). In 
addition, the 17q21.31 deletion region has not been reported to show copy number 
variation in normal individuals (Database of Genomic Variants; http://projects.tcag. 
ca/variation/). 
 
We identified the deletions at 17q21.31 in a 3-year-old, moderately mentally retarded girl 
(individual 1), a 17-year-old, moderately mentally retarded woman (individual 2) and a 
26-year-old, moderately mentally retarded male (individual 3). In all three individuals, 
severe hypotonia was present from birth onwards, leading to severely delayed motor 
development. None of the individuals could stand and/or walk before the age of three 
years. Upon physical examination, we noted characteristic facial features. All showed a 
long hypotonic face with ptosis, blepharophimosis, large, low-set ears, tubular pear-
shaped nose with bulbous nasal tip, long columella with hypoplastic alae nasi and a broad 
chin (Figure 4.1). In addition, they all had long fingers, nasal speech and displayed an 
amiable and friendly disposition. The individuals had wide ventricles, as assessed by 
magnetic resonance imaging before the age of 1 year, whereas individual 1 had additional 
periventricular white matter abnormalities. Both individual 2 and individual 3 developed a 
hallux valgus, a pes cavus and, at 13 years of age, a thoracal scoliosis, probably due to 
marked hypotonia (Table 4.2). 
 
 
Figure 4.2 
Analysis of individuals with the 17q21.31 microdeletion syndrome. (a) Chromosome 17 array CGH 
profile of individual 1 with a copy number loss of eight adjacent BAC clones on 17q21.31 (arrow). 
Clones are ordered on the x axis according to physical mapping positions; log2-transformed test-over-
reference (T/R) intensity ratios for each clone are given on the y axis. (b) Multiplex ligation-dependent 
probe amplification (MLPA) analysis, showing a deletion of two probes in CRHR1 and one probe in MAPT 
for both individual 2 (triangles) and individual 3 (squares). The circles represent the MLPA ratios of 
healthy controls. FISH validation of the 17q21.31 deletion in individuals 1, 2 and 3 (c-e) and testing for 
de novo occurrence in the accompanying parents (f-k) using BAC clone RP11-656O14 (red) which is 
located within the deleted region. The centromere 17 probe was included for reference (green). All 
individuals show only one signal for RP11-6565O14 (arrow indicating aberrant chromosome 17). The de 
novo occurrence for the deletion was proven in all individuals. 
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Figure 4.3 
Genotyping for H1 and H2 lineage and parent-of-origin analysis. (a) Genotyping for the H1 (483 bp) 
and H2 (245 bp) lineages. Far left and far right: 100-bp marker lanes. Individual 3 carries the deletion 
on the H2 lineage and is of maternal origin. (b) Individual 1 and the parents were genotyped using 
D17S810, DG17S142 and D17S920 to determine the parental origin of the deletion. The deletion was of 
paternal origin, and was present on the H2 haplotype.  
 
 
 
Notably, the deletions in 17q21.31 are all located within a genomic region that was 
recently reported to harbor a common 900-kb inversion polymorphism (Stefansson et al. 
2005). For this region, two main and highly divergent haplotypes, designated H1 and H2, 
have been found. The H2 lineage, representing the 900-kb inversion polymorphism, is 
found at a frequency of 20% in Europeans and can be distinguished from the H1 lineage 
by genotyping of a dinucleotide marker (DG17S142) in intron nine of MAPT and by a 
characteristic 238-bp deletion in the same intron (Stefansson et al. 2005). For all three 
individuals, one of the parents carried the H2 haplotype: the father of individuals 1 and the 
mother of individual 2 were heterozygous for this haplotype, and the mother of individual 
3 was homozygous (Figure 4.3). Parent-of-origin analysis showed that the deletion 
occurred on the H2 haplotype in individual 1 and 3, whereas the results for individual 2 
were inconclusive (Figure 4.3). Notably, the H2 haplotype differs from the H1 by a 
directly oriented low-copy repeat (LCR), LCR17qE (Figure 4.4) that immediately flanks 
the breakpoints in all three individuals. This suggests that these deletions have resulted
from nonallelic homologous recombination (Lupski 1998), mediated by this H2-specific 
LCR. Consequently, carriers of the H2 lineage are likely to be predisposed to nonallelic
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Table 4.2: Clinical data from individuals with a 17q21.31 deletion 
 Individual 1 Individual 2 Individual 3 
Level of MR Moderate Moderate Moderate 
Hypotonia +++ ++ +++ 
Characteristic face    
   Long + + + 
   Blepharophimosis + + + 
   Ptosis + + + 
   Tubular pear-shaped nose + + + 
   Long columella/ hypoplasic 
   alae nasi 
+ + + 
   Broad nasal tip + + + 
   Large ears + + + 
   Broad chin + + + 
Friendly/amiable behavior + + + 
Brain anomalies WV, PWM WV WV 
MR: mental retardation; +: present; -: absent. Hypotonia: +: mild; ++: moderate; +++: severe.  
Brain anomalies: WV: wide ventricles; PWM: periventricular white matter. 
 
 
 
 
homologous recombination, similarly to predisposing inversion polymorphisms, which have 
been observed in other microdeletion syndromes such as Williams-Beuren syndrome, 
Angelman syndrome and Sotos syndrome (Feuk et al. 2006). 
 
We detected the three individuals with a similar 17q21.31 microdeletion in an unselected 
European cohort of 1,200 individuals with mental retardation, resulting in an overall 
detection frequency of 0.3%. As mental retardation occurs in 2–3% of the general 
population, it can be estimated that the prevalence of this new syndrome is between 1 in 
13,000 and 1 in 20,000. This makes it less common than the estimated population 
prevalence of the 22q11 deletion (DiGeorge-velocardiofacial syndrome) of 1 in 4,000 
(Lindsay 2001) but similar in frequency to Williams-Beuren syndrome, which has a 
frequency of 1 in 10,000 to 1 in 20,000 (Donnai & Karmiloff-Smith 2000). Notably, two 
other single cases have been reported (Shaw-Smith et al. 2004; Varela et al. 2006).  
 
The 17q21.31 deletion encompasses two known genes, CRHR1 (NM_004382) and MAPT 
(NM_005910), and at least two putative genes, IMP5 (NM_175882) and STH 
(NM_001007532). Loss-of-function mutations have not been reported for any of these 
genes in humans. However, gain-of-function mutations in MAPT, encoding the 
microtubule-associated protein TAU, cause autosomal dominant forms of frontotemporal 
dementia and parkinsonism (Hutton et al. 1998; Rademakers et al. 2004). Abnormal 
filamentous TAU deposits have been reported as a pathological characteristic in several 
other neurodegenerative diseases (Rademakers et al. 2004). Haploinsufficiency for the 
microtubule-associated protein TAU may affect axonal elongation and neuronal migration, 
thereby explaining the major clinical features observed in the 17q21.31 microdeletion-
positive individuals (that is, severe hypotonia and moderate mental retardation). In 
support of this, Tau-deficient mice showed muscle weakness and memory disturbance 
(Ikegami et al. 2000; Takei et al. 2000). 
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Figure 4.4 
Transcript map and genomic architecture for the H1 and H2 lineage of the 17q21.31 region based on 
Cruts et al. (2005) and Takai et al. (2000). (Dotted) black lines represent the deleted 17q21.31 region 
identified in the three individuals. Genes located within this region are depicted by black arrows. The H1 
and H2 lineage LCR17q structures are depicted as rectangles with colors signifying shared homology 
and horizontal arrows showing relative orientation (LCR17qA, red; LCR17qB, green; LCR17qC, purple; 
LCR17qD, blue; LCR17qE, yellow). Note the different genomic orientation of H2, the absence of 
LCR17qC and presence of LCR17qE. Cen, centromeric; Tel, telomeric.  
 
 
 
In conclusion, we report a previously unknown, clinically recognizable syndrome defined by 
a 17q21.31 microdeletion that includes MAPT. The deletion is flanked by LCRs and is 
associated with a common inversion polymorphism. This observation underscores the 
relevance of genomic architectural features as the main determinant for the de novo 
occurrence of recurrent segmental aneuploidies. 
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Abstract 
 
Recent studies have revealed a new type of variation in the human genome encompassing 
relatively large genomic segments (~100 kb – 2.5 Mb), commonly referred to as copy 
number variation (CNV). The full nature and extent of CNV and its frequency in different 
ethnic populations is still largely unknown. In this study we characterized a set of twelve 
CNVs previously detected by array CGH. More than 300 individuals from five different 
ethnic populations, including three distinct European, one Asian and one African 
population, were tested for the occurrence of CNV using multiplex ligation-dependent 
probe amplification (MLPA). Seven of these loci indeed showed CNV, i.e., showed copy 
numbers that deviated from the population median. More precise estimations of the actual 
genomic copy numbers for (part of) the NSF gene locus, revealed copy numbers ranging 
from two to at least seven. Additionally, significant inter-population differences in the 
distribution of these copy numbers were observed. These data suggest that insight into 
absolute DNA copy numbers for loci exhibiting CNV is required to determine their potential 
contribution to normal phenotypic variation and, in addition, disease susceptibility. 
 
 
Introduction 
 
The genomic landscape shows marked variation in the distribution of a number of features 
such as single nucleotide polymorphisms (SNPs), various repeats such as LINEs and 
SINEs, microsatellite repeat polymorphisms and insertion/deletion polymorphisms. 
Recently, the use of genome-wide molecular methods such as array-based comparative 
genomic hybridization (array CGH) (Iafrate et al. 2004; de Vries et al. 2005; Sharp et al. 
2005), representational oligonucleotide microarray analysis (ROMA) (Sebat et al. 2004), 
fosmid end-sequencing (Tuzun et al. 2005) and SNP arrays (Wirtenberger et al. 2006) 
have revealed the existence of an additional class of large-scale genomic variations. These 
variations may encompass genomic segments ranging in size from ~100 kb to ~2.5 Mb, 
and are commonly referred to as copy number variations (CNVs). In addition, ~1,000 
intermediate length common deletion variants (<10 kb) have been identified and 
characterized in the human genome by taking advantage of technologies designed to 
catalogue SNPs present in the human population (Conrad et al. 2006, Hinds et al. 2006; 
McCarroll et al. 2006). Remarkably, comparison of DNA copy number variations identified 
in the studies mentioned above showed very little overlap (Eichler 2006). Even when 
regions were reported to show CNV in multiple studies, the frequencies at which they were 
reported often differed markedly. 
 
The discrepancies observed between these studies may be due to differences in the 
technologies used to identify copy number variation, i.e., the resolution of the platforms 
used and the difficulty in discriminating between true variation and experimental noise due 
to lack of proper validation. In addition, the discrepancies may be related to the selection 
of normal control individuals used for assessing the CNVs. For insertion/deletion 
polymorphisms, for example, it is known that allele frequencies differ between populations 
with different ethnic backgrounds (Weber et al. 2002). As yet, there is almost no 
information available on the actual copy numbers at which different CNV regions are 
present within a given population. Because of the comparative nature of most array-based 
studies, regions are reported to show a relative loss or gain as compared to a reference 
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sample or a pool of references. Based on the variation present, however, the selection of 
references may affect the relative frequencies of gains or losses observed. 
 
Although the mechanisms by which CNVs arise are largely unknown, it has been suggested 
that certain genomic features such as low copy repeats (LCRs) may be involved in the 
formation of common CNVs (Hind et al. 2006; McCarroll et al. 2006). LCRs are defined as 
genomic segments >1kb in size that occur in two or more copies per haploid genome, with 
the different copies sharing >90% sequence identity. These LCRs may mediate nonallelic 
homologous recombination (NAHR), a mechanism known to lead to the formation of 
deletions and duplications associated with genomic disorders (Inoue & Lupski 2002; Shaw 
& Lupski 2004). Additionally, gaps in the genome assembly, representing sequences with 
high repeat content including LCRs, may point at regions prone to CNV (Bailey et al. 2001; 
Zody et al. 2006). 
 
For this study we selected twelve recently detected CNV regions, based on their reported 
high frequencies in the general population (Iafrate et al. 2004; de Vries et al. 2005; 
http://projects.tcag.ca/variation). We characterized these regions for genomic 
architectural features and used multiplex ligation-dependent probe amplification (MLPA; 
Schouten et al. 2002; White et al. 2004) to determine CNV frequencies in five ethnic 
populations, including three distinct European, one Asian and one African population, in 
total comprising more than 300 individuals. In addition, using these semi-quantitative 
MLPA results we attempted to estimate the actual DNA copy numbers present in the 
different populations tested. Our analyses underscore the presence of both intra- and 
inter-population differences in DNA copy number variation. These differences may be 
relevant for normal phenotypic variation and/or disease susceptibility. 
 
 
Material and Methods 
 
Individuals of different ethnic populations 
DNA samples from normal, healthy individuals from five different ethnicities (Dutch 
(n=84), Turkish (n=64), Finnish (n=36), Indonesian (n=88) and African Pygmy (n=37)) 
were used to assess CNV distribution by multiplex ligation-dependent probe amplification 
(MLPA; see below). All DNA samples were isolated from peripheral blood leucocytes and 
were obtained through appropriate informed consent. The Dutch, Finnish and Turkish 
DNAs were isolated using a QIAamp kit (QIAgen, Valencia CA) according to instructions of 
the manufacturer. The remaining samples were isolated using standard desalting DNA 
isolation procedures. 
 
Selection of regions with CNV 
From the database of genomic variation (http://projects.tcag.ca/variation) twelve CNV 
regions were selected for assessment (Table 5.2). This selection was based on their 
estimated high frequencies in the general population (>5%). All CNVs were previously 
identified by array CGH (Table 5.2). 
 
MLPA probe design 
MLPA probe design was performed as described by Schouten et al. (2002), and White et 
al. (2004). The oligonucleotides were purchased from Illumina Inc. (San Diego, CA) or 
Isogen (IJsselstein, the Netherlands). At least two probes were selected within each
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genomic region, and exon sequences were preferentially chosen. Control probes were 
selected from known autosomal dominant disease genes (CREBBP, EP300, EXT1, EXT2), 
which would not be deleted or duplicated without an obvious phenotype. For genes 
classified as single copy in the genome browser, probes were designed such that they only 
recognized a single genomic sequence. For genes known to be present in duplicons, 
probes were designed such that they only recognized sequences within the selected 
region. Where significant homology to multiple regions was indicated by BLAT analysis 
(Kent 2002) an attempt was made to position the ligation site of the two oligonucleotides 
over a mismatch, thus allowing accurate discrimination from related sequences. The probe 
sequences are listed in Table 5.1. 
 
MLPA assay and data analysis 
The MLPA assay was carried out as described before (White et al. 2004). In short, for each 
MLPA reaction 100-200 ng genomic DNA was used, and the PCR reactions were performed 
for 31-33 cycles. Subsequently, the PCR products were analyzed on either an ABI 3700 or 
an ABI 3730 capillary sequencer (Applied Biosystems) and the obtained data were 
normalized as described before (White et al. 2004). Briefly, probes in a given colour were 
normalized against at least two control probes of the same colour. For each locus there 
was at least one probe in each colour, so each locus was in fact analyzed by two 
independent calculations. 
 
The height of each probe-specific peak was divided by the sum of at least two control 
peaks to give a ratio. The median ratio for each locus across all samples per population 
within an assay was calculated and used to normalize the ratios around a value of 1. Initial 
analysis set thresholds for gains or losses of 1.25 and 0.75, respectively. A gain or loss 
was only scored if at least two probes within a given locus were outside the thresholds. 
 
For validation of CNV detection by MLPA, normalized MLPA results for several individual 
CNV regions were log2 transformed and subsequently compared to array CGH results that 
were previously obtained by de Vries et al. (2005). For these validation studies, the same 
series of 100 patient DNA samples was used as described in de Vries et al. (2005). For the 
DEFB, NSF and TBC1D3 loci, in which most variation was seen, further analysis was 
performed by averaging the value of all probes within each locus per sample.  
 
Genotyping H1 and H2 on 17q21.31 
The presence of a 238-bp deletion in intron 9 of the MAPT gene, characteristic for the H2 
line, was used to genotype the Dutch individuals. The 238-bp deletion was determined 
through visualizing PCR products on agarose gels. PCR reactions were performed using 
primer sequences GGAAGACGTTCTCACTGATCTG (sense) and AGGAGTCTGGC-
TTCAGTCTCTC (antisense) as described previously (Baker et al. 1999) in a 25 µl reaction 
mixture containing 50 ng of template DNA, 10 pmol of each primer, 0.4 mM dNTPs, 1.6 
mM MgCl2, and 1.25 U Amplitaq Gold Polymerase (Invitrogen). PCR conditions were as 
follows: 3 min 94°C followed by 5 cycles 94°C for 30s, 60°C for 30s, 72°C for 45s. 
Subsequently, a 10 cycle touchdown from 60°C to 50°C was performed, followed by 20 
cycles 94°C for 30s, 50°C for 30s, 72°C for 45s, with a final extension 72°C for 10 min. 
 
LCR identification by computational analyses 
The presence and location of LCR structures were reconstructed using computational 
analysis. In brief, genomic sequences were downloaded from the UCSC genome browser 
and interspersed high copy repeat sequences were eliminated by RepeatMasker 
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(http://genome.ucsc.edu). Next, the repeat-masked genomic sequence was analyzed 
using NCBI BLAST2 for the identification of LCRs (http://www.ncbi.nlm.nih.gov/ 
blast/bl2seq/bl2.html). 
 
 
Results 
 
Selection, characterization and validation of recurrent CNVs 
From the Database of Genomic Variants, we selected twelve genomic regions for the 
assessment of CNV in different ethnic populations. These regions, all recently detected by 
array CGH, were reported to show frequent CNV (http://projects.tcag.ca/variation) and 
varied in size from 119 kb to 2.57 Mb. Although for most regions multiple studies have 
indicated the presence of CNV, the frequencies at which CNV was detected differed 
markedly (Table 5.2). Since genomic architectural features such as LCRs and gaps in the 
genome assembly may be related to the presence of CNV at specific genomic locations, we 
evaluated the presence of such features for the twelve regions selected (Table 5.2 and 
Figure 5.1). Gaps present within 100 kb of a CNV were documented for three of the 
selected regions, i.e., 8p23.1, 10q11.22 and 17q12. LCRs within or flanking a CNV were 
found to be present in eight of the selected regions, and insertion/deletion polymorphisms 
were reported in one of the selected regions (2q35). In three regions, combinations of 
gaps and LCRs were observed, thus contributing to the complexity of the regions under 
evaluation. In addition to LCRs and gaps, another genomic architectural feature was 
observed, namely a 900 kb inversion polymorphism within the 17q21.31 region 
(Stefansson et al. 2005). These data support the notion that these specific genomic 
architectural features may be related to the occurrence of CNV. 
 
The presence of gaps and complex repeat structures within and/or in close proximity to 
loci exhibiting CNV could hamper MLPA probe design, thereby affecting the detection of 
CNVs in the individuals to be tested. Therefore, we first validated the MLPA performance 
for this type of analysis. In addition, the MLPA results for six of the twelve regions were 
compared to previously obtained array CGH results in a cohort of 100 patients with mental 
retardation (de Vries et al. 2005). Figure 5.2 shows an example of such a correlation for 
the CNV locus at 17q12. The MLPA probes showed a consistent performance over two 
experiments. Furthermore, all patient samples showing gains and losses by array CGH also 
showed higher and lower MLPA values, respectively, for the probe(s) located within this 
CNV region. Similar results were obtained for the five other regions tested. From these 
data we conclude that the MLPA technique is suitable for the reliable detection of DNA 
copy number variation. 
 
Assessment of selected recurrent CNVs in different ethnic populations 
In order to assess the occurrence of recurrent CNVs in different ethnic populations, the 
twelve selected CNV regions were tested by MLPA in DNAs derived from 309 individuals 
from Dutch, Finnish, Turkish, Pygmy and Indonesian origin. All data were independently 
normalized per population, allowing the detection of inter- and intra-population 
differences. It is important to note that an MLPA value of 1.0 in this study represents the 
population-specific copy number median, and does not necessarily represent the usual 
standard of two copies. As a first analysis, the number of individuals with either a gain or a 
loss at each locus was determined. For this analysis, thresholds for relative gain and loss 
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from the median of the population were set at 1.25 and 0.75, respectively. These values 
have been routinely used in MLPA screening for deletions and duplications in single copy 
loci. Using this approach, CNV was observed in all populations tested for seven out of 
twelve selected loci. CNV frequencies at these seven loci ranged from 3% to 52% (of all 
309 individuals; Table 5.3). In the remaining five regions, however, no significant CNV 
was observed in any of the populations tested (Table 5.3). 
 
For four of the seven regions showing moderate CNV, including 5q13.2, 10q11.22, 14q11 
and 22q11.21, no significant difference was seen between populations for any of the loci 
tested (Bionominal test with normal approximation p>0.05). The regions exhibiting the 
highest degree of CNV within each population encompassed the beta defensin cluster 
(8p23.1; 26% of all individuals showed CNV), the TBC1D3 gene (17q12; 24% of all 
individuals showed CNV), and the proximal part of the NSF gene (17q21.31; 52% of all 
individuals showed CNV). 
 
In an attempt to estimate the actual copy numbers present for the three most variable loci 
within each population, we analyzed the MLPA results semi-quantitatively. This was 
achieved by calculating the average probe values within each locus per individual, which 
were then ranked from low to high. In addition, the percentiles 10%, 25%, 50%, 75% and 
90% were calculated in order to observe inter-population differences in the distribution of 
the actual copy numbers (Figure 5.3). By doing so, we observed a ~3.5 fold change 
between the lowest and highest MLPA values for the beta defensin gene cluster. With a 
previously determined minimal copy number of two (Hollox et al. 2003), our data indicate 
a copy number range from two to seven in the majority of all populations. The 10% to 
90% percentiles for the beta defensin gene region, however, differed by <10% over all 
populations, suggesting that the frequencies of the actual copy numbers are largely the 
same within each population. There were, however, clear differences in the percentiles 
between populations for TBC1D3 (Figure 5.3). Significant differences can be found when 
performing Fisher's exact test on pairwise comparisons of population-specific discretized 
ratios using various cut-offs for the TBC1D3 locus (1.3, 1.4, 1.5; p<0.05), while the same 
comparisons yielded no significant differences with the same discretizations for the beta 
defensin gene cluster. However, since we are not able to estimate absolute copy numbers, 
we cannot take this analysis for either the beta defesin gene cluster or the TBC1D3 gene 
locus any further. 
 
In contrast, subgroups of individuals displaying different NSF gene copy numbers were 
evident in all populations tested (Figure 5.4a-b). Subgroups were identified and 
 
 
 
Figure 5.1 
Examples of genome architecture and MLPA probe locations. (a), 17q12 (b) and 17q21.31. Note that 
for the 17q21.31, a 900-kb inversion polymorphism including the NSF locus has been observed in the 
general population, represented by the H1 and H2 orientation (Stefansson et al. 2005). For all regions, 
Mb position, cytoband, BAC clones, genes located within the region, LCRs/ GAPs (if present) and the 
location of the MLPA probes are depicted. The BAC clones that were previously reported to show CNV 
are colored red (Genome Variation Database). The LCR structures, if present, are depicted in colors to 
better represent their positional orientation with respect to each other. The locations of the MLPA 
probes are indicated by vertical orange solid lines, whereas dotted orange lines indicate alternative 
MLPA locations, sharing high homology to the region the probe was originally designed for. 
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confirmed by applying hierarchical clustering using complete linkage. For estimations of 
the NSF copy numbers present in the populations tested, we extrapolated the findings of a 
previous study using an Icelandic population (Stefansson et al. 2005), which indicated that 
the minimum copy number present for this region is two. Based on the best-fit correlation 
coefficient all populations, apart from the Pygmy population, appeared to have copy 
numbers ranging from two to at least seven (Figure 5.4c). In the Dutch and Turkish 
populations the median copy number was three, whereas in the Finnish, Pygmy and 
Indonesian populations this median was four (Figure 5.5). The actual degree of CNV in 
four of the populations, i.e., individuals with a copy number deviating from the median, 
was virtually identical, ranging from 66% to 69%. In the Pygmy population only 49% of 
the individuals showed CNV. The relative frequency of different copy numbers between the 
five populations did show marked differences (Chi-square test; p<0.001) (Figure 5.5). A 
highly significant difference was seen between the Dutch and Indonesian populations (Chi-
square test; p<0.001). The Indonesian population showed a skew towards higher copy 
numbers, with 40% of the individuals having five or more copies. This percentage was 
markedly different from the Dutch population, in which only 12% of individuals exhibited 
five or more copies. In contrast, there was no significant difference observed between the 
Dutch and Turkish populations (Chi-square test; p=0.469). 
 
For the 900-kb inversion polymorphism at 17q21.31, containing the NSF gene, two main 
and highly divergent haplotypes, designated H1 and H2, have been unveiled (Stefansson 
et al. 2005). H2 can be distinguished from H1 by a characteristic 238-bp deletion in intron 
nine of the MAPT gene (Baker et al. 1999). In order to establish a correlation between the 
NSF copy numbers and the respective genotypes, individuals from the Dutch population 
were genotyped for these haplotypes. Previous work by Stefansson et al. (2005) has 
shown that the H2 allele contains two copies of the proximal part of the NSF gene. All 
individuals with an H2/H2 haplotype showed MLPA ratios compatible with the presence of 
four copies (Figure 5.4d), thus further confirming our copy number estimates. In 
addition, all individuals with two copies as indicated by MLPA analysis were genotyped 
H1/H1, whereas individuals showing three copies for the NSF gene exhibited a H1/H2 
 
 
 
Figure 5.2 
Validation of the MLPA assay for detection of CNV exemplified by the 17q12 region and MLPA probes 
TBC1D3 probe exon 4 and TBCID3 probe exon 12 respectively. (a) For each region, two MLPA probes 
were designed. Panel A shows the correlation between the two probes, TBC1D3 probe exon 4 and 
TBC1D3 probe exon 12, targeted to the 17q12 region in one experiment (R2=0.8179). (b) The 
reproducibility was tested by determining the correlation between two successive experiments. For this, 
the correlation between the mean of the two TBC1D3 probes in experiment 1 and the mean of the two 
TBC1D3 probes in experiment 2 was determined (R2=0.7950). (c) Correlation between array CGH 
results and MLPA results for CNV at 17q12. For this, the average array CGH log2 T/R ratios for the 
clones located in the CNV at 17q12 was calculated (x axis) and compared to the average MLPA value of 
the two MLPA probes for the 17q12 region (y axis). The diagonal black line is a regression line for the 
correlation between the two techniques (R2=0.50). (d) Correlation between array CGH interpretation 
and MLPA results for the same 17q12 CNV locus. Based on array CGH results, patients were categorized 
as ‘loss’, ‘normal’ or ‘gain’, for showing relative copy number loss or gain, respectively (de Vries et al. 
2005). On the y-axis, the average MLPA values of all patients per category are shown. The black 
horizontal bars indicate mean MLPA value per category for the 17q12 locus. 
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Figure 5.3 
Interpopulation percentile differences for the beta defensin gene cluster and the TBC1D3 and NSF gene 
loci. MLPA normalized ratios at the percentiles 10%, 25%, 50% 75% and 90% for the beta defensin 
gene cluster (a), TBC1D3 gene locus (b) and NSF gene locus (c). For the beta defensin gene cluster, 
the percentiles differ <10% between populations, whereas for the TBC1D3 and NSF gene loci 
differences were observed that suggest distinct inter-population differences in copy number 
distribution. 
 
 
 
heterozygous haplotype (Figure 5.4d). Together, these results suggest a relationship 
between the haplotype and the NSF copy numbers observed.  
 
 
Discussion 
 
In contrast to SNPs, of which over one million variants and their frequencies in four 
different ethnic populations have recently been described (International HapMap 
consortium 2005), little is known about the relative DNA copy numbers and frequencies of 
CNVs in different ethnic populations. Previous studies, using a combination of different 
array platforms and computational algorithms, have provided a first insight into the
a b 
c 
  
  
 
  
  
  
  
  
 
8
1
 
  
 
T
a
b
le
 5
.3
: 
C
N
V
 f
r
e
q
u
e
n
c
y
 i
n
 e
th
n
ic
 p
o
p
u
la
ti
o
n
s
 
                  
 
 
C
N
V
 r
e
g
io
n
 
1
p
3
2
.3
 
2
q
3
1
.1
 
2
q
3
5
 
5
q
1
3
.2
 
7
p
2
1
.1
 
7
q
3
5
 
8
p
2
3
.1
 
P
o
p
u
la
ti
o
n
 
lo
s
s
a
 
G
a
in
b
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
P
y
g
m
y
 (
n
=
3
7
) 
0
 
0
 
0
 
0
 
0
 
0
 
5
 
5
 
0
 
0
 
0
 
0
 
1
1
 
2
1
 
In
d
o
n
e
s
ia
n
 (
n
=
8
8
) 
0
 
0
 
0
 
0
 
0
 
0
 
2
 
2
 
1
 
0
 
0
 
0
 
1
4
 
1
3
 
D
u
tc
h
 (
n
=
8
4
) 
0
 
0
 
0
 
0
 
0
 
0
 
2
 
6
 
0
 
0
 
0
 
0
 
1
0
 
1
5
 
T
u
rk
is
h
 (
n
=
6
4
) 
0
 
0
 
0
 
0
 
n
d
 
n
d
 
2
 
6
 
n
d
 
n
d
 
0
 
0
 
1
3
 
1
6
 
F
in
n
is
h
 (
n
=
3
6
) 
0
 
0
 
0
 
0
 
6
 
0
 
3
 
0
 
0
 
0
 
0
 
0
 
6
 
1
7
 
T
o
ta
l 
(n
=
3
0
9
) 
0
 
0
 
0
 
0
 
<
1
 
0
 
3
 
4
 
<
1
 
0
 
0
 
0
 
1
1
 
1
5
 
C
N
V
 r
e
g
io
n
 
1
0
q
1
1
.2
2
 
1
4
q
1
1
 
1
7
q
1
2
 
1
7
q
2
1
.3
1
-N
S
F
 
e
x
o
n
 2
,9
,1
2
 
1
7
q
2
1
.3
1
-N
S
F
 
e
x
o
n
 1
4
c
 
2
2
q
1
1
.2
1
 
P
o
p
u
la
ti
o
n
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
lo
s
s
 
g
a
in
 
P
y
g
m
y
 (
n
=
3
7
) 
0
 
8
 
0
 
5
 
1
6
 
1
6
 
1
9
 
1
1
 
0
 
0
 
3
 
5
 
In
d
o
n
e
s
ia
n
 (
n
=
8
8
) 
0
 
3
 
2
 
6
 
1
1
 
1
9
 
2
4
 
2
0
 
1
 
1
 
1
 
1
 
D
u
tc
h
 (
n
=
8
4
) 
1
 
6
 
4
 
6
 
4
 
1
0
 
2
8
 
2
9
 
0
 
0
 
0
 
1
 
T
u
rk
is
h
 (
n
=
6
4
) 
3
 
8
 
8
 
9
 
8
 
1
3
 
2
3
 
3
6
 
0
 
0
 
0
 
2
 
F
in
n
is
h
 (
n
=
3
6
) 
0
 
1
1
 
3
 
6
 
1
7
 
1
1
 
3
1
 
2
5
 
3
 
0
 
6
 
6
 
T
o
ta
l 
(n
=
3
0
9
) 
1
 
6
 
4
 
7
 
1
0
 
1
4
 
2
4
 
2
8
 
<
1
 
<
1
 
1
 
2
 
    81 
a
: 
P
e
rc
e
n
ta
g
e
 o
f 
in
d
iv
id
u
a
ls
 w
it
h
 a
t 
le
a
s
t 
tw
o
 p
ro
b
e
s
 h
a
v
in
g
 a
 n
o
rm
a
li
z
e
d
 r
a
ti
o
 b
e
lo
w
 0
.7
5
  
b
: 
P
e
rc
e
n
ta
g
e
 o
f 
in
d
iv
id
u
a
ls
 w
it
h
 a
t 
le
a
s
t 
tw
o
 p
ro
b
e
s
 w
it
h
 a
 n
o
rm
a
li
z
e
d
 r
a
ti
o
 a
b
o
v
e
 1
.2
5
 
c
: 
C
a
lc
u
la
ti
o
n
s
 f
o
r 
N
S
F
 e
x
o
n
 1
4
 a
re
 b
a
s
e
d
 o
n
 a
 s
in
g
le
 p
ro
b
e
. 
n
d
 =
 n
o
t 
d
e
te
rm
in
e
d
 
     Chapter 5      
   
 
            
82 
occurrence of CNVs in normal healthy individuals (Fredman et al. 2004; Iafrate et al. 
2004; Sebat et al. 2004; de Vries et al. 2005; Sharp et al. 2005; Tuzun et al. 2005; 
Conrad et al. 2006; Hinds et al. 2006; McCarroll et al. 2006). Here, we have focused on 
twelve genomic regions previously identified as showing recurrent CNV. Using multiplex 
ligation-dependent probe amplification (MLPA), a technique perfectly suited for semi-
quantitative analysis of a large cohort of individuals (Schouten et al. 2002; Koolen et al. 
2004; Rooms et al. 2006), we found significant CNV in seven of these twelve regions in all 
ethnic populations studied. In addition, we observed significant inter-population 
differences in DNA copy number frequencies for the TBC1D3 and NSF gene loci. 
 
The five regions for which no CNV was detected differ from the other seven in several 
aspects. Four of these regions were reported to show CNV in only one study (Iafrate et al. 
2004), whereas all other regions were reported to show CNV in multiple studies. Related to 
this, the identification of these five CNVs in the original study by Iafrate et al. (2004) was 
based on a single array target, i.e., one BAC clone, whereas the other seven CNV regions 
were identified by multiple array targets. The fact that these results were based on only 
one measurement in one study, not validated by other technologies, questions the validity 
of these initial CNV observations. The genomic architecture of these five regions also 
differs from the other seven. All regions for which CNV was identified in this study were 
flanked or (partly) covered by LCRs. Additional indications for the involvement of LCRs in 
these common CNV regions are provided by our detailed analysis of the NSF gene locus for 
which four MLPA probes were tested. Three of these probes were located within a LCR that 
partly covers the NSF gene, whereas one probe was located more proximally, outside this 
LCR. CNV was only observed for the MLPA probes that were located within the LCR. Our 
data therefore support the hypothesis that recurrent large-scale and intermediate-sized 
CNVs (‘CNV hotspots’) are mediated by LCRs. In addition, there may be a second class of 
CNVs that is only detected in single parent-offspring trios (‘rare variants’), which may not 
be mediated by specific genomic architectural features such as LCRs. The five regions not 
showing CNV in this study could represent such rare variants, although they were 
specifically chosen based on presumed frequencies of >5% reported in one or more
 
 
 
Figure 5.4 
Examples of normalized copy number ratios of the NSF gene for the Indonesian and Dutch populations. 
For each individual the average value of the probes within the CNV was calculated and, subsequently, 
ordered from low to high. Subgroups corresponding to different DNA copy numbers were defined by eye 
and cluster analysis, and are delineated by vertical dotted lines. By calculating the relative differences 
between each subgroup (‘steps’), we estimated the actual DNA copy numbers. For the Indonesian 
population (a) the lowest ratio is ~0.50 with steps of ~0.25. For the Dutch population (b) the lowest 
ratio is ~0.66 with steps of ~0.33. The lowest copy number in each population is two copies, indicating 
that the median copy number within the Indonesian population is four whereas for the Dutch population 
a median copy number of three is observed. Both populations, however, show a similar copy number 
range from two to at least seven copies. The best-fit regression analyses (c) show that copy numbers 
are reliably estimated for the Indonesian (R2 =0.9967; red) and Dutch populations (R2=0.9964; black), 
respectively. (d) Genotypes for H1 and H2 of individuals of the Dutch population (indicated by red 
boxes in panel c). All individuals exhibiting the presence of two copies by MLPA analysis were 
genotyped H1/H1, whereas individuals with three copies showed a H1/H2 genotype. In addition, a 
number of the individuals showing four copies by MLPA analysis showed a homozygous H2/H2 
genotype.  
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previous studies. Several examples of this class of rare variants have been reported before 
(de Vries et al. 2005; Conrad et al. 2006). Alternatively, technical aspects may be the 
explanation for not detecting CNV for these five regions. One such aspect is the MLPA 
probe location. For each region, the MLPA probes are targeted to only (a few) hundred 
basepairs of the BAC clones described. Therefore, if only a part of the BAC clone (with an 
average genomic size of ~170 kb) shows CNV, this CNV may be missed by the MLPA 
assay. 
 
For seven genomic regions, significant CNV was detected in all populations. We analyzed 
this variation by two different approaches. First we used a standard classification into copy 
number gain, copy number loss or no copy number variation, using MLPA thresholds for 
copy number gain and loss of 1.25 and 0.75, respectively. By doing so, copy number 
variation of these seven loci was observed in all populations tested. Furthermore, we found 
that the percentages of the population showing CNV for a locus, i.e., the percentages of 
individuals with copy numbers other than the population median, were virtually identical 
between the populations tested. Regions for which most variation was observed (24-52%) 
included 8p23.1, 17q12 and 17q21.31. For four other regions, 5q13.2, 10q11.22, 14q11 
and 22q11.21, we observed CNV at lower frequencies (3-11%). The percentages of 
individuals showing CNV for these seven regions were within the range of frequencies as 
reported previously by others (see Table 5.2). Although this analysis was useful for 
gaining insight into the frequencies of occurrence, it failed to provide detailed information 
on the actual copy numbers of the CNV loci tested. 
 
Therefore, as a second approach, we set out to obtain such detailed information from our 
semi-quantitative MLPA analyses. After ranking the MLPA values from low to high per 
population, we could clearly define subgroups for (part of) the NSF gene. These MLPA-
defined subgroups indicated a copy number range from two to seven in four out of five 
populations tested, which is in concordance with a previous report by Stefansson et al. 
(2005). The frequencies at which these actual copy numbers were detected within 
populations differed markedly. In addition, the population-specific median copy numbers 
varied between populations. By using traditional approaches for looking at CNVs, these 
inter-population differences would have escaped attention. In fact, based on our first 
approach, these populations seemed rather similar to each other regarding CNV, all having 
~50% of individuals showing CNV (see Table 5.3). Furthermore, this semi-quantitative 
copy number analysis resulted in higher CNV percentages as compared to the standard 
copy number analysis. For instance, after estimation of the actual copy numbers for the 
NSF gene locus, approximately 70% of individuals within four of the populations tested 
showed copy numbers different from the population median, as compared to 52% of the 
individuals by our first approach. These observations strongly suggest that the standard 
approach of classifying individuals into ‘loss’, ‘normal’ and ‘gain’ to characterize CNVs is 
inadequate. 
 
The 17q21.31 region, containing the NSF gene, is associated with a complex genomic 
architecture, involving an inversion polymorphism (Stefansson et al. 2005). Two main 
haplotypes have been identified for this inversion, designated H1 and H2, respectively. The 
H2 lineage, representing the inversion polymorphism, is found at a frequency of 20% in 
European populations, whereas a frequency of 1% is found in Asian populations. 
Interestingly, de novo deletions within this inversion polymorphism have recently been
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Figure 5.5 
Inter-and intra-population differences in NSF copy number estimations. Different copy numbers are 
displayed as a percentage of the total population (see also Figure 5.4). The most significant difference 
is seen between the Dutch and Indonesian populations. (p<0.0001). 
 
 
 
described and define a previously unrecognized genomic disorder, potentially accounting 
for as many as 1% of all mental retardation cases (Chapter 4; Shaw-Smith et al. 2006; 
Sharp et al. 2006). Our results showed that Dutch individuals homozygous for the H2 
haplotype carry four copies of the NSF region exhibiting CNV (exons 2, 9 and 12), whereas 
individuals with two copies showed a H1/H1 haplotype. These results indicate that the H1 
allele contains one NSF copy whereas the H2 allele contains two NSF copies, which is in 
concordance with previous results (Stefansson et al. 2005). This notion is further 
substantiated by the observation that H1/H2 heterozygous individuals showed three copies 
of the NSF gene. We observed a small percentage of Indonesian individuals with three NSF 
copies, which may be explained by the low frequency of the H2 haplotype in Asian 
populations. The presence of copy numbers of four and higher can be explained by the fact 
that the H1 haplotype can be subdivided into HD1 and HD3, containing one and three copies 
of the proximal part of the NSF gene, respectively (Stefansson et al. 2005). This 
subdivision may also explain why not all individuals of the Dutch population with four 
copies showed a homozygous H2/H2 genotype, i.e., individuals homozygous for H1 but 
with HD1 and HD3 alleles will also have four copies of the proximal part of the NSF gene.  
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Another region for which actual copy numbers were estimated is the beta defensin gene 
cluster region at 8p23.1. Assuming that the lowest copy number is two, the majority of 
individuals of all populations have either three or four copies of the beta defensin gene, 
with a copy number range from two to seven, which is consistent with previous studies 
(Hollox et al. 2003). In contrast to the NSF locus, we did not observe any differences in 
distribution of the actual copy numbers between populations. Estimation of the actual copy 
numbers appeared to be more problematic for the TBC1D3 gene (17q12), because no 
obvious subgroups were observed. These results are consistent with relatively high copy 
numbers in all populations tested. Further support for this observation comes from the 
signal intensity of the two TBC1D3 probes used, which was consistently the highest of all 
probes present in the assay. In agreement with this notion, detailed analysis of the LCR 
structures within this region showed that TBC1D3, encompassing the MLPA probes, is 
located within an LCR which is present in eight copies in 17q12. 
 
The first biological consequences of copy number variation for a single gene have recently 
been reported (Gonzalez et al. 2005; Aitman et al. 2006). Here, we show the presence of 
a continuous spectrum of copy numbers in several CNV hotspots, ranging from two to at 
least seven. We and others hypothesize that different copies within this spectrum may 
have different phenotypic consequences and, ultimately, may lead to disease if copy 
numbers exceed certain threshold levels (Pinkel & Albertson 2005). Similar mechanisms 
are known to cause monogenic diseases such as autosomal dominant facioscapulohumeral 
muscular dystrophy (FSHD1A), which is known to be due to variations in the D4Z4 repeat. 
This repeat consists of identical 3.3 kb units, varying from 11 to 100 copies (33 kb – ~300 
kb) in normal healthy individuals, whereas patients with FSHD1A carry 1–10 copies 
(Wijmenga et al. 1992; van Deutekom et al. 1993). We suggest that insight into the actual 
DNA copy numbers for loci exhibiting CNV is required to determine their potential 
contribution to normal phenotypic variation and, in addition, disease susceptibility.  
 
In conclusion, we have shown CNV for seven out of twelve selected loci in multiple 
populations using MLPA, and analyzed the observed variation by two approaches. A 
detailed analysis of actual copy numbers showed inter- and intra-population differences, 
implying that there is more to studying CNV than ‘simply’ scoring individuals for copy 
number gain or loss. Such information may turn out to be essential for understanding the 
role of DNA copy numbers in normal phenotypic variation and disease susceptibility. 
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Abstract 
 
Recent molecular cytogenetic data have shown that the constitution of complex 
chromosome rearrangements (CCRs) may be more complicated than previously thought. 
The complicated nature of these rearrangements challenges the accurate delineation of the 
chromosomal breakpoints and mechanisms involved. Here, we report a molecular 
cytogenetic analysis of two patients with congenital anomalies and unbalanced de novo 
CCRs involving chromosome 17p using high-resolution array-based comparative genomic 
hybridization (array CGH) and fluorescent in situ hybridization (FISH). In the first patient, 
a 4-month-old boy with developmental delay, hypotonia, growth retardation, coronal 
synostosis, mild hypertelorism, and bilateral club feet, we found a duplication of the 
Charcot-Marie-Tooth disease type 1A (CMT1A) and Smith-Magenis syndrome (SMS) 
chromosome regions, inverted insertion of the Miller-Dieker lissencephaly syndrome 
(MDLS) region into the SMS region, and two microdeletions including a terminal deletion of 
17p. The latter, together with a duplication of 21q22.3-qter detected by array CGH, are 
likely the unbalanced product of a translocation t(17;21)(p13.3;q22.3). In the second 
patient, an 8-year-old girl with mental retardation, short stature, microcephaly and mild 
dysmorphic features, we identified four submicroscopic interspersed 17p duplications. All 
17 breakpoints were examined in detail by FISH analysis. We found that four of the 
breakpoints mapped within known low-copy repeats (LCRs), including LCR17pA, middle 
SMS-REP/LCR17pB block, and LCR17pC. Our findings suggest that the LCR burden in 
proximal 17p may have stimulated the formation of these CCRs and, thus, that genome 
architectural features such as LCRs may have been instrumental in the generation of these 
CCRs. 
 
 
Introduction 
 
The majority of constitutional chromosomal abnormalities are thought to be simple 
rearrangements, involving less than three breaks in one or two chromosomes. It is known 
that genomic architectural features such as low-copy repeat (LCR) structures may play an 
important role in the formation of these abnormalities (Lupski 1998; Stankiewicz & Lupski 
2002). LCRs, also termed segmental duplications or duplicons, encompass apparently 
normal stretches of genomic DNA, often containing genes. LCRs are present in more than 
one copy in the genome and are defined by a ≥ 1 kb size and a >90% sequence identity 
(Bailey et al. 2001; Eichler 2001; Bailey et al. 2002). LCRs can mediate recurrent DNA 
rearrangements such as deletions, duplications and inversions through chromosome or 
chromatid misalignment followed by nonallelic homologous recombination (NAHR). The 
majority of the currently known chromosome microdeletion/duplication syndromes result 
from NAHR between large (usually >10 kb), highly identical (>95%) LCRs and are, 
therefore, also termed genomic disorders (Lupski 1998; Stankiewicz & Lupski 2002; Lupski 
& Stankiewicz 2006). In addition to recurrent events, breakpoints of nonrecurrent 
rearrangements have been associated also with genomic architectural features including 
LCRs and AT-rich palindromic sequences (Stankiewicz et al. 2003; Shaw & Lupski 2004; 
Shaw & Lupski 2005; Kriek et al. 2006; Lee et al. 2006). 
 
Complex chromosome rearrangements (CCRs) are relatively rare events, and can be 
classified into groups based on the number of breakpoints and type of rearrangement, 
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being (i) three way exchange with three breaks in three involved chromosomes, (ii) two 
way exchange that coincide with two separate reciprocal translocations and (iii) 
exceptional CCRs with multiple breaks and complicated rearrangements (Bartels et al. 
2007). CCRs have been observed in phenotypically normal individuals as well as in 
individuals with mental retardation and/or congenital abnormalities (Pai et al. 1980; 
Battisti et al. 2003; Kuechler et al. 2005). As a consequence, the characterization of these 
rearrangements is essential for reaching a proper clinical diagnosis and for estimation of 
the recurrence risk. In standard clinical practice, this characterization is usually achieved 
by conventional cytogenetic approaches only, thus submicroscopic imbalances at the 
breakpoints will remain undetected because of the low resolution of such approaches. 
Recently, the use of high-resolution molecular techniques such as array-based 
comparative genomic hybridization (array CGH) have contributed to a growing awareness 
of the presence of CCRs and cryptic imbalances in patients with MR and/or congenital 
anomalies (Vissers et al. 2003; Weise et al. 2003; Lespinasse et al. 2004; Patsalis et al. 
2004; Shaw-Smith et al. 2004; Vermeulen et al. 2004; Borg et al. 2005; de Vries et al. 
2005; Chen et al. 2006; Gajecka et al. 2006; Karmous-Benailly et al. 2006). Although 
molecular mechanisms have been studied in recurrent, simple rearrangements, the role of 
genomic architecture underlying the occurrence of nonrecurrent CCRs, remains as yet 
poorly understood because until recently detailed identification of the exact breakpoints 
was lacking. 
 
Here, we investigated the potential involvement of genome architectural features such as 
LCRs in the occurrence of nonrecurrent 17p CCRs in two patients with congenital 
anomalies. The proximal chromosome 17p arm is associated with a wide variety of 
recurrent chromosome aberrations resulting from NAHR between LCRs including four well 
known genomic disorders: Charcot-Marie-Tooth disease type 1A (CMT1A) [MIM 118220], 
hereditary neuropathy with liabilities to pressure palsies (HNPP) [MIM 162500], Smith-
Magenis syndrome (SMS) [MIM 182290] and the Potocki-Lupski syndrome associated with 
duplication 17p11.2 (Pentao et al. 1992; Reiter et al. 1996; Chen et al. 1997; Potocki et 
al. 2000; Inoue et al. 2001; Shaw et al. 2002; Bi et al. 2003; Potocki et al. 2007). By 
applying high-resolution array CGH to these two novel CCRs we observed an unexpected 
level of complexity. Subsequent FISH analyses revealed the presence of LCRs at the CCR 
breakpoints, thus providing a potential mechanistic basis for the occurrence of the CCRs 
studied. We propose that genomic architectural features such as LCRs may underlie the 
occurrence of these CCRs. 
 
 
Patients, Materials, and Methods 
 
Clinical description of patients 
Patient 1 
The male proband was born to a 42-year-old woman and 43-year-old man at 39 week’s 
gestation by Caesarean section. Because of an abnormal ultrasound showing prominent 
nuchal fold, growth retardation, club feet, and hyperechoic bowel, amniocentesis was 
performed at 20 weeks of gestation and an abnormal karyotype with 17pter monosomy 
and 17p13.1p13.3 trisomy was identified. The birth weight was 2,840 g (10th centile), 
length 51 cm (60th centile), and head circumference 36 cm (50th centile). Apgar scores 
were 6 and 8 at 1 and 5 minutes, respectively. The bilateral club feet were corrected by 
   
 
            
93 
surgery. Echocardiogram revealed bicuspid aortic valve. Physical exam at 11 months 
revealed weight and height at the 3rd centile while his head circumference had increased to 
the 75th centile. There was a premature closure of the metopic suture, with anterior 
fontanel still open (2 × 2 cm) and mild hypertelorism. At the age of 16 months, he was an 
amiable, interpersonally interactive little boy who had developmental delay with babbling 
but no clear words. In addition, he suffered from truncal hypotonia but he was able to pull 
to stand. His skin was dry with marked eczema and the right testis was still undescended. 
 
Patient 2 
This 8-year-old, moderately mentally retarded girl was born after an uneventful pregnancy 
at 40 week’s gestation, with a normal birth weight of 3,400 g. Apgar scores were 3, 5, and 
6 at 1 min, 5 min, and 10 min, respectively. Feeding problems were present from birth. 
Her development was moderately delayed with an IQ score of 50 points at the age of 4 
years and 9 months. At the age of 6 years and 10 months, she had a short stature of 110 
cm (< 3rd centile) and a head circumference of 49 cm (10th centile) with distinctive facial 
features such as synophrys, upward slanting palpebral fissures, flattened upper-ear helices 
with large ear lobules, an upturned nasal tip, and a broad mouth with a long philtrum and 
full lower lip. She had a cardiac murmur; short broad hands with clinodactyly of the fifth 
fingers and absence of distal interphalangeal joint creases; short broad feet with short 
toes and a slight skin syndactyly between the second and third toes bilaterally. She had an 
outgoing personality and easily approaches strangers. At the age of 8 years, she started to 
complain about painful feet and developed a bilateral pes cavus deformity. Neurological 
examination showed areflexia and electromyography (EMG) studies were consistent with a 
demyelinating neuropathy. In addition, treatment for precocious puberty was started. 
 
We obtained samples from the patients and their family members after acquiring informed 
consent approved by the Institutional Review Board for Human Subject Research at Baylor 
College of Medicine, Houston, and Radboud University University Nijmegen Medical Centre, 
Nijmegen. 
 
Array-based comparative genomic hybridization 
Genomic DNA was isolated from peripheral blood lymphocytes or from lymphoblastoid cell 
lines by routine procedures. Two pools of reference DNA were used – one containing equal 
amounts of genomic DNA from 10 healthy male blood donors and one containing equal 
amounts of genomic DNA from 10 healthy female blood donors. Isolation of genomic DNA, 
DNA labeling, hybridization of labeled DNA to a 32,447-BAC array, and spot identification 
were performed as described elsewhere (de Vries et al. 2005). In brief, 500 ng of genomic 
DNA from each patient was labeled by random priming with Cy3-dUTP or Cy5-dUTP 
(Amersham Biosciences) and hybridized to the sex-mismatched reference pool. Test and 
reference samples were mixed with 120 µg of human Cot-1 DNA (Roche), co-precipitated, 
and resuspended in 120 µl of a hybridization solution containing 50% formamide, 10% 
dextran sulfate, 2SSC, 4% SDS, and 10 mg/ml of yeast tRNA (Invitrogen). Hybridization 
and post-hybridization washing procedures were performed using a GeneTac Hybridization 
Station (Genomic Solutions). An 18-h hybridization at 37°C with active circulation of the 
probe was performed, followed by five post-hybridization wash cycles in 50% formamide 
and 2SSC at 45°C, and five wash cycles in phosphate buffer at 20°C. Slides were dried 
by centrifugation and scanned using a GenePix Autoloader 4200AL laser scanner (Axon 
Instruments). Spot dentification and two-color fluorescence intensity measurements were 
obtained using the GenePix 5.1 software, and all data were entered into a database for
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Figure 6.1. 
Patient 1 (a-c) at the age of 4 months. Patient 2 (d-e) at the age of 6 years and 10 months. 
 
 
 
 
subsequent analysis. Following normalization, the log2-transformed test-over-reference 
ratios were analyzed for loss and gain of genomic regions by a standard Hidden Markov 
Model (HMM) (Rabiner 1989; de Vries et al. 2005). 
 
Fluorescent in situ hybridization (FISH) 
PAC and BAC probes specific for human chromosome 17p were selected based on their 
physical location within the affected 17p region (Inoue et al. 2001; Bi et al. 2002; 
http://genome.ucsc.edu/). DNA was isolated from liquid cultures using Perfectprep Plasmid 
Mini (Eppendorf, Hamburg, Germany). The relative alignments of the selected BACs were 
determined by BLAST searches against the high-throughput genome sequence database 
(http://www.ncbi.nlm.nih.gov/blast) and assembled using the Sequencher software (Gene 
Codes Corp., Ann Arbor, MI, USA). FISH was essentially performed as described 
(Stankiewicz et al. 2001a). In brief, 100–200 ng of isolated BAC or PAC DNA was labeled 
with biotin or digoxigenin by nick-translation (BioNick Labeling System, Invitrogen; DIG-
Nick Translation Mix, Roche) and visualized with FITC avidin (Vector) or rhodamine-labeled 
antibodies (Sigma). Patient’s chromosomes derived from lymphoblast cell lines were 
counterstained with DAPI (Sigma). The signals from the normal chromosomes 17 were 
used as internal control. Cells were analyzed using a Zeiss Axioskop fluorescence 
microscope equipped with an appropriate filter combination and a CCD camera. 
Monochromatic images were captured and pseudocolored using MacProbe 4.2.2 
(Perceptive Scientific Instruments, League City, TX, USA) on a Power Macintosh G4 
system. 
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Figure 6.2 
Chromosome 17 (patient 1 and 2) and chromosome 21 (patient 1) array CGH profiles. On the x axis, 
clones are ordered by Mb position on chromosome 17 and 21, respectively, and on the y axis log2 T/R 
ratios are shown. Hidden Markov Model was used to identify the duplications (green lines) and deletions 
(red lines) in patient 1 and 2. (a) In patient 1, chromosome 17 shows two interspersed deletions of 
~600 kb (17p13.3 – Del I) and ~2.2 Mb (17p12 – Del II), respectively, and a duplication of ~6.1 Mb 
(Dup I). (b) Additionally, a 4.4 Mb duplication of 21q22.3 was observed (Dup II). (c) Patient 2 showed 
four interspersed duplications on 17p11-p13 (Dup I - Dup IV), in total comprising ~8.8 Mb of genomic 
sequence. All alterations were proven to be de novo. 
 
 
 
Computational analyses 
For the identification of novel LCRs associated with the CCRs, ~100 kb fragments of 
genomic sequence flanking breakpoints for which no LCRs are known currently, were 
analyzed for sequence homology (http://genome.ucsc.edu; May 2004 freeze). 
Interspersed repeat sequences within the downloaded DNA sequence were eliminated by 
RepeatMasker (http://genome.ucsc.edu) and the repeat masked genomic sequences were 
analyzed using NCBI BLAST2 (http://www.ncbi.nlm.nih.gov/blast/ bl2seq/bl2.html). 
 
 
Results 
 
Cytogenetic and molecular analyses of patient 1 
Conventional cytogenetic analysis at 550-band resolution of patient 1 (Figure 6.1a-c) 
revealed an abnormal male karyotype with an apparent complex rearrangement involving 
the short arm of chromosome 17. Parental chromosomes at 600-band resolution were 
normal. FISH analysis confirmed this complex rearrangement and, in addition, revealed a 
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   Table 6.1: Summary of the array CGH and FISH results patient 1 
 
 
Chr. band Clonea 
 Distance 
from pter 
(Mb)e 
Der 
(17) 
Technique(s) 
 
17p13.3 CTD-2348K1  0.1 - array CGH  
17p13.3 CTD-2326F1 R 0.1 - array CGH/ FISH  
17p13.3 CTD-2573J8  0.2 - array CGH del I 
17p13.3 RP11-1260E13 G 0.3 - FISH  
17p13.3 RP11-143G11  0.6 - array CGH  
17p13.3 RP11-488O17  0.6 normal array CGH  
17p13.3 RP11-411G7  0.6 normal FISH  
       
17p13.3 RP1-95H6b R 2.7 inv ins FISH 
17p13.2 RP11-148L19  4.1 inv ins FISH 
17p13.2 GS-202L17c G 4.9 inv ins FISH 
17p13.2 RP11-373N8  5.5 inv ins FISH 
middle  
SMS-REP/ 
LCR17pB 
       
17p12 RP11-466J1  11.1 normal array CGH  
17p12 RP11-22L4  11.2 normal FISH  
17p12 RP11-271N1  11.4 normal array CGH  
17p12 RP11-165H21  11.5 - array CGH  
17p12 RP11-802E21  11.6 - array CGH  
17p12 RP11-64L11  13.1 - FISH del II 
17p12 RP11-352N24  13.2 - array CGH  
17p12 RP11-590H8  13.4 - array CGH  
17p12 RP11-112H7  13.6 normal array CGH  
       
17p12 CTD-2120F7  13.7 normal array CGH  
17p12 RP11-687M21  13.9 ++ array CGH  
17p12 RP11-78J16  14.1 ++ array CGH  
17p12 RP1-150M12d R 15.4 ++ FISH  
17p11.2 RP11-209J20  16.3 ++ FISH  
17p11.2 RP11-525O11 G 17.6 ++ FISH dup I 
17p11.2 RP1-178F10  18.4 ++ FISH  
17p11.2 RP11-28B23  18.7 ++ FISH  
17p11.2 RP11-1113L8  19.3 ++ FISH  
17p11.2 RP11-277B5  19.4 ++ FISH  
17p11.2 CTD-2019P4  19.6 ++ array CGH/ FISH  
17p11.2 CTD-2020J20  19.7 normal array CGH  
17p11.2 RP11-78O07  19.7 normal FISH  
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   Table 6.1 (continued) 
 
 
  
 
 
 
 
 
 
deletion of 17pter, a duplication of the genomic region containing the SMS and the CMT1A 
regions, and an inversion involving the Miller-Dieker lissencephaly syndrome (MDLS) 
region. The presence of these abnormalities in the parental chromosomes was excluded by 
FISH. The patient’s karyotype was designated as: 
 
46,XY,der(17).ish del(17)(p13.3)dup(17)(p11.2p12)inv(17)(p11.2p13.3) dn. 
 
Subsequently, array CGH was used to refine the breakpoints and genomic sizes of the 
complex 17p rearrangement. The deletion involving the telomeric region of 17p was 
determined to be ~600 kb in size, whereas the duplication containing the SMS and CMT1A 
region was ~6.1 Mb in size. Interestingly, array CGH revealed two additional 
submicroscopic alterations that had remained undetected using previous approaches. 
These included an ~2.2 Mb interstitial deletion in 17p12 and an ~4.4 Mb duplication in 
21q22.3 (Figure 6.2a-b). 
 
Dual color FISH experiments were performed to independently map each of the 
chromosome breakpoints (Figure 6.3; Table 6.1). FISH analyses confirmed the deletion 
of the 17p telomeric region (Figure 6.3a) as well as the dup(17)(p11.2p12) (Figure 
6.3b). The FISH results of the duplication were consistent with a tandem duplication 
(Figure 6.3b). Interestingly, the MDLS region was found to be inserted into the middle 
SMS-REP/LCR17pB block in the genomic region involved in SMS (Figure 6.3c). 
Unexpectedly, the duplicated fragment 21q22.3qter was localized on der(17), likely 
representing the product of an unbalanced translocation t(17;21)(p13.3;q22.3) (Figure 
6.3d). FISH analyses on the parental chromosomes excluded the presence of a balanced 
t(17;21)(p13.3;q22.3). Based on these results, the patient’s karyotype was redefined as:  
 
 
 
 
 
 
 
 
Chr. band Clonea 
 Distance 
from pter 
(Mb)e 
Der 
(21) 
Technique(s) 
 
21q22.3 
RP11-690D9 
 
42.5 
normal array CGH  
21q22.3 
RP11-282I20 
 
42.6 
++ array CGH  
21q22.3 RP11-40L10 G 44.2 ++ FISH 
21q22.3 RP11-16B19 R 45.1 ++ FISH 
dup II  
Located 
der(17) 
21q22.3 RP11-1000I21  46.8 ++ array CGH  
‘-’ Deleted; ‘++’ duplicated; ‘inv ins’ inverted inversion. Extent of deletion and 
duplication is indicated at the right; Breakpoint-associated LCRs are indicated in bold. 
a: Clones indicated by R (for red) or G (for green) are shown in Figure 6.3a-d in the 
respective  colors 
b: LIS1-specific PAC clone (Chong et al. 1997) 
c: Adapted from Knight et al. 2000 
d: PMP22-specific PAC clone 
e: Distance from pter to the clone midpoints  
46,XY,der(17).ish del(17)(p13.3)del(17)(p12p12)dup(17)(p11.2p12)ins(17) 
(p11.2p13.3p13.2)t(17;21)(p13.3;q22.3). arr cgh 17p13.3(CTD-2348K1-RP11-
143G11)x1, 17p12(RP11-165H21-RP11-590H8)x1,17p12p11.2(RP11-687M21-
CTD2019P4) x3,21q22.3(RP11-282I20-RP11-1000I21)x3 dn. 
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Figure 6.3 
Schematic representation of a normal 17p and der(17) (black & white) with translocated chromosome 
21 material (blue). The location of the FISH probes are shown on the left side of each figure panel; 
der(17) is indicated on FISH pictures by a white arrow. (a) Terminal deletion of 17pter was validated 
using BAC clones RP11-1260E13 (red) and CTD-2326F1 (green). (b) FISH with PMP22-specific PAC 
RP1-150M12 (red) and RAI1-specific BAC RP11-525O11 (green) revealed direct duplication of the 
CMT1A and SMS regions in 17p12p11.2. (c) FISH with PAC RP1-95H6 (red) and BAC GS-202L17 
(green) showed inverted insertion of the MDLS region into the SMS region. (d) Array CGH also 
identified a duplication of 21q22.3. Additional FISH analysis using BAC clones RP11-40L10 (green) and 
RP11-16B19 (red) revealed that the duplicated material of 21q22.3 was translocated onto der(17). 
Summary of FISH results is provided in Table 6.1. 
 
 
 
Cytogenetic and molecular analyses of patient 2 
Conventional cytogenetic analysis at the 550-band resolution in patient 2 (Figure 6.1d-e) 
showed a normal 46,XX karyotype. Multiplex ligation-dependent probe amplification 
revealed normal disomic copy numbers of the subtelomeric regions. Subsequent array 
CGH revealed four interspersed microduplications involving the short arm of chromosome 
17, in total comprising 8.8 Mb of genomic sequence (Table 6.2). De novo occurrence was 
established by a similar array CGH analysis with DNA obtained from the accompanying 
parents (Figure 6.2c; de Vries et al. 2005). Duplication I in 17p13.2 was determined as 
~2.9 Mb in size; duplication II in 17p13.1 was assessed as ~1.4 Mb in size; duplication III 
in 17p12 was estimated as ~2.9 Mb in size and included the PMP22 gene known to cause 
CMT1A disease with dosage-specific overexpression of PMP22 (Patel et al. 1992). 
Duplication IV in 17p11.2 was determined as being ~1.5 Mb in size. 
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Figure 6.4 
Schematic representation of the normal 17p and der(17). The locations of the FISH probes are shown 
on the left side of each figure panel. (a) Duplication I showed relatively simple fluorescence signal 
pattern with probes RP11-810M2 (green; normal) and RP11-597I9 (red; duplicated) for the distal 
breakpoint, and (b) RP11-222J21 (green; duplicated) and RP11-98D15 (red; normal) for the proximal 
breakpoint. (c) Direct orientation of duplication III was shown using BAC clones RP11-601N13 (green) 
and RP11-726O12 (red). (d) For the distal breakpoint of duplication IV, BAC clones RP11-448D22 
(green) and CTD-2145A24 (red) showed duplicated signals on der(17), indicating that both middle 
SMS-REP and LCR17pB are duplicated as a block. Note four red signals on der(17) representing two 
normal and two duplicated copies of LCR17pA/B (dupIII) and LCR17pB (dupIV) and four green signals 
depicting three normal copies of SMS-REPs and the duplicated middle SMS-REP. Summary of FISH 
results is provided in Table 6.2. 
 
 
Dual color FISH analysis was used to independently confirm the array CGH results (Figure 
6.4; Table 6.2). In addition, the parental chromosomes were evaluated for predisposing 
rearrangements within chromosome 17p potentially explaining the complexity of the CCR, 
however, no such rearrangements were observed. The patients karyotype was finally 
designated as: 
 
 
 
 
46,XX.ish dup(17)(p13.1p13.2)dup(17)(p13.1p13.1)dup(17)(p12p12)dup(17) 
(p11.2p11.2). arr cgh 17p13.1p13.2(RP11-597I9-RP11-222J21)x3,17p13.1 
(RP11-63C7-RP11-324C22)x3, 17p12(RP11-333I5-RP11-640N23)x3, 17p11.2 
(RP11-304M17-CTD-2022C7)x3 dn. 
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      Table 6.2: Summary of the array CGH and FISH results patient 2 
Chr. band Clonea 
 Distance 
from pter 
(Mb) b 
Der 
(17) 
Technique(s) 
 
17p13.2 RP11-810M2 G 4.0 normal array CGH/ FISH  
17p13.2 RP11-597I9 R 4.1 ++ array CGH/ FISH  
17p13.2 RP11-106A7  4.3 ++ array CGH/ FISH  
17p13.2 RP11-217O7  4.3 ++ array CGH  
17p13.1 RP11-816H10  6.7 ++ array CGH dup I 
17p13.1 RP11-417F20  6.9 ++ array CGH/ FISH  
17p13.1 RP11-558E15  7.1 ++ array CGH  
17p13.1 RP11-222J21 G 7.2 ++ array CGH/ FISH  
17p13.1 RP11-98D15  R 7.3 normal array CGH/ FISH  
       
17p13.1 RP11-205D17  7.3 normal array CGH  
17p13.1 RP13-626G5  7.4 normal array CGH  
17p13.1 RP11-63C7  7.7 ++ array CGH  
17p13.1 RP11-441N13  7.8 ++ array CGH/ FISH  
17p13.1 RP11-452D1  8.1 ++ array CGH/ FISH  
17p13.1 RP11-111I3  9.0 ++ array CGH/ FISH dup II 
17p13.1 RP11-85B7  9.1 ++ array CGH  
17p13.1 RP11-342E3  9.1 ++ array CGH/ FISH  
17p13.1 RP11-324C22  9.2 ++ array CGH  
17p13.1 RP11-482E13  9.2 normal array CGH/ FISH  
17p13.1 RP11-589N11  9.2 normal array CGH  
       
17p12 RP11-560N10  12.3 normal array CGH/ FISH  
17p12 RP11-674I3  12.5 normal array CGH  
17p12 RP11-746E8  12.5 ++ FISH  
17p12 RP11-333I5  12.6 ++ array CGH/ FISH  
17p12 RP11-601N13 G 13.9 ++ FISH  
17p12 RP11-686G16  15.1 ++ Array CGH dup III 
17p12 RP11-726O12 R 15.2 ++ Array CGH/ FISH  
17p12 RP11-385D13  15.4 ++ FISH  
17p12 RP11-640N23  15.5 ++ Array CGH  
17p12 RP11-640I15  15.6 ++ FISH LCR17pA 
17p12 CTD-3157E16  15.7 normal FISH  
17p12 RP11-59N13  15.7 normal array CGH  
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     Table 6.2 (continued) 
 
 
 
 
 
 
 
 
Overview of the 17p breakpoints in both patients 
In total, 17 breakpoints were identified and molecularly characterized at one BAC clone 
resolution in these two patients, with nine breaks in patient 1 and eight breaks in patient 
2. In patient 1, one of the nine breakpoints (inverted insertion of the MDLS region) was 
mapped within the middle SMS-REP/LCR17pB block after FISH with these LCR flanking 
clones RP1-178F10 and RP11-28B23. In patient 2, three of the eight breakpoints were 
associated with LCRs in proximal 17p. The proximal breakpoint of duplication III was 
located in LCR17pA, between subunits LCR17pA/B and LCR17pA/D using FISH with 
LCR17pA/B-specific BAC clone RP11-640I15 and LCR17pA/D- and LCR17pA/C- specific 
BAC clone CTD-3157E16 that are known to cross-hybridize to their homologous copies 
LCR17pB, LCR17pD and LCR17pC, respectively (Stankiewicz et al. 2004). BAC clone RP11-
640I15 showed four fluorescent signals on der(17) (representing two normal and two 
duplicated copies of LCR17pA/B (dup III) andLCR17pB (dup IV) and CTD-3157E16 three 
signals on der(17) in analyzed interphase nuclei (depicting normal, not duplicated copies 
of LCR17pA/D, LCR17pC, and LCR17pD). In duplication IV the distal breakpoints was 
mapped in the middle SMS-REP, between PAC clone RP1-178F10 (flanks the middle SMS-
REP on the telomeric side) and BAC clone RP11-448D22 (middle SMS-REP-specific) 
(Figure 6.4d). The proximal breakpoint of dup IV was mapped in LCR17pC using FISH 
with its specific BAC clone RP11-121A13. DNA sequence analysis of the genomic regions 
surrounding the remaining 13 chromosome breakpoints revealed no significant homology 
or evidence of low-copy repeats. Figure 6.5 shows an overview of the proximal 17p 
breakpoints and its association with genomic architectural features observed in both 
patients. In addition, a selected set of breakpoints previously reported in other patients 
with 17p aberrations that are associated with LCRs is displayed. 
Chr. band Clonea 
 Distance 
from pter 
(Mb) b 
Der 
(17) 
Technique(s) 
 
17p11.2 RP11-484D23  18.3 normal  array CGH  
17p11.2 RP11-667E24  18.4 normal  array CGH  
17p11.2 RP1-178F10  18.4 normal  FISH 
17p11.2 RP11-448D22 G 18.6 ++  FISH 
 Middle 
SMS-REP/ 
17p11.2 RP11-304M17  18.6 ++  array CGH LCR17pB 
17p11.2 CTD-2145A24 R 18.7 ++  FISH    
17p11.2 RP11-137E6  20.0 ++  array CGH/ FISH  dup IV 
17p11.2 CTD-2022C7  20.0 ++  array CGH  
17p11.2 RP11-121A13  20.1 ++  FISH  LCR17pC 
17p11.2 CTD-2313N10  20.3 normal  array CGH  
17p11.2 RP11-185K8  20.4 normal  array CGH  
‘++’ Duplicated; Extent of duplication is indicated at the right; Breakpoint-associated 
LCRs are indicated in bold.  
a: Clones indicated by R (for red) or G (for green) are shown in Figure 6.4a-d in the 
respective colors 
b: Distance from pter to the clone midpoints  
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Discussion 
 
The availability of molecular genome profiling techniques such as array CGH have 
markedly enhanced the resolution of chromosome studies and enabled high resolution 
genome analysis, thus proving a more accurate method for the identification and 
delineation of chromosomal rearrangements (Vissers et al. 2003; Shaw-Smith et al. 2004; 
Cheung et al. 2005; de Vries et al. 2005; Johnston et al. 2007). As a result, precise 
definitions of CCRs and their true complexity can now be better established. An apparent 
underestimation of the full complexity of CCRs is well demonstrated in patient 1, in whom 
a complex karyotype was identified, including an inverted insertion of the MDLS region into 
the middle SMS-REP/LCR17pB block, two microdeletions (terminal and interstitial in 
17p12) and a microduplication involving both SMS and CMT1A chromosome regions. 
Furthermore, a duplication of 21q22.3qter translocated onto 17p13.3 was identified. The 
interstitial deletion on 17p12, as well as the duplication of 21q22.3, were not identified 
prior to array CGH analysis. Thus, by unraveling the complexity of CCRs using array CGH, 
the added value of this technique to conventional karyotyping was demonstrated. It is, 
however, noteworthy that current array CGH techniques are incapable of detecting 
balanced alterations such as inversions, and only provide information regarding genomic 
gains and losses. FISH can augment the study of CCRs by providing genomic positional 
and orientational information of imbalances. This is well demonstrated by the apparently 
balanced inverted insertion of the MDLS region into the middle SMS-REP/LCR17pB block in 
patient 1, which would have escaped attention if array CGH would have been the only 
technique employed. 
 
A total of 106 genes in patient 1 and 133 genes in patient 2 were affected by genomic 
imbalances (gains and losses) because of the CCRs. For patient 1, the number of genes 
affected is less than expected based on the average number of 15 genes/Mb on 
chromosome 17 and 6 genes/Mb on chromosome 21. It thus seems that the CCR in 
patient 1 affected relatively gene poor regions. For patient 2, the total number of genes 
affected was in concordance with the expected number of genes affected by the CCR. 
Given the large number of genes affected in each patient, it is difficult to correlate any 
specific gene with the observed phenotypes. However, a few genes affected by the CCRs 
are well established dosage-sensitive genes, including RAI1 in patient 1 and PMP22 in 
patient 2, which are known to cause disease when duplicated. Recently, duplication of 
RAI1 has been shown to cause a physical and behavioral phenotype termed Potocki-Lupski 
syndrome (Potocki et al. 2007). However, due to the young age of patient 1, as well as the 
imbalances of other genomic regions, assessing phenotype-genotype correlations is not 
possible. One of the genes affected by the CCR in patient 2 is the dosage-sensitive PMP22 
gene. Duplication of this gene causes CMT1A, a common inherited neuropathy 
characterized by myelin degeneration (Patel et al. 1992). Indeed, the first clinical signs of 
CMT1A were present in this patient. 
 
Genome profiling techniques provide a readily accessible platform for the delineation of 
complex rearrangements at the breakpoint level, thus allowing the study of the molecular 
mechanisms underlying such rearrangements. For recurrent as well as nonrecurrent 
alterations, it has been shown that genomic architectural features such as LCRs and 
smaller repetitive elements including Alu sequences are capable of mediating and/or 
stimulating the occurrence of deletions and duplications (Pentao et al. 1992; Chen et al.
1997; Shaw & Lupski 2005). LCRs in proximal 17p comprise more than 23% of the
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Figure 6.5 
Top: Cytogenetic chromosome bands 17p12, and sub-bands 17p11.2 and 17p11.1 are shown. 
Breakpoints of the chromosome rearrangements in patients 1 and 2 associated with architectural 
features in proximal 17p are shown by vertical dotted blue arrows. In patient 1, one breakpoint is 
located within the middle SMS-REP/LCR17pB block, whereas in patient 2 breakpoints are located within 
LCR17pA (proximal Dup III), middle SMS-REP (distal Dup IV) and LCR17pC (proximal Dup IV). 
Duplication III and IV in patient 2 are indicated by horizontal blue lines. Bottom: Previously identified 
rearrangements associated with LCRs in 17p. Breakpoints of translocations and isochromosome 17q are 
indicated by vertical black arrows whereas common ~4 Mb and uncommon ~5 Mb SMS deletions and 
marker chromosomes are indicated by black horizontal lines. The LCR17p structures are depicted in 
colors to better represent their positional orientation with respect to each other; the shaded rectangles 
and horizontal black arrows represent the orientation of the LCRs. 
 
 
 
 
genomic sequence, which is approximately fourfold higher than might be expected based 
on virtual analysis of the entire human genome (Stankiewicz et al. 2003). It might be 
anticipated that the breakpoints of the uncommon nonrecurrent chromosomal aberrations 
as observed in this study occurred by chance alone within one of these LCRs. However, of 
five breakpoints that occurred within the proximal part of 17p, four were located within a 
LCR structure. The remaining 10 breakpoints were located in the LCR-poor distal fragment 
of 17p. Thus, it appears that the location of the breakpoints is associated with local 
genome architecture, i.e, LCRs. Based on the abundance of genomic architectural features 
in proximal 17p, it remains to be determined whether the two CCRs described in this study 
are representative for other CCRs. However, a comparable genomic complexity has been 
observed in other genomic regions. For instance, LCRs in 22q11.2 have been shown to be 
responsible for recurrent and nonreccurrent chromosome deletions, duplications, and 
translocations (Shaikh et al. 2001; Spiteri et al. 2003). Thus, it can be expected that 
additional complex rearrangements with genomic architecture playing a mediating role, 
will be identified.  
     Chapter 6      
   
 
            
104 
The molecular characterization of the complex rearrangements enabled the identification 
of nine and eight breakpoints in the CCRs in patient 1 and 2, respectively. Of all these 17 
breakpoints, four involved known LCRs being the middle SMS-REP/LCR17pB block in 
patient 1 and the middle SMS-REP, LCR17pA and LCR17pC in patient 2. The remaining 
breakpoints did not reveal any significant similarity and/or any evidence for the presence 
of LCRs. The proximal breakpoint of duplication III in patient 2 was located within 
LCR17pA. This genomic region has previously been found to be involved in several other 
constitutional and evolutionary rearrangements, including t(4;19) in Gorilla Gorilla 
(Stankiewicz et al. 2001a; Stankiewicz et al. 2001b; Stankiewicz et al.2003; Stankiewicz 
et al. 2004; Shaw et al. 2004a; Lupski & Stankiewicz 2005; Yatsenko et al. 2005; Ou et al. 
2006). The distal breakpoint of this duplication, however, was not located within a 
genomic segment sharing sequence homology with LCR17pA. Breakpoints of duplication IV 
were mapped within non-homologous LCR copies, middle SMS-REP and LCR17pC. The 
middle SMS-REP/LCR17pB was also insertion target of the MDLS region in patient 1. These 
observations suggest that other recombination mechanisms, such as nonhomologues end-
joining (NHEJ), may have facilitated these CCRs. NHEJ may play a prominent role in 
nonrecurrent rearrangements as has been shown for PLP1 deletions and duplications 
(Inoue et al. 2002; Lee et al. 2006). It remains to be determined to what extent NHEJ is a 
mechanism for genomic rearrangements, since other potential replication-based 
mechanisms may occur with nonrecurrent rearrangements (Lee et al. 2006). 
 
The detailed molecular information gathered on the breakpoints does, however, allow for 
speculation on the mechanism underlying CCR formation in our patients. We propose 
models based upon the principle of parsimony and the minimal amount of breaks required 
for formation of the CCRs. Although predisposing inversion(s) and translocations rendering 
susceptibility to rearrangements in the offspring similar to what is known for several 
genomic disorders have been excluded in the parental chromosomes (Axton 2006; Lupski 
2006), alternative mechanisms of CCR formation cannot be excluded fully. The complex 
rearrangement observed in patient 1 includes nine breakpoints, with one insertion, two 
microdeletions, one microduplication and one translocation. We propose that the breaks in 
der(17), 17p13.3, 17p12 and 17p11.2 as well as the break in chromosome 21q22.3 arose 
simultaneously. This resulted in the insertion of the MDLS region into the middle SMS-
REP/LCR17pB block, loss of the subtelomeric region 17p13.3 and part of 17p12, and 
duplication of the CMT1A and SMS regions. Additionally, the duplicated 21q22.3 region 
was translocated to the 17p subtelomeric region (Figure 6a), most likely by a telomere 
healing mechanism. The complex rearrangement in patient 2 includes eight breaks. For 
the most parsimonious mechanism, a single breakpoint is involved in both, the formation 
of, as well as the insertion of, the duplicated segment. Thus, for each duplication observed 
in patient 2, one of the breakpoints is involved in the formation of the duplication and 
provides at the same time the site for inserting the duplicated segment. We suggest that 
also in this case all breaks in chromosome 17 occurred concurrently, resulting in four 
interspersed directly orientated microduplications (Figure 6b). 
 
In conclusion, the human genome contains many genomic architectural features such as 
LCRs, of which several have been identified at the breakpoints of (recurrent) chromosome 
rearrangements. As such, these chromosome rearrangements do not appear to represent 
random events but, instead, result from underlying genomic architectural features. Here, 
we present two patients with unique de novo complex chromosome rearrangements, of
   
 
            
105 
 
Figure 6.6 
Schematic representation of the proposed mechanism for CCR formation in patient 1 and patient 2. (a) 
The complex rearrangement observed in patient 1 includes ten breakpoints, with one insertion, two 
microdeletions and two microduplications. We propose that the breaks in chromosome 17, p13.3, p12 
and p11.2 as well as the break in chromosome 21q22.3 arose simultaneously. This resulted in the 
insertion of the MDLS region into the middle SMS-REP/LCR17pB block, loss of telomeric 17p and part of 
17p12 and duplication of the CMT1A region. Additionally, the duplicated 21q22.3 fragment was 
translocated to the 17p subtelomeric region. (b) The complex rearrangement in patient 2 included eight 
breaks. We suggest that breaks in chromosome 17, p13.2, p13.1, p12 and p11.2 occurred at the same 
time, resulting in four interspersed directly orientated microduplications. Note: arrows do not represent 
a chronological order of events. 
 
 
 
which several breakpoints are located within LCRs. These results provide evidence for the 
first time that in addition to previously reported chromosome deletions, duplications, 
inversions, translocations and marker chromosomes, genomic architectural features such 
as LCRs are mechanistically important for the origin of some complex chromosome 
rearrangements. 
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Until recently, it was impossible to analyze the entire human genome for the presence of 
submicroscopic copy number variations. The development and subsequent implementation 
of various microarray-based genome profiling technologies such as array CGH, however, 
has enabled such whole-genome analyses at a resolution that vastly exceeds that of 
conventional karyotyping. In this chapter, several aspects of this revolutionizing 
technology will be discussed, including its implications for current and future clinical 
applications and genome research. 
 
 
7.1 The continuously increasing resolution of genome profiling technologies 
 
Genome profiling technologies, such as array CGH, have dramatically changed the nature 
of human genome analysis by combining the targeted high-resolution approach of the 
FISH technology and the whole-genome approach of the karyotyping technology. Many 
laboratories have started their array CGH studies using low-density custom made arrays 
encompassing probes specifically targeted at selected genomic regions. Examples of these 
are arrays targeting all subtelomeric regions (Veltman et al. 2002; Harada et al. 2004), 
arrays targeting regions known to be involved in ‘microdeletion/microduplication 
syndromes’ (Yu et al. 2003; Klein et al. 2004; Locke et al. 2004; Shaw et al. 2004b; van 
Buggenhout et al. 2004; Wang et al. 2004), or arrays targeting other chromosomal 
regions of interest (Buckley et al. 2002; Veltman et al. 2003a; Ekong et al. 2004; Solomon 
et al. 2004; Veltman et al. 2004; Koolen et al. 2005). The ultimate power of the 
microarray technology for copy number assessment lies, however, in the ability to screen 
the entire human genome, without a priori knowledge of the genomic region involved. To 
this end, high-density arrays were constructed covering the entire human genome, initially 
with a 0.75 to 1.4 Mb resolution using ~3,000 BAC clones and, more recently, with a 
resolution of 50-100 kb using ~32,000 BAC clones (Snijders et al. 2001; Vissers et al. 
2003; Shaw-Smith et al. 2004; Ishkanian et al. 2004; de Vries et al. 2005). Although 
these arrays have found a wide application in genetic diagnostics and research (see 
paragraphs 7.2-7.4), the resolution of these microarrays does not allow analysis at the 
level of individual genes, let alone individual exons. Thus, efforts were made to further 
increase the resolution of existing genome profiling technologies. 
 
The subsequent use of alternative array elements such as oligonucleotides targeting 
random sequences or SNPs have indeed taken this resolution to a next level (Barrett et al. 
2004; Larrabee et al. 2004; Rauch et al. 2004; Schaeffer et al. 2004; Schoumans et al. 
2004, Herr et al. 2005; Slater et al. 2005; Friedman et al. 2006; Peiffer et al. 2006). 
Currently, the highest density oligonucleotide-based microarrays encompass over 500,000 
probes, resulting in an average genome-wide spacing of one oligonucleotide every 6 kb. In 
the near future, this resolution is expected to increase even further with the commercial 
availability of microarrays encompassing a million or more probes. Recently developed 
custom made arrays have already enabled a reliable copy number assessment at a 
resolution <1 kb for targeted genomic regions. These include arrays targeting exon 
sequences from a limited set of known disease genes (Dhami et al. 2005) and arrays 
targeting known microdeletion syndromes (Sharp et al. 2006; Johnston et al. 2007). 
 
In addition to its high resolution, commercially available microarrays have several 
advantages over in-house produced microarrays such as (i) the minimization of costs due 
to the large-scale production, (ii) the wide-spread availability of microarrays to research
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Figure 7.1 
Impact of the increasing resolution of molecular karyotyping on disease gene identification. 
 
 
 
and diagnostic laboratories (iii) the availability of large (combined) data sets from control 
and test samples and (iv) the possibility to directly compare data sets from different 
laboratories (Veltman 2006). An additional advantage of oligonucleotide-based SNP arrays 
is the ability to simultaneously measure variations in signal intensity and allelic 
composition, thus allowing the detection of both copy number variation and copy-neutral 
loss-of-heterozygosity (LOH) events. The detection of copy-neutral LOH, i.e., the detection 
of LOH without copy number reduction, has already successfully been applied to the 
genomic analysis of chronic lymphocytic leukaemia (Pfeiffer et al. 2007) and 
medulloblastoma (Langdon et al. 2006). It is anticipated that such analyses will 
increasingly be applied to the identification of epigenetically regulated and/or imprinted 
genes that may be linked to disease.  
 
Apart from increasing resolution for the detection of copy number variation, technological 
developments are ongoing to interrogate the human genome at the highest level of 
resolution possible, i.e., at the single base pair level. Currently, the key limitations for 
individual whole-genome re-sequencing are the high costs involved and relative low 
throughput. For example, if performed today, an individual human genome sequence 
would cost approximately €10 million, and it would take 30 standard sequencing 
instruments 1 year to finish the sequence (Bentley 2006). Novel whole-genome 
sequencing platforms such as those from 454 Life Sciences and Solexa, will dramatically 
increase throughput and lower the costs, thus bringing the concept of personalized 
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genome sequencing within reach. Such personalized genome sequence will not only 
facilitate the identification of single gene mutations, but may also allow for copy number 
detection and the identification of (submicroscopic) balanced rearrangements.  
 
In conclusion, microarrays with a resolution of 1 kb, or even beyond, will soon become 
available on a genome-wide scale. In combination with upcoming whole-genome 
sequencing approaches, all chromosomal rearrangements, including submicroscopic 
balanced rearrangements, will be detectable in the near future. It is envisioned that this 
increase in resolution will lead to a concomitant increase in disease gene discovery 
(Figure 7.1). 
 
 
7.2 Diagnostic molecular karyotyping 
 
In chapter 2 we have shown that array CGH-based molecular karyotyping, using genome-
wide 1 Mb BAC arrays, allows the detection of causative microdeletions and/or duplications 
in 10% of individuals with mental retardation with or without additional congenital 
malformations. Additional studies have provided insight into the quality and reproducibility 
of the procedure, the need for validation of the microarray data by independent 
technologies such as FISH or MLPA, as well as the way to translate these data into clinical 
practice (Shaw-Smith et al. 2004; Schoumans et al. 2005; Tyson et al. 2005). The clinical 
usefulness of molecular karyotyping was further substantiated in larger, less selected, 
cohorts of individuals with mental retardation using 1 Mb resolution BAC arrays (Menten et 
al. 2006; Rosenberg et al. 2006), tiling-resolution BAC arrays (de Vries et al. 2005), or 
100k SNP arrays (Friedman et al. 2006). When taking these studies together, two main 
conclusions can be drawn (i) in addition to submicroscopic subtelomeric chromosome 
imbalances, submicroscopic interstitial chromosome imbalances are responsible for a 
considerable proportion of cases with mental retardation varying between 5 and 20% 
depending on the clinical pre-selection of the individuals, and (ii) these interstitial 
submicroscopic chromosome imbalances occur all over the genome without preference for 
specific loci (reviewed by Knight & Regan 2006; Veltman 2006). 
 
Remarkably, we found that the diagnostic yield did not increase when using higher 
resolution microarrays, i.e., ~1 Mb versus ~100 kb BAC arrays, respectively (Chapter 2; 
de Vries et al. 2005). It must, however, be noted that the diagnostic yield of this approach 
heavily depends on the number and quality of previous cytogenetic studies performed as 
well as on the clinical selection of the patients prior to the array studies. Indeed, the first 
pilot studies were performed on small series of patients that were stringently selected, 
leading to an over-estimation of the overall diagnostic yield. The current, and most 
reliable, estimated diagnostic yield is based on the analysis of 500 karyotypically normal 
patients with mental retardation in which subtelomeric abnormalities had been excluded, 
but without any further clinical pre-selection, using a tiling resolution BAC array. This 
study revealed 48 de novo disease-related interstitial submicroscopic copy number 
imbalances (9.6%) (Koolen et al. manuscript in preparation). Approximately half of these 
imbalances were below the level of <1 Mb, thus underscoring the importance of using 
arrays beyond the resolution of ~1 Mb. As stated above, experimental and technical 
aspects will ultimately no longer be the limiting factors in the detection of (submicroscopic) 
deletions and duplications. So far, the resolution to detect chromosome rearrangements 
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has increased 100-fold, that is, from a 10 Mb resolution using conventional karyotyping to 
a 100 kb resolution using molecular karyotyping by tiling resolution BAC arrays. However, 
the ultimate resolution at a single base pair level will be another four orders of magnitude 
larger than the current resolution. The above estimated diagnostic yield of ~10% is 
therefore undoubtedly an underestimation for interstitial submicroscopic rearrangements 
causative for mental retardation.  
 
The increase in resolution of genome analysis technologies has also led to the identification 
of frequently occurring large scale genomic imbalances, denoted as copy number 
variations (CNVs), which may be inherited from unaffected parents. In our first study, 
using a ~1 Mb microarray, we identified three submicroscopic rearrangements 
representing such CNVs in a series of 20 patients (Chapter 2). More recently, de Vries et 
al. (2005) identified 258 CNVs inherited through one of the apparently healthy parents in 
99 of 100 patients with mental retardation using a tiling resolution BAC array. In order to 
discriminate between causative alterations and benign CNVs, the validation for de novo 
occurrence has become inevitable. Together, these results indicate that the ultimate 
challenge of using high-resolution arrays for molecular karyotyping lies in the clinical 
interpretation of the data obtained, as the majority of copy number imbalances detected 
will represent CNVs inherited from one of the phenotypically normal parents (see also 
paragraph 7.6). 
 
When a new cytogenetic diagnostic technique replaces an old(er) technique, the new 
technique needs to have added value. Approximately 5% of mental retardation is caused 
by chromosomal rearrangements detectable by conventional karyotyping (de Vries et al. 
2005). Molecular karyotyping has already shown added value by increasing this 
percentage to ~20%, including the detection of 2-3% microscopically visible unbalanced 
rearrangements, 6% submicroscopic subtelomere rearrangements, and 10% interstitial 
submicroscopic rearrangements. Driven by the commercial availability of genome-wide 
high-density microarrays, combined with automation of the procedure, it is expected that 
molecular karyotyping will soon find widespread diagnostic application.  
 
Currently, molecular karyotyping is restricted to postnatal analysis whereas conventional 
karyotyping is also used in a prenatal setting. There may, however, be two important 
advantages of using molecular karyotyping, (i) the more reliable detection of subtle 
rearrangements that may be difficult to detect on prenatal samples, i.e., small telomeric 
abnormalities, and (ii) the detection of abnormalities that are not detectable even by an 
optimal karyotype, i.e., cryptic telomeric deletions and duplications or microdeletions and 
duplications leading to known syndromes (Sahoo et al. 2006). It is, however, questionable 
whether genome-wide microarrays should be used in a prenatal setting as the clinical 
interpretation of the vast majority of the (submicroscopic) de novo copy number variations 
as well as inherited copy number variations remains elusive (see also paragraph 7.6). 
However, targeted arrays to exclude the presence of (cryptic) telomere rearrangements 
and known microdeletion syndromes could serve as an alternative. Although the incidence 
of the individual disorders tested on such targeted arrays are rare, their combined live-
birth incidence is significant and could be as high as 1:500. Moreover, such targeted 
arrays have already been successfully applied in prenatal diagnosis (Sahoo et al. 2006).  
 
In conclusion, submicroscopic subtelomeric and/or interstitial chromosome 
rearrangements together explain up to 20% of the cases of mental retardation, whereas 
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Figure 7.2 
Schematic overview of CHD7 mutations and chromosomal rearrangements detected in patients with 
CHARGE syndrome. (a) Nonsense mutations (circles) are depicted above the schematic representation 
of the CHD7 gene, whereas missense (square), frameshift (diamond) and splice site (triangle) 
mutations are depicted below. Nonsense, frameshift and splice site mutations are scattered throughout 
the gene, whereas missense mutations are concentrated in the SNF2 domain. (b) Deletions ranging 
from microscopic (P1) to submicroscopic (P8) are indicated for patients 1-8 (P1-P8). Translocation 
partners disrupting the CHD7 gene included chromosomes 2, 6, and 13 (P9-P11). Chromosomal bands 
are indicated by grey and white blocks. Deleted chromosomal regions are represented by black bars, 
whereas white bars indicate normal chromosome regions. 
 
 
 
only 5% of the cases is explained by microscopically visible chromosomal rearrangements. 
Thus, it is anticipated that this technology will soon replace routine chromosome analysis 
in the postnatal diagnosis of patients with mental retardation. In addition, it may be 
expected based on its successful application to mental retardation that molecular 
karyotyping will soon be used as a screening tool for microdeletions and microduplications 
in other diseases as well, including common complex and/or multifactorial diseases such 
as asthma, epilepsy, autism, rheumatoid arthritis and schizophrenia. 
 
 
7.3 Resolving the genetic cause of known syndromes 
 
In addition to screening individuals with mental retardation, high-resolution genome 
profiling technologies may also facilitate the identification of disease genes underlying 
known syndromes for which the genetic cause has remained elusive. The specific 
phenotype observed in patients with such syndromes allows for a stringent pre-selection of 
patients whose DNA can subsequently be interrogated using such high-resolution genome 
a 
 
b 
 
     Chapter 7      
   
 
            
116 
profiling techniques. In Chapter 3 we describe the localization and identification of the 
gene underlying CHARGE syndrome, through the detection and characterization of 
microdeletions by array CGH. Sequence analysis of nine genes located within the minimal 
region of deletion overlap revealed causative mutations in CHD7, a novel member of the 
chromodomain helicase DNA-binding gene family, in the majority of individuals with 
CHARGE syndrome without deletions. From these results, we concluded that CHARGE 
syndrome is caused by haploinsufficiency of the CHD7 gene, either by microdeletions 
encompassing the CHD7 gene, or by mutations within this gene. 
 
After our initial identification of CHD7 as the causative gene for CHARGE syndrome, four 
follow-up studies have reported on the frequency and spectrum of CHD7 mutations in over 
200 individuals with CHARGE syndrome (Aramaki et al. 2006; Jongmans et al. 2006; 
Lalani et al. 2006; Sanlaville et al. 2006). In this series, an overall detection rate of CHD7 
mutations of ~65% was achieved. The mutations were scattered throughout the coding 
exons and conserved splice sites of CHD7 (Figure 7.2a). The majority of mutations 
represented nonsense or frame shift mutations (74%), predicted to result in premature 
termination of the protein, most likely leading to haploinsufficiency. However, we assume 
that the mutation detection rate of 65% is an underestimation, as three of four studies 
were not designed to identify exonic deletions (Jongmans et al. 2006; Lalani et al. 2006; 
Sanlaville et al. 2006) and, in addition, all four studies included patients not strictly 
fulfilling the CHARGE criteria (Blake et al. 1998). In one study, 38 of such ‘CHARGE-like’
patients were included for CHD7 mutation analysis (Jongmans et al. 2006). In none of 
these patients mutations could be identified. Exclusion of such ‘CHARGE-like’ patients from 
this study would increase the mutation rate to 96% for patients that strictly fulfil the 
CHARGE criteria. 
 
Although CHD7 point mutations are the main cause of CHARGE syndrome, several 
additional microdeletions encompassing the CHD7 gene have been detected (Figure 
7.2b). These deletions range from a submicroscopic intragenic deletion of exons 8-12 
(Aramaki et al. 2006) to a large cytogenetically visible ~18 Mb deletion encompassing the 
region 8q11.2-q13 (Arrington et al. 2005). In addition to CHD7 deletions, also 
translocations disrupting the CHD7 gene have been identified, including a 
t(8;13)(q11.2;q22) in a monozygotic twin pair (Johnson et al. 2006). The 
frequency of (sub)microscopic chromosome rearrangements (deletions and translocations) 
of CHD7 in individuals with CHARGE syndrome is at present ~5% (Vissers et al. 
unpublished results). 
 
As yet, the exact biological function of CHD7 remains to be established. However, like its 
family members, CHD7 is thought to play an important role in chromatin remodeling 
during early development, allowing a level of epigenetic control over target genes 
expressed in mesenchymal cells derived from the cephalic neural crest. Embryonic 
expression profiling studies of mouse and chicken Chd7 showed expression in exactly 
those tissues that are affected in human CHARGE syndrome patients (Bosman et al. 2005; 
Aramaki et al. 2007). Moreover, mRNA in situ hybridization analysis of the CHD7 gene 
during early human development emphasized a role of CHD7 in the development of the 
central nervous system, inner ear, and neural crest of pharyngeal arches, thus, 
underscoring a good correlation between the CHD7 expression pattern and the various 
developmental anomalies observed in CHARGE syndrome (Sanlaville et al. 2006). 
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Placed in a broader perspective, molecular karyotyping may be best suited for resolving 
the genetic cause of known syndromes that involve haploinsufficiency as the disease 
causing mechanism. Whether this latter is the case, may be impossible to predict from the 
phenotype alone. For example, much effort went into a strategy that aimed at the 
identification of the gene that causes Noonan syndrome by detecting deletions in individual 
patients with a Noonan-like phenotype (Caballin et al. 1891; Onufer et al. 1987; Robin et 
al. 1995; Ion et al. 2000). This strategy, however, failed because all causative mutations 
of the PTPN11 gene and KRAS gene turned out to be missense mutations (Tartaglia et al. 
2001; Schubbert et al. 2006). A further constraint on the use of deletion and duplication 
screening for disease gene identification is related to the local genome composition. The 
frequency of patients with large rearrangements appears to depend on the sequence 
characteristics of the region involved, which may contain repeats such as LCRs that 
predispose to deletion (Stankiewicz & Lupksi 2002; paragraph 7.5). Another relevant 
consideration is the presence of further genes in the region that are subject to gene 
dosage effects. Significant mental retardation, for instance, predicts the presence of 
microdeletions for a number of single gene conditions, such as Rieger syndrome (de Baere 
et al. 2003), Saethre-Chotzen syndrome (Johnson et al. 1998) and Aniridia Type II (Ton et 
al. 1991; Crolla & van Heyningen 2002). In addition, combinations of clinical features may 
occur through contiguous gene syndromes, which continue to be defined (paragraph 7.4, 
Table 7.1). In the case of CHARGE syndrome, the index patient with the ~5 Mb deletion 
presented with relatively severe mental retardation (Chapter 3). Thus, selection of 
individual cases presenting with mental retardation and additional clinical features will 
increase the chance of disease gene discovery. 
 
The relatively low frequency of microdeletions in CHARGE syndrome indicates that it is 
difficult to predict a priori how many patients need to be tested before submicroscopic 
rearrangements are encountered which, subsequently, may lead to disease gene 
discovery. This is nicely illustrated by the discovery of NMYC as the causative gene for 
Feingold syndrome. A 4 Mb microdeletion was identified in one out of five families with the 
Feingold syndrome that were studied for linkage on chromosome 2 (Celli et al. 2000). 
Haploinsufficient point mutations of the NMYC gene were subsequently identified in several 
additional families, but also a second 1.2 Mb microdeletion, thus yielding a provisional 
estimate of 10% occurrence for microdeletions in this syndrome (van Bokhoven et al. 
2005).  
 
In conclusion, microdeletions and/or microduplications may comprise up to 15% of all 
mutations underlying monogenic diseases. Thus, molecular karyotyping can be used as a 
powerful disease gene identification strategy, especially when straightforward linkage 
mapping is impractical or impossible due to reproductive lethality. This strategy may 
become even more succesfull when combined with whole-genome sequencing. 
 
 
7.4 Unravelling the genetic cause of new syndromes 
 
The possibility to screen patients with mental retardation in a high throughput manner at a 
genome-wide scale using array CGH has substantially increased the chance to identify 
novel ‘microdeletion/microduplication syndromes’. In general, the identification of novel 
syndromes is based on an accurate phenotype-genotype correlation. From an historical 
perspective, this correlation relied on a detailed and accurate phenotypic description of the 
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patients after which overlapping chromosomal rearrangements were uncovered. 
Nowadays, obtaining a genotype has become much easier and, in addition, has never been 
more accurate. As a result, the identification of novel syndromes may start with the 
identification of overlapping genotypes, i.e., the identification of overlapping 
microdeletions and/or duplications in heterogeneous patient groups. Such overlapping 
microdeletions and/or duplications are most likely identified in large patient cohorts 
screened in a high-throughput diagnostic setting using high-resolution genome profiling 
technologies (see above 7.2). This approach has been proven successful as reported in 
Chapter 4. Screening of 1,200 individuals with mental retardation in a diagnostic setting 
using a tiling resolution microarray and MLPA analysis revealed three patients with similar-
sized overlapping microdeletions on 17q21.31. Subsequent detailed clinical examination of 
these patients revealed a clear phenotypic overlap, thus defining a new syndrome. The 
overlapping deletions encompass six known genes, including CRHR1, and MAPT. Both 
latter genes are highly expressed in brain and have been implicated in several 
neurodegenerative and behavioral phenotypes. These characteristics turn these genes into 
excellent candidates for dosage-sensitive genes underlying the 17q21.31 microdeletion 
syndrome (see also paragraph 7.5). 
 
Interestingly, the 17q21.31 microdeletion syndrome is associated with the presence of an 
inversion-bearing haplotype (H2 allele), in which low-copy repeats are re-organized in 
such way that they predispose the chromosome to microdeletions in meiotic 
recombination. The 17q21.31 inversion haplotype is carried at a frequency of ~20% in 
populations of European ancestry, with evidence that it is under positive selection. In other 
populations a lower frequency for this H2 allele is observed (Stefansson et al. 2005). 
Rearrangements mediated by this structurally different haplotype could account for up to 
1% of the total population of mental retardation, but with the inversion haplotype carried 
at different frequencies in different ethnic populations, the microdeletion frequency is likely 
to differ as well (Axton 2006). Predisposing parental inversion are a common finding in 
other microdeletion syndromes, such as Angelman syndrome, Williams Beuren syndrome 
and Sotos syndrome (Osborne et al. 2001; Gimelli et al. 2003; Visser et al. 2005). The 
breakpoints of the inversion polymorphism are identical to the breakpoints of the common 
microdeletion, and are thus flanked by low-copy repeat structures (Gimelli et al. 2003). As 
such, the predisposing inversion can be considered a genomic polymorphism that 
facilitates the occurrence of the disease-associated rearrangement. Due to the emerging 
availability of high-resolution genome profiling technologies, it is expected that such 
predisposing submicroscopic inversions will be identified at an increasing rate. 
 
This newly identified 17q21.31 microdeletion syndrome is not the only example of a novel 
syndrome identified by high-resolution, genome-wide profiling technologies. Recurrent 
overlapping submicroscopic rearrangements have also been identified at chromosome 
1q21.1, 2q22.3-q23, 5q35.1, and 15q24, for which assessment of the phenotypic overlap 
in the patients is currently ongoing (Sharp et al. 2007; Table 7.1). Together, these 
findings emphasize the need to search for additional de novo genomic rearrangements as 
a cause of congenital abnormalities (Lupski 2006) and indeed confirm the use of genome-
profiling technologies as a tool for the elucidation of such novel syndromes. In order to 
facilitate genotype-phenotype correlations and the identification of additional syndromes, 
databases have been designed, including (i) ECARUCA (European Cytogeneticists 
Association Register of Unbalanced Chromosome Aberrations), a database collecting and 
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providing cytogenetic and clinical information on rare chromosomal disorders including 
microdeletions and microduplications (Feenstra et al. 2006; www.ecaruca.net/), and (ii) 
DECIPHER (DatabasE of Chromosome Imbalance and Phenotype in Humans Using Ensembl 
Resources), a database fully dedicated to submicroscopic chromosome rearrangements 
(www.sanger.ac.uk/PostGenomics/decipher/). 
 
In conclusion, genotype-phenotype correlations are facilitated by the use of genome 
profiling technologies and can lead to the assignment of specific phenotypic traits to 
individual genes. Moreover, these detailed genotype-phenotype correlations can lead to 
the identification of novel syndromes.  
 
 
7.5 Single gene disorder, contiguous gene syndrome or genomic disorder? 
 
Chromosome rearrangements may occur via two main molecular mechanisms, (i) 
nonallelic homologous recombination (NAHR) and (ii) non-homologous recombination, 
including non-homologous DNA end joining (NHEJ). NAHR appears to be the predominant 
mechanism underlying recurrent rearrangements that are caused by misalignment of 
LCRs, sharing long regions of high homology. For non-recurrent rearrangements, in which 
such long stretches of homology are not present, joining of the DNA ends appears to occur 
predominantly by NHEJ (Shaw & Lupski 2004; Lupski & Stankiewicz 2005; Shaw & Lupski 
2005; Lieber et al. 2006; Lupski & Stankiewicz 2006). In order to classify a newly 
identified syndrome as a single gene disorder, a contiguous gene syndrome or a genomic 
disorder, the first step is to determine which of the above mechanisms has mediated the 
genomic rearrangement. A first clue for this may come from the genomic size and the 
exact breakpoint locations of the identified rearrangements. If the genomic size of the 
rearrangement in different patients is largely identical, and the breakpoints cluster 
together, it is likely that genomic architectural features such as LCRs or other repeat 
sequences (Alu sequences, LINE and SINE elements) have predisposed to genome 
rearrangements observed (Shaw & Lupski 2004). Next, detailed in silico analyses using 
bioinformatic tools may be used to identify such genomic architectural features located at 
the breakpoints. These genomic architectural features, if present, should be mapped 
according their respective orientation since directly orientated repeats may mediate the 
formation of microdeletions and microduplication through NAHR. In case directly 
orientated repeat sequences are observed, the disease meets all criteria for a genomic 
disorder. However, this does not classify the disease as a contiguous gene syndrome. In 
general, multiple genes are affected by submicroscopic rearrangements, but not all genes 
may contribute to the phenotype. Thus, extensive genotype-phenotype correlations should 
be performed to determine whether the observed phenotype can be attributed to dosage 
variation of a single gene located within the rearranged interval, classifying the disease as 
a single gene disorder, or whether multiple genes located within the rearranged interval 
are responsible for distinct clinical features, classifying the disease as a contiguous gene 
syndrome. In this thesis three disease-related rearrangements are reported that can be 
classified according to the above-mentioned criteria, i.e, CHARGE syndrome, 17q21.31 
microdeletion syndrome and non-recurrent complex rearrangements involving the short 
arm of chromosome 17. 
 
CHARGE syndrome can be classified as a single gene disorder, since the majority of 
patients carry a single point mutation in the CHD7 gene, whereas only in a minority of
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Figure 7.3 
Schematic representation of the causes of a single gene disorder and a genomic disorder and the 
molecular mechanisms involved. The normal genomic orientation is given first with below the mutations 
leading to disease. (a) Single gene disorder such as CHARGE syndrome. The majority of individuals 
have a mutation in a dosage-sensitive gene, whereas the minority of individuals exhibit a 
(sub)microscopic deletion. The deletions are all of different size and the respective breakpoints are 
scattered. All deletions, however, include the dosage-sensitive gene. (b) Genomic disorders such as 
17q21.31 microdeletion syndrome. The majority of individuals have a submicroscopic deletion caused 
by nonallelic homologous recombination between the directly orientated LCRs, whereas a minority of 
individuals has a mutation in a dosage-sensitive gene within the deleted region. 
 
 
 
patients the disease is caused by a genomic rearrangement affecting the CHD7 gene and, 
in some cases, a few other genes (paragraph 7.3). This notion is supported by several 
other observations. The severity of the phenotype, for example, does not seem to 
correlate with the nature of the anomly, i.e., patients with a point mutation in CHD7 are 
similarly affected as patients exhibiting chromosomal (micro)deletions involving various 
additional genes. In addition, the (micro)deletions are non-recurrent and different in size 
and, thus, exhibit a variable distribution of the breakpoints. Furthermore, detailed in silico 
analyses of the breakpoints of these non-recurrent rearrangements thus far failed to 
reveal the presence of genomic architectural features such as LCRs (Vissers et al. 
unpublished results). Therefore, other mechanisms, such as NHEJ, have most likely have 
mediated the formation of the observed (micro)deletions and translocations in CHARGE 
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syndrome. Based on these data we conclude that CHARGE syndrome is a genuine single 
gene disorder, sporadically caused by a microdeletion (Figure 7.3a).  
 
The second example described in this thesis is the newly discovered 17q21.31 
microdeletion syndrome. All three patients, as well as ~25 patients reported by others, 
exhibited similar sized microdeletions and LCRs flanking the deletions (Chapter 4; Sharp et 
al. 2006; Shaw-Smith et al. 2006, Koolen et al. manuscript in preparation). These 
characteristics classify the 17q21.31 microdeletion syndrome as a true genomic disorder 
(Figure 7.3b). Given the genomic complexity of the 17q21.31 region, the detection of 
deletions and inversions, it may only be a matter of time before a (predictable) reciprocal 
duplication syndrome is identified. Whether the 17q21.31 microdeletion syndrome is a 
contiguous gene syndrome with sporadic point mutations, or a single gene disorder with 
sporadic microdeletions, still remains to be determined. The contribution of individual 
genes located within the deletion interval to the disease phenotype still awaits elucidation. 
Identification of such mutations may, however, be more difficult than anticipated. In 
contrast to CHARGE syndrome, the phenotypic spectrum of the 17q21.31 microdeletion 
syndrome is not fully established yet and, as such, does not allow for a stringent patient 
selection for subsequent mutation analysis. Additionally, patients with a mutation may 
present with a completely different phenotype than observed so far for patients exhibiting 
a microdeletion. Alternatively, there may be no patients with point mutations, and all 
patients with this syndrome may have microdeletions. However, if a mutated gene exists 
for this syndrome, the only requirement is that it is dosage-sensitive, thus, leading to 
haploinsufficiency when mutated. A widely used strategy is to sequence all genes within 
the deletion interval in patients that fulfill the clinical criteria, but do not carry a 
microdeletion. Such strategy is relatively easy to accomplish if only a few genes reside 
within the interval, but may become laborious if many genes reside in it. In the latter case, 
additional experimental data may provide insight into which gene(s) may serve as 
candidates, i.e., are dosage-sensitive. For instance, RNA expression-profiling of patients 
with a microdeletion may reveal decreased expression of one (or few) of the genes located 
within the deletion interval. Subsequent sequence analysis of such gene(s) in individuals 
fulfilling the phenotypic criteria, but without microdeletions, may establish whether it is the 
causative gene for the syndrome under investigation (Figure 7.4). Additionally, RNA 
expression-profiling data may point to dosage-sensitive gene(s) located outside the 
deletion interval, which may be affected due to a position effect (Merla et al. 2006). 
 
The vast majority of all microdeletions and microduplications represent, however, 
sporadic, non-recurrent rearrangements. In Chapter 6 examples of two such patients are 
described, both exhibiting a complex rearrangement involving the short arm of 
chromosome 17. In total, 17 breakpoints were analyzed of which four were located within 
LCR structures, suggesting NAHR as the underlying mechanism. The remaining 
breakpoints were not linked to particular genomic features suggesting that, in addition to 
NAHR, other mechanisms may have been responsible for the formation of the 
rearrangements. Although these two examples are not representative for the majority of 
sporadically occurring rearrangements due to their complexity, they do indicate that NAHR 
may not be the predominant mechanism in the formation of these rearrangements. 
Preliminary analysis of 100 chromosomal rearrangements identified in a diagnostic setting, 
revealed that the majority of the breakpoints did not coincide with currently known 
genomic architectural features (Koolen et al. unpublished results). Thus, as most 
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Figure 7.4 
Schematic overview of the procedure for finding a dosage-sensitive gene(s). Molecular karyotyping 
reveals a microdeletion containing genes ‘a’ to ‘e’ in 3 individual patients. Subsequent expression 
profiling using RNA from these patients (preferably from a tissue affected by the disease) shows one of 
the genes, in this example gene d, to be decreased in expression relative to a normal control. Sequence 
analysis of gene d in patients with similar phenotypic features but without a microdeletion, may identify 
mutations in gene d, thus explaining the phenotype (in the majority) of the patients. 
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submicroscopic rearrangements are sporadic and non-recurrent, these observations stress 
the need to search beyond these architectural features and the mechanisms of NAHR and 
NHEJ. Alternative architectural features may include common fragile sites, recombination 
hotspots and/or various recombination-associated motifs. These features are known to 
predispose to chromosomal rearrangements (Visser et al. 2005; Arlt et al. 2006; 
Hellenthal & Stephans 2006; Lindsay et al. 2006), but their exact role in the occurrence of 
sporadic rearrangements remains to be elucidated. 
 
In conclusion, it appears that (syndromic) recurrent rearrangements are mainly caused by 
NAHR, mediated by the presence of directly orientated LCRs, whereas sporadic, non-
recurrent, rearrangements are mainly caused by NHEJ. Since the majority of 
rearrangements are non-recurrent in nature, future research should be focused on NHEJ 
(or similar mechanisms) and the genomic architectural features that may mediate these 
recombination phenomena. 
 
 
7.6 The complexity of copy number variation 
 
Since the introduction of chromosome banding techniques, there has been awareness of a 
certain degree of gross genomic variation without clinical significance. Examples of these 
include variation in heterochromatic centromeric regions, variation in p-arms of acrocentric 
chromosomes and the occurrence of certain pericentric inversions. In analogy with these 
cytogenetically visible variations, submicroscopic copy number variations (CNVs) have 
recently been identified in healthy individuals due to the increased resolution of genome-
wide screening technologies such as array CGH. An inventory of such submicroscopic 
structural CNVs is supported by two databases, i.e., the Database of Genomic Variants 
(http://projects.tcag.ca/variation/), aiming at cataloging large-scale variation >1kb 
published in peer-reviewed literature, and the Human Structural Variation Database 
(http://hgvbase.cgb.ki.se/), a catalogue of human genomic polymorphisms ascertained by 
experimental and computational analyses. With the publication of a first-generation CNV 
map of the human genome, it became apparent that CNVs are much more predominant 
than anticipated until recently. A total of 1447 different CNVs were revealed in 270 healthy 
individuals (Redon et al. 2006a). These CNVs encompass ~12% of the total human 
genome (~360 Mb), and can be classified into five different types, being (I) loci showing 
deletions, (II) loci showing duplications, (III) loci showing both deletions and duplications, 
(IV) loci showing multi-allelic variation, and (V) complex loci whose precise nature was too 
difficult to discern. In Chapter 5, a series of 12 genomic loci reported to exhibit CNV in 
healthy individuals was characterized in detail using MLPA analysis. By doing so, for only 
seven of these loci CNV was confirmed, whereas based on the initial array CGH data, all 
regions were classified as type III CNV. In addition, after detailed MLPA analysis, at least 
three out of the seven loci showed multi-allelic variation, thus classifying these three as 
type IV CNV. The other four loci remain to be classified as type III CNV. These results 
underscore the need for (i) validation of CNVs by independent methods and (ii) detailed 
copy number analyses before cataloging CNVs in databases.  
 
Thousands of functional sequences are affected by loci exhibiting CNV, including genes 
associated with olfaction, immunity and protein secretion (Nguyen et al. 2006; Redon et 
al. 2006a). These genes may be amenable to copy number variation as a means to adapt 
to environmental changes (Zhang et al. 2006). However, there is also increasing evidence
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Figure 7.5 
Schematic representation of disease-related copy number variation (CNV). (a) Old concept: all genes 
are present in two genomic copies in a healthy person, and deletion or duplication of one copy causes 
disease. (b) New concept: for genes located in CNV loci multiple copies exist without causing disease; 
instead, they may affect normal phenotypic variation. (c) For a subset of such genes, disease may be 
elicited when the DNA copy number exceeds a certain threshold. (d) For complex diseases, two or more 
genes in multiple CNV loci need to exceed these thresholds in order to cause disease. Threshold levels 
for disease are indicated by dark gray within the triangle indicating the distribution of DNA copy 
numbers within the population. 
 
 
 
that CNV loci encompass genes that are related to disease. Examples of such genes 
include the Fcgr3 gene in renal disease (Aitman et al. 2006) and the CCL3L1 gene in HIV 
infection (Gonzalez et al. 2005). The latter two studies have shown that detailed analysis 
of the exact copy numbers of genes located within such regions is of utmost importance 
since different copy numbers may have different phenotypic consequences. With this 
discovery, the dogma that every gene within the genome has two copies and that loss or 
gain of one such copy may cause disease has become obsolete (Figure 7.5a). Instead, 
the new paradigm is that genes located within CNV loci vary in copy number and that 
these genes may cause disease once their copy numbers reach above or below certain 
thresholds (Figure 7.5b-c). Additionally, diseases may be caused by a concerted action of 
two or more genes located in different CNV loci (Figure 7.5d). Most likely, linking CNV loci 
to disease will not be as straightforward as linking a specific gene mutation to a single 
gene disorder. Instead, linking CNV loci to disease will be similar to linking single 
nucleotide polymorphisms (SNPs) to common diseases, i.e., the revelation of disease 
association and disease susceptibility. Related to this notion, it may be expected that some 
diseases are caused by a combination of CNV loci and SNPs, thus interlinking several levels 
of normal human variation to disease. 
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With the new paradigm as described above, the assumption that CNVs are not causative 
for disease, simply because they are also encountered in healthy individuals, may no 
longer be justified. Especially in a diagnostic setting this conclusion may have serious 
consequences, as CNVs inherited through non-affected parents are currently not 
considered to be causative for disease. This is, however, questionable for a number of 
reasons apart from those mentioned above. The inherited CNV may, for example, unmask 
a recessive mutation on the second allele (Lupski & Stankiewicz 2005; Lesnik Oberstein et 
al. 2006; Marongiu et al. 2007). In order to find such a recessive mutation, all genes 
located within the deleted region have to be sequenced. This is relatively easy to achieve 
in case only one inherited copy number imbalance is identified containing a limited number 
of genes. On average, however, 30-50 CNVs ≥10 kb are encountered, all containing 
multiple genes, thus making this approach extremely laborious (Conrad et al. 2006; Hinds 
et al. 2006; McCarroll et al. 2006). Another reason for not rejecting inherited CNVs as 
causative is that it has been found that affected individuals may inherit a CNV through 
transmission from an unaffected parent which, instead of being clinically irrelevant, may 
point at a variable penetrance resulting from dosage variation (Lupski et al. 1991; Chance 
et al. 1993; Redon et al. 2006a). 
 
In addition to functional genes, 99% of all currently reported CNVs overlap with conserved 
non-coding sequences (Redon et al. 2006a). Conserved non-coding sequences (CNSs) 
represent stretches of DNA that are not genic, i.e., they do not produce transcripts (coding 
or non-coding) with functional properties. There are approximately 327,000 CNSs in the 
human genome, which together represent 1-2% of this genome. The majority of CNSs are 
intergenic, thus essentially populating regions not occupied by genes (Dermitzakis et al. 
2004; Dermitzakis et al. 2005). Evolutionary analyses strongly support a conserved 
functional role for these CNSs (Duret et al. 1993; Hardison et al. 1997; Hardison 2000; 
Glazko et al. 2003; Tanabe et al. 2002) and mutations in CNSs are known to cause 
disease, such as β-thalassaemia, preaxial polydactyly, and X-linked deafness type 3 
(Kioussis et al. 1983; Driscoll et al. 1989; Lettice et al. 2002; Lettice et al. 2003; de Kok 
et al. 1995b; de Kok et al. 1996). As CNSs may be dosage-sensitive, copy number 
variation of CNSs may contribute to phenotypic variation and/or disease. Categorizing 
CNSs located in CNV loci according to their functional characteristics will be a valuable first 
step in furthering our understanding of the role of CNSs, and their relation to copy number 
variation in health and disease. 
 
In conclusion, it has undisputedly been acknowledged that large-scale copy number 
variation within the human genome is much more extensive and complex than anticipated 
before. Future research should be aimed at studying the genomic content of these CNVs 
(both genic and non-genic) and a detailed assessment of the copy number spectrum of its 
sequences. It is anticipated that, in the end, a considerable number of CNVs may be linked 
to disease, either directly by causing disease, or indirectly by affecting disease 
susceptibility. 
 
 
7.7 Concluding remarks 
 
In February 2001, the International Human Genome Sequencing Consortium and Celera 
Genomics reported the first draft sequence of the human genome (Lander et al. 2001). In 
the years that followed, this draft sequence has been instrumental for the systematic 
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analysis of the human genome, including the identification/annotation of novel genes, the 
elucidation of regional differences in genome composition and the identification of single 
nucleotide polymorphisms. In addition, new high-throughput approaches such as array 
CGH were developed that facilitated and markedly accelerated the analysis of the human 
genome at a large scale, including the detection of an unprecedented level of copy number 
variation within it. Together, these approaches have contributed significantly to the rapid 
development of molecular karyotyping, which allows disease phenotypes to be directly 
linked to gene dosage alterations. 
 
The new concept of molecular karyotyping has significantly changed the field of clinical 
cytogenetics and clinical diagnostics in the last 4 years and, without doubt, will continue to 
do so in the years to come. The ability to obtain detailed quantitative copy number 
information has already led to a significant improvement in diagnostic yield in e.g. patients 
with mental retardation and is likely to do so for other diseases as well. These diseases will 
not only include rare congenital disorders but also common complex disorders such as 
autism, epilepsy, and schizophrenia. The genetic basis of several clinical syndromes has 
been uncovered by this approach and many more new syndromes await discovery. Finally, 
detailed insight into human genome plasticity will be obtained by unraveling the genomic 
architectural features and mechanisms underlying copy number variation in health and 
disease. 
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Summary  
 
Chromosomal rearrangements can lead to a wide variety of serious clinical manifestations, 
including mental retardation and congenital malformation syndromes. Chromosomal 
rearrangements larger than 5-10 Mb in size can be detected by conventional karyotyping. 
A considerable number of clinical disorders, however, is caused by submicroscopic 
chromosomal rearrangements smaller than 5-10 Mb in size. To routinely detect these 
rearrangements, an efficient and robust genome-wide technology is needed. One such 
technology is array-based comparative genomic hybridization (array CGH), an approach 
which is also referred to as molecular karyotyping (Chapter 1). In analogy to the 
application of array CGH in cancer research, we reasoned that this technology might also 
be suited for the detection of submicroscopic chromosomal rearrangements in patients 
with unexplained mental retardation and/or congenital malformation syndromes. The 
specific aim of this thesis was to explore the feasibility of the array CGH technology for the 
delineation of DNA copy number alterations for (i) applied clinical genetic and (ii) basic 
genome research purposes.  
 
Array CGH for the detection of single copy chromosome imbalances in patients 
with unexplained mental retardation 
Mental retardation occurs in 2-3% of the general population. Although a considerable 
number of cases can be explained by the presence of gross chromosomal rearrangements, 
in the majority of cases the etiology has so far remained unknown. Submicroscopic 
chromosomal rearrangements are likely to explain the etiology of mental retardation in at 
least a proportion of the cases. As outlined above, array CGH may serve as a suitable new 
technique to capture these rearrangements. In Chapter 2 we described the generation of a 
microarray consisting of BAC clones selected to cover the entire human genome with a 1 
Mb resolution. After optimization, array CGH was employed using this microarray to screen 
20 patients with unexplained mental retardation and congenital anomalies for the presence 
of submicroscopic chromosome rearrangements. Five such rearrangements were identified 
within this series, two of which appeared to be associated with the clinical features 
observed. The three remaining rearrangements were considered to be benign copy number 
variants, as they were also encountered in one of the phenotypically normal parents. 
 
After this pilot study, additional follow-up studies showed that submicroscopic 
subtelomeric and/or interstitial chromosome rearrangements together explain up to 20% 
of the previously unexplained cases of mental retardation. Based on these observations we 
argue that genome-wide copy number profiling technologies, such as array CGH, merit a 
rapid implementation in the diagnostic testing of patients with unexplained mental 
retardation (Chapter 7). 
 
Array CGH for resolving the genetic cause of known syndromes 
It has been reported that microdeletions may occur at low frequencies in single gene 
disorders. Based on this information, we hypothesized that the identification of such 
microdeletions might be instrumental for resolving the genetic causes of clinical disorders 
with unknown etiologies. In Chapter 3 we tested this hypothesis for CHARGE syndrome, a 
congenital malformation syndrome denoting a nonrandom pattern of phenotypic features 
including choanal atresia, malformations of the heart, inner ear and retina. Although 
several aspects pointed at the involvement of a genetic factor, its cause had remained 
elusive. Using the genome-wide 1 Mb-resolution BAC array (see above), we identified 
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overlapping microdeletions on chromosome 8q12 in two patients with CHARGE syndrome. 
Screening of 17 additional patients with CHARGE syndrome using a tiling resolution 
chromosome 8 BAC array did not reveal any new microdeletions. Subsequently, all genes 
residing within the shortest region of deletion overlap were sequenced in these 17 
patients. In the majority of them we identified mutations in the CHD7 gene, thereby 
resolving the genetic cause of CHARGE syndrome. Subsequent follow-up studies revealed 
a mutation rate of ~65%, whereby the mutations were scattered throughout the CHD7 
gene without apparent genotype-phenotype correlations. In addition, several 
(micro)deletions affecting the CHD7 gene were reported by others, ranging from small 
exonic deletions to large cytogenetically visible deletions. 
 
By resolving the genetic cause of CHARGE syndrome, we have shown that array CGH can 
be used as a powerful disease gene identification strategy. As microdeletions and 
microduplications may comprise up to 15% of all mutations underlying single gene 
disorders, we anticipate that this strategy will also be applicable to a variety of other 
clinical disorders in which genetic factors are suspected to be involved (Chapter 7). 
 
Array CGH for unraveling the genetic cause of new syndromes 
The possibility to screen large numbers of patients with mental retardation in a high-
throughput manner at a genome-wide scale, has significantly increased the chance to 
identify novel microdeletion and/or microduplication syndromes. Array CGH potentially 
allows the identification of such novel syndromes through the identification of (partially) 
overlapping deletions or duplications, without phenotypic preselection of patients. In 
Chapter 4 we reported the identification of a new microdeletion syndrome involving 
chromosome region 17q21.31. A total of three overlapping microdeletions within this 
region were uncovered in a large cohort of patients with mental retardation using high-
resolution genome profiling approaches. Detailed clinical examination of these patients 
revealed a clear phenotypic overlap, including mental retardation, hypotonia and 
characteristic facial features.  
 
The use of genome-wide profiling technologies does not only facilitate the identification of 
novel clinical syndromes, but also the establishment of genotype-phenotype correlations. 
Ultimately, this may lead to the assignment of specific phenotypic traits to individual genes 
(Chapter 7).  
 
The assessment of large-scale DNA copy number variation within the human 
genome 
Since the introduction of chromosome banding techniques, there has been awareness of a 
certain degree of genomic variation between individuals, without apparent clinical 
consequences. The use of high-resolution genome profiling technologies has resulted in 
the identification of a novel form of genomic variation, i.e., submicroscopic copy number 
variation (CNV). Such CNVs may encompass large genomic segments ranging in size from 
a single kilobase to multiple megabases. Due to its recent discovery, the full nature and 
extent of these CNVs in the human genome is still largely unexplored. In Chapter 5 we 
described a detailed analysis of twelve CNVs in five different ethnic populations. We 
characterized the genomic architecture of the chromosomal regions involved and 
determined individual CNV frequencies in the different ethnic populations. Moreover, we 
estimated the actual DNA copy numbers of several of the CNVs and used this information 
to determine the relative distribution of DNA copy numbers. These analyses showed 
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significant inter- and intra-population differences in CNV distributions and actual DNA copy 
numbers. Our results indicate that (semi-) quantitative analyses of CNVs are a prerequisite 
for the definite establishment of their role in health and disease.  
 
This notion was further supported by the observation that CNVs play a role in disease 
susceptibility when DNA copy numbers surpass certain thresholds. In conjunction with 
recent reports indicating that ~12% of the human genome exhibits CNV, it is generally 
accepted now that CNVs are much more common and complex than anticipated before. 
Although additional studies are required to fully unravel the nature and role of CNVs, it is 
expected that a considerable number of them will be linked to disease and/or disease 
susceptibility (Chapter 7). 
 
The role of genomic architecture in mediating copy number variation 
As yet, little is known about the etiology of CNVs. It is known, however, that certain 
genomic architectural features such as low-copy repeats (LCRs) may facilitate CNV 
formation. Due to extensive sequence homology, LCRs can mediate meiotic misalignment, 
followed by a molecular mechanism referred to as non-allelic homologous recombination 
(NAHR). Most clinically recognizable microdeletion syndromes appear to result from LCR-
mediated NAHR. As such, the recurrent nature of these CNVs does not represent a random 
event but, instead, reflects the underlying genomic architectural feature. 
 
The vast majority of disease-causing CNVs identified to date is, however, non-recurrent in 
nature and, consequently, questions the involvement of genomic architectural features 
such as LCRs in their etiology. In Chapter 6 two examples of complex, non-recurrent, 
rearrangements involving chromosome 17p are presented, for which we examined the 
involvement of genomic architectural features, including LCRs. To this end, we mapped in 
detail all breakpoints using array CGH and dual color FISH. Our results suggest that LCRs 
in proximal 17p may have facilitated the formation of at least some of these CNVs and, 
thus, that these genomic architectural features may also be involved in the generation of 
non-recurrent CNVs. The observation that not all breakpoints coincided with LCRs suggests 
the presence of other architectural features and/or molecular mechanisms within the 
human genome that may facilitate the etiology of CNVs. These features and/or 
mechanisms still remain to be resolved (chapter 7). 
 
Concluding remarks 
Over the last few years, the concept of molecular karyotyping has rapidly changed the 
field of clinical genetics and genome research and, without any doubt, will continue to do 
so in the years to come. In case of clinical genetics, we conclude that molecular 
karyotyping has led to (i) a significant increase in the diagnostic yield in patients with 
unexplained mental retardation and/or malformation syndromes, (ii) the identification of a 
gene underlying CHARGE syndrome, and (iii) the identification of a novel microdeletion 
syndrome involving chromosome 17q21.31. In case of genome research, we conclude that 
molecular karyotyping has led to novel insight into (i) the occurrence of copy number 
variation within the human genome, and (ii) recombination mechanisms and genomic 
architectural features underlying the occurrence of copy number variation. Based on the 
above, we conclude that molecular karyotyping serves as a powerful tool for linking gene 
dosage alterations to (disease) phenotypes. 
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Samenvatting 
 
Chromosoomafwijkingen kunnen tot ernstige klinische aandoeningen leiden zoals 
verstandelijke handicaps en aangeboren afwijkingen. Chromosoomafwijkingen, groter dan 
5-10 Mb, kunnen worden gedetecteerd via conventionele karyotypering. Een aanzienlijk 
aantal klinische aandoeningen wordt echter veroorzaakt door submicroscopische 
afwijkingen, kleiner dan 5-10 Mb en zijn derhalve niet detecteerbaar met karyotypering. 
Om deze kleine afwijkingen routinematig op te kunnen sporen is een nieuwe efficiënte 
techniek nodig om het genoom te onderzoeken met een resolutie die hoger is dan 
conventionele karyotypering. Een techniek die daarvoor in aanmerking komt is 
‘microarray-based comparative genomic hybridization’ (array CGH), een methode die ook 
met de term ‘moleculaire karyotypering’ wordt aangeduid (Hoofdstuk 1). Op basis van de 
succesvolle toepassingen van array CGH in het kankeronderzoek, veronderstelden wij dat 
deze technologie ook toepasbaar zou kunnen zijn voor het opsporen van 
submicroscopische afwijkingen in patiënten met onverklaarde mentale retardatie 
(verstandelijke handicap) en/of aangeboren malformatie syndromen. Het specifieke doel 
van dit proefschrift was dan ook om de toepasbaarheid van array CGH te onderzoeken 
voor de detectie van (submicroscopische) chromosoomafwijkingen in (i) toegepast klinisch 
genetisch onderzoek en (ii) fundamenteel genoomonderzoek. 
 
Array CGH voor de detectie van submicroscopische chromosoom afwijkingen in 
patiënten met onverklaarde mentale retardatie 
Mentale retardatie komt in 2-3% van de populatie voor. Hoewel de oorzaak van de 
mentale retardatie in een deel van de patiënten verklaard wordt door de aanwezigheid van 
grote chromosoomafwijkingen, wordt in de meerderheid van de patiënten nooit een 
verklaring gevonden. In een deel van deze patiënten kan de mentale retardatie wellicht 
verklaard worden door de aanwezigheid van submicroscopische chromosoomafwijkingen. 
Zoals hierboven beschreven zou array CGH een geschikte techniek kunnen zijn om deze 
afwijkingen te detecteren. Hoofdstuk 2 beschrijft de ontwikkeling van een microarray die 
het humane genoom representeert met één BAC kloon per megabase. Na optimalisatie 
werd deze microarray aangewend om 20 patiënten met onverklaarde mentale retardatie 
en aangeboren afwijkingen te screenen op de aanwezigheid van submicroscopische 
chromosoomafwijkingen. In deze serie werden vijf van zulke afwijkingen gevonden, 
waarvan twee geassocieerd lijken te zijn met de klinische kenmerken van de patiënt. De 
drie overige afwijkingen werden beschouwd als goedaardige DNA kopieafwijkingen omdat 
ze tevens werden teruggevonden in één van de niet aangedane ouders. 
 
Na deze eerste studie heeft aanvullend onderzoek laten zien dat submicroscopische 
subtelomere en/of interstitiële chromosoomafwijkingen tezamen ~20% van alle mentale 
retardaties verklaart. Gebaseerd op deze cijfers stellen wij voor om technieken die 
genoomwijde DNA kopieaantallen bepalen, zoals array CGH, op snelle wijze te 
implementeren in het diagnostisch testen van patiënten met onverklaarde mentale 
retardatie (Hoofdstuk 7). 
 
Array CGH voor de detectie van de genetische oorzaak van bekende syndromen  
Eerder werd gerapporteerd dat microdeleties in een lage frequentie kunnen voorkomen bij 
monogene aandoeningen. Gebaseerd op deze bevinding postuleerden wij dat het 
identificeren van dergelijke microdeleties van essentieel belang kan zijn om de genetische 
oorzaak van klinische aandoeningen met een vooralsnog onbekende etiologie te 
achterhalen. In Hoofdstuk 3 hebben we deze hypothese getoetst aan de hand van CHARGE 
syndroom, een aangeboren aandoening die gekarakteriseerd wordt door een combinatie 
van fenotypische kenmerken, waaronder afwijkingen van het hart, oor, oog en mentale 
retardatie. Hoewel verscheidene aspecten wijzen op de betrokkenheid van een genetische 
factor werd deze nooit opgehelderd. Door gebruik te maken van een 1 Mb resolutie BAC 
array hebben we in twee patiënten met CHARGE syndroom overlappende microdeleties 
gevonden in de chromosomale regio 8q12. Het screenen van 17 additionele patiënten met 
CHARGE syndroom, gebruik makend van een ‘tiling resolution’ chromosoom 8 array, leidde 
niet tot de identificatie van extra overlappende microdeleties. Derhalve werd bij deze 17 
patiënten de exacte DNA-sequentie bepaald van alle genen die in het minimale gebied van 
deletieoverlap gesitueerd waren. In de meerderheid van de patiënten werd een mutatie 
gevonden in het CHD7 gen, waarmee de genetische oorzaak van CHARGE syndroom 
opgehelderd werd. Vervolgstudies hebben inmiddels laten zien dat ~65% van de patiënten 
met CHARGE syndroom een mutatie heeft in het CHD7 gen en dat de mutaties verspreid 
zijn over het hele gen, zonder duidelijke genotype-fenotype correlaties. Tevens zijn er 
additionele (micro)deleties gevonden die het CHD7 gen bevatten, variërend in grootte van 
exondeleties tot cytogenetisch zichtbare deleties. 
 
Met de opheldering van de genetische oorzaak van CHARGE syndroom is aangetoond dat 
array CGH kan fungeren als een krachtige genidentificatie strategie. Geschat wordt dat 
~15% van alle monogene aandoeningen veroorzaakt wordt door microdeleties en/of 
microduplicaties. Op basis hiervan verwachten wij dat deze genidentificatie strategie ook 
succesvol kan zijn voor een scala van andere syndromen waarvan de genetische oorzaak 
nog niet opgehelderd is (Hoofdstuk 7). 
 
Array CGH voor het ontrafelen van nieuwe syndromen 
Array CGH heeft het mogelijk gemaakt om grote aantallen patiënten met mentale 
retardatie op genoomwijde schaal te onderzoeken, waardoor de kans om nieuwe 
syndromen te ontdekken significant verhoogd is. Hoofdstuk 4 rapporteert de ontdekking 
van een nieuw microdeletie syndroom waarbij de chromosomale regio 17q21.31 betrokken 
is. In een grote cohort van patiënten met mentale retardatie werden drie overlappende 
microdeleties geïdentificeerd met behulp van array CGH. Gedetailleerde klinische evaluatie 
van deze drie patiënten liet, naast mentale retardatie, duidelijke andere overeenkomsten 
zien, waaronder verlaagde spierspanning en karakteristieke gezichtskenmerken.  
 
Het toepassen van genoomwijde onderzoekstechnieken zoals array CGH vergemakkelijkt 
niet alleen het ontrafelen van nieuwe syndromen, maar ook genotype-fenotype 
typeringen. Uiteindelijk kan dit leiden tot het koppelen van specifieke fenotypen aan 
individuele genen (Hoofdstuk 7). 
 
De bepaling van grootschalige DNA kopieaantal varianten in het menselijk 
genoom 
Sinds de introductie van conventionele karyotypering is bekend dat er een bepaalde mate 
van genomische variatie bestaat tussen individuen zonder dat er klinische consequenties 
aan verbonden zijn (normale variatie). Het gebruik van nieuwe genoomwijde technieken 
heeft naast de ontdekking van ziekte-gerelateerde veranderingen in DNA kopieaantallen 
geresulteerd in de ontdekking van een nieuwe vorm van normale variatie, namelijk 
submicroscopische DNA kopieaantal variatie (‘CNV’). CNVs kunnen genomische segmenten 
omvatten die in grootte variëren van één kilobase tot meerdere megabasen.  
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Omdat CNVs pas recentelijk zijn ontdekt, zijn de verschillende eigenschappen en de totale 
omvang ervan nog grotendeels onbekend. Hoofdstuk 5 beschrijft de gedetailleerde analyse 
van twaalf CNVs in vijf etnisch verschillende populaties. We karakteriseerden de 
genoomarchitectuur van de chromosomale regio’s waarin de CNVs voorkomen en 
bepaalden de frequentie van de CNVs in de verschillende etnische populaties. Daarnaast 
bepaalden we het daadwerkelijke DNA kopieaantal en gebruikten we deze informatie om 
de relatieve verdeling van DNA kopieaantallen te bepalen. Deze analyses brachten 
significante verschillen in CNV verdeling en daadwerkelijke DNA kopieaantallen aan het 
licht, zowel binnen populaties als tussen populaties. Onze resultaten geven aan dat (semi-) 
kwantitatieve CNV analyses van essentieel belang zijn voor het definitief vaststellen van 
hun rol in gezondheid en ziekte. 
 
Deze conclusie wordt ondersteund door de recente bevinding dat CNVs een rol spelen bij 
de aanleg voor ziekte als het exacte DNA kopieaantal een bepaalde grenswaarde 
overschrijdt, alsmede door de recente observatie dat 12% van het menselijk genoom 
onderhevig is aan submicroscopische DNA kopievariatie. Het is nu algemeen geaccepteerd 
dat CNVs vaker voorkomen en complexer zijn dan voorheen gedacht werd. Hoewel 
aanvullend onderzoek noodzakelijk is, is het aannemelijk dat een aanzienlijk aantal van 
deze CNVs uiteindelijk geassocieerd zal kunnen worden met ziekte en/of de aanleg voor 
ziekte (Hoofdstuk 7). 
 
De rol van genoomarchitectuur in het ontstaan van CNV 
Tot op heden is weinig bekend over de ontstaanswijze van CNVs. Het is echter wel bekend 
dat bepaalde genomische structuren, zoals ‘low-copy repeats’ (LCRs), het ontstaan van 
CNVs kunnen bevorderen. Zo kunnen bijvoorbeeld LCRs, door hun omvangrijke 
overeenkomsten in sequentie, tijdens de meiose verkeerd rangschikken waardoor een 
moleculair mechanisme gestimuleerd wordt dat bekend is onder de naam ‘nonallelic 
homologous recombination’ (NAHR). De meeste CNVs die ten grondslag liggen aan 
microdeletie syndromen lijken hun oorsprong te vinden in LCR-gemedieerde NAHR. 
Hierdoor berust het veelvuldig voorkomen van CNV op een bepaalde genomische locatie 
niet op toeval, maar op de onderliggende genoomarchitectuur. 
 
De meerderheid van alle CNVs die tot ziekte leidt is echter van sporadische aard en dit 
plaatst vraagtekens bij de betrokkenheid van genomische structuren zoals LCRs in het 
ontstaan van deze categorie van CNVs. In Hoofdstuk 6 worden twee voorbeelden gegeven 
van complexe, sporadische afwijkingen op chromosoom 17p voor welke we de 
betrokkenheid van deze genomische structuren hebben onderzocht. Daartoe hebben we 
alle CNV breukpunten gedetailleerd in kaart gebracht met behulp van array CGH en FISH. 
Onze resultaten suggereren dat LCRs in het proximale deel van 17p het ontstaan van (een 
deel van) de CNVs gemedieerd hebben. Hiermee is aangetoond dat deze genomische 
structuren ook betrokken kunnen zijn bij het genereren van sporadische CNVs. De 
bijkomende observatie dat LCRs niet bij alle breukpunten gevonden werden, suggereert de 
aanwezigheid van andere genoomstructuren en/of mechanismen die het ontstaan van 
CNVs kunnen stimuleren. Toekomstig onderzoek zal moeten uitwijzen wat de 
karakteristieken van dergelijke nieuwe genoomstructuren en/of mechanismen zijn 
(Hoofdstuk 7). 
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Tot slot 
In de laatste jaren heeft moleculaire karyotypering in razend tempo het vakgebied van de 
klinische genetica en het genoomonderzoek veroverd. Deze trend zal zich zonder twijfel de 
komende jaren blijven voorzetten. Voor de klinische genetica heeft de invoering van 
moleculaire karyotypering geleid tot (i) een significant verhoogde detectie van 
chromosomale afwijkingen bij patiënten met onverklaarde mentale retardatie en/of 
aangeboren aandoeningen, (ii) de identificatie van het gen voor CHARGE syndroom, en 
(iii) de ontdekking van een nieuw 17q21.31 microdeletie syndroom. Met betrekking tot het 
genoomonderzoek kunnen we concluderen dat moleculaire karyotypering geleid heeft tot 
nieuwe inzichten in (i) het voorkomen van DNA kopieaantal variaties in het menselijk 
genoom, en (ii) de recombinatiemechanismen en genoomstructuren die DNA kopieaantal 
variaties veroorzaken. Samenvattend concluderen we dat moleculaire karyotypering een 
krachtige strategie gebleken is om veranderingen in gendosis te koppelen aan (ziekte) 
fenotypen. 
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URLs for data presented in this thesis are as follows: 
 
Affymetrix 
http://www.affymetrix.com 
BACPAC Resources Center 
http://www.chori.org/bacpac/ 
BACPAC Resources Center’s Human BAC Minimal Tiling Set Web site: 
http://bacpac.chori.org/pHumanMinSet.htm 
Database of Genomic Variants 
http://projects.tcag.ca/variation/ 
DECIPHER 
http://www.sanger.ac.uk/PostGenomics/decipher/ 
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http://www.ecaruca.net/ 
Ensembl 
http://www.ensembl.org 
Human Genome Variation database 
http://hgvbase.cgb.ki.se/  
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http://www.mlpa.com/index.htm  
NCBI Blast2 
http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html  
Online Mendelian Inheritance in Man (OMIM) 
http://www.ncbi.nlm.nih.gov/Omim/  
Repeatmasker through UCSC genome browser: 
http://genome.ucsc.edu 
   
 
            
161      Chapter 9      
   
 
            
162 
   
 
            
163 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dankwoord 
 
 
 
 
 
 
   
 
            
164 
Het dankwoord schrijven van mijn proefschrift is het laatste wat ik moet doen voordat het 
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‘perfect’ iets is dat niet bestaat. Bedankt voor al je vertrouwen in mij, vooral bij de 
voorbereidingen van de presentatie voor de ASHG. Tijdens de voorbereidingen van mijn 
eerste literatuurbespreking moest je letterlijk de deur op slot draaien omdat ik het 
verschrikkelijk eng vond. Wie had dan kunnen voorzien dat het geven van een presentatie 
het hoogtepunt van mijn promotieonderzoek zou worden?! Zonder jouw steun was dit 
nooit gelukt. 
 
Beste Han, bedankt voor de kans om binnen de afdeling Antropogenetica dit 
promotieonderzoek te mogen doen, en voor al je goede ideeën en adviezen die je me 
tijdens het onderzoek hebt gegeven.  
 
Beste collega’s van de microarray groep, Irene, Walter, Simon, Roland, Rolph, Eveline, 
Marloes, Terry, Suzanne, Ramprasath, Eric, Ine, Ineke, Diederick, Jayne, Christian, 
Michael en Markus, maar ook iedereen die er nu niet meer werkt, Judith, Gerard, Yvonne, 
Martin, Martijn, Huub, Ton en Corine, jullie wil ik bedanken voor alles wat jullie gedaan 
hebben voor dit proefschrift. Jullie verdienen een speciaal plekje want jullie waren degene 
die al die BAC clones voor de 32K set bij elkaar pipetteerden, de arrays print(t)en, 
zorg(d)en voor het optimale protocol en validatie van alle afwijkingen. Als iemand zich ooit 
afvraagt wat de betekenis is van de uitdrukking “There is no I in TEAM” moeten ze eens 
naar deze groep komen kijken. Ik ben blij om in een dergelijk team onderzoek te mogen 
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doen. Een niet onbelangrijk deel van ons TEAM vind ik de gezelligheid die altijd aanwezig 
is. Vooral de koffie ’s ochtends met iedereen is een goed begin van de dag. Ik wil ook 
iedereen bij tumorcytogenetica, Lilian, Lianne, Klaas, Linda, Diederik, Anke, en degene die 
intussen naar elders zijn gegaan, Imke, Helma, Jan, José, Anita, Erik, Marga, Anke, 
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Admiraal bedanken voor het in kaart brengen van de gehoorsafwijkingen bij de patiënten 
met CHARGE syndroom. I thank dr. Hurst for providing DNA of the t(6;8)(6p8p;6q8q) 
patient. 
 
Natuurlijk ook iedereen van de celkweek bedankt voor het telkens weer opgroeien van alle 
cellijnen en het aanleveren van de celpellets. Vanzelfsprekend ook iedereen bij cyto-
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Dear Paweł and Jim, a special thanks to you for having me in Houston. When I started my 
PhD project, I read all your papers and was overwhelmed by your impressive 
achievements and contributions to science. I would never have dreamt of actually working 
with you. Or come to that, publish a joint paper that joins us forever in PubMed! I would 
like to thank you for what you taught me, and for making my stay in Houston a great one. 
Also, thank you Beata and Marta for teaching me the true meaning of “shop-till-you-drop”!  
 
Ook wil ik dr. Stefan White, dr. den Dunnen, prof. dr. Breuning uit Leiden bedanken voor 
de prettige samenwerking. Beste Stefan, het heeft heel wat voeten in aarde gehad, maar 
het is ons uiteindelijk toch nog gelukt om onze paper te publiceren.  
 
Beste Mirjam en Hanka, jullie wil ik bedanken voor al het werk dat jullie me uit handen 
hebben genomen tijdens het uitvoeren van jullie stageprojecten. Ik heb er bewondering 
voor hoe jullie beiden hebben laten zien dat een carrière als topsportster en onderzoekster 
te combineren is. Mirjam, zet hem op volgend jaar op de Olympische Spelen. Ik zal 
beloven samen met Joris naar de wedstrijden te kijken en hem dan nogmaals uitleggen 
dat het geen volleybalelftal is maar een volleybalteam. Hanka, zet hem op tijdens je 
promotieonderzoek. Als het jou niet lukt om het gat tussen de informatici en biologen te 
dichten, dan lukt het niemand. Ik weet zeker dat je er in zult slagen.  
 
Lieve Linda en Mariëlle, ik ben ontzettend blij dat jullie mijn paranimfen willen zijn. 
Mariëlle het was heerlijk om buiten het werk om met iemand te kunnen kletsen over het 
onderzoek, wetende dat je begreep waar ik het over had. Linda, het was heerlijk om met 
je over het onderzoek te kletsen, wetende dat je vaak geen flauw idee had waar ik het 
over had. Ik heb genoten van de weekendjes skiën, Parijs, en alle etentjes en 
hockeytoernooien. Dat jullie hier vandaag naast mij staan is geweldig! 
166 
Lieve pap en mam, ontzettend bedankt voor jullie onvoorwaardelijke steun. Zonder deze 
steun was ik nooit zo ver gekomen als ik nu ben. Mam, stiekem is dit boekje ook een 
beetje jouw boekje omdat je altijd gezegd hebt dat, als je een beroep zou mogen kiezen, 
je zou doen wat ik nu doe. Pap, ontzettend bedankt voor alle keren dat jij en mama klaar 
stonden om me weer te verhuizen in Nijmegen. Nooit geweten dat je vijf keer kunt 
verhuizen binnen een halve vierkante kilometer. Maar nu is dat over… ik heb nu met Mark 
mijn eigen huisje gevonden. Ik ben jullie ontzettend dankbaar voor alles. Lieve Marinka en 
Marty, het is super om te zien dat jullie nu samen eindelijk het geluk gevonden hebben 
wat jullie zo verdiend hebben. Er is niets mooiers om dat geluk in december bekroond te 
zien worden met mijn eerste neefje of nichtje. Dear Ron, Yvonne and Darren, thank you 
for all your love and support. You are the best parents-in-law and brother-in-law one could 
wish for. I have really enjoyed our Christmas in Cornwall. I wish we lived closer so we 
could do such things more frequently.  
 
Lieve Mark, jij bent de laatste in het rijtje. Je Nederlands is goed genoeg om te weten ‘lest 
best’. Jou wil ik bedanken omdat je er altijd voor me bent. Je hebt me de rust en ruimte 
geven als het nodig was, ook als dat op zondagmiddag was. Nu is dat niet meer nodig, het 
proefschrift is af. Tijd om extra veel van elkaar te gaan genieten in ons eigen paleisje. 
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Figure 1.2 
Schematic overview of the array CGH procedure. Genomic DNA samples from a test (patient; left) and 
reference (normal control; right) are differentially labeled with different fluorochromes, usually Cy3 and Cy5 
(for green and red, respectively). The two DNA samples are mixed in equal amounts and hybridized to the 
microarray, onto which large-insert clone DNAs (e.g. BACs) have been robotically spotted as targets. 
Subsequent computer imaging assesses the relative fluorescence levels of each labeled DNA for each array 
target. Clones to which equal amounts of patient DNA and reference DNA have been hybridized, will appear in 
yellow, clones deleted in the patient DNA compared to the reference DNA will appear in red, and clones that are 
duplicated in the patient DNA compared to the reference DNA will appear in green. The ratio between the test 
and reference DNA for each clone on the array can be plotted to visualize chromosome imbalances, marked by 
a deviation from the normal log2 T/R ratio. 
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Figure 2.2  
Detailed genomic profiles and FISH validation of copy number abnormalities identified in five cases with 
unexplained mental retardation. Panels a–e represent individual profiles of the affected chromosomes for each 
case, with clones ordered, for each chromosome, from pter to qter, on the basis of the physical mapping 
positions obtained from the November 2002 freeze of the UCSC genome browser. The centromeric region is 
indicated by a vertical gray dash, the thresholds for copy number gain (log2T/R value 0.3) and copy number 
loss (log2 T/R value -0.3) are indicated by horizontal lines. Panels f-j represent the FISH validation using (one 
of) the target clone(s) identified by array CGH. Affected chromosomes are indicated by an asterisk (*). Panel a 
shows the deletion on 7q11 in patient 1, with 14 clones in this region showing an average log2 intensity ratio of 
-0.5. FISH validation of this case is shown in the adjacent panel f, in which one of the deleted clones on 7q11 is 
shown in red and an undeleted control probe is shown in green. Panel b shows the microdeletion on 2q22 in 
patient 2 with a total of three clones crossing the threshold for copy number loss, with FISH validation in the 
adjacent panel g. Deletion of a single clone on 1p21 is shown in panel c for patient 3; this clone was confirmed 
by FISH to be deleted not only in the patient (panel h) but also in the father of the patient. Copy number gain 
detected in a single clone is shown in panels d and e for patients 4 and 5, with FISH confirmation in panels i 
and j. 
a 
b 
c 
d 
e 
f 
h 
g 
i 
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Figure 3.1 
Array CGH profiles of two individuals with CHARGE syndrome and FISH validation. (a) Array CGH genome-wide 
profile of the index individual with a copy number deletion of three adjacent clones on 8q12 (arrow). This 
profile represents the result of a single hybridization experiment; analysis of the replicate experiment identified 
only the 8q12 clones as being reproducibly deleted. Vertical lines indicate chromosome boundaries. (b) Profile 
of the same individual (brown squares) on the tiling chromosome 8 BAC array with 31 clones characterizing the 
deletion, and the chromosome 8 profile of an individual (black circles) with an apparently balanced t(6;8) 
translocation that overlaps with the deletion of the index individual. (a, b) Clones are ordered on the x axis 
according to physical mapping positions; log2 transformed test-over-reference ratios for each clone are given on 
the y axis. (c-g) FISH validation of the deletion in individual 1 (c) and testing for de novo occurrence in the 
accompanying parents (d-e) with clone RP11-91I20. (f) Determination of proximal deletion boundary (RP11-
310L18 in red is normal; RP11-44D19 in green is deleted) and (g) determination of distal deletion boundary; 
RP11-274C23 in green is deleted whereas RP11-252M13 in red is normal. (h-k) FISH validation of the two 
distinct deletions in individual 2 and determination of the deletion boundaries. (h) The proximal deletion 
contains RP11-44D19 (green) on the centromeric site but not RP11-310L18 (red), and on the telomeric site (i) 
RP11-696A12 (red) but not RP11-630K16 (green). (j) Normal region between the two deletions is indicated by 
RP11-360N16 (red), whereas RP11-91I20 (green) marks the distal deletion. (k) This distal deletion contains 
RP11-265K14 (red) on the telomeric site, but not RP11-317H6 (green). 
a b 
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Figure 3.2  
Detailed genomic view of 8q12, organization of the CHD7 gene and mutations detected. (a) Transcript map of 
the deleted 8q12 genomic region. The shortest region of deletion overlap in the two individuals is shown. Genes 
in green were screened for mutations. Cen, centromeric; Tel, telomeric. (b) Genomic structure of CHD7 
indicating the positions of seven nonsense mutations (circles), two missense mutations (squares) and one 
intron-exon boundary mutation (triangle). The corresponding functional CHD7 domains are marked (colored 
bars). (c) Partial electropherograms obtained by direct sequencing of PCR products showing two nonsense 
mutations in individual 5 (1714C>T) and individual 8 (5418C>G) and one missense mutation in individual 7 
(3770T>G). 
a  
b  
c  
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Figure 4.2 
Analysis of individuals with the 17q21.31 microdeletion syndrome. (a) Chromosome 17 array CGH profile of 
individual 1 with a copy number loss of eight adjacent BAC clones on 17q21.31 (arrow). Clones are ordered on 
the x axis according to physical mapping positions; log2-transformed test-over-reference (T/R) intensity ratios 
for each clone are given on the y axis. (b) Multiplex ligation-dependent probe amplification (MLPA) analysis, 
showing a deletion of two probes in CRHR1 and one probe in MAPT for both individual 2 (triangles) and 
individual 3 (squares). The circles represent the MLPA ratios of healthy controls. FISH validation of the 
17q21.31 deletion in individuals 1, 2 and 3 (c-e) and testing for de novo occurrence in the accompanying 
parents (f-k) using BAC clone RP11-656O14 (red) which is located within the deleted region. The centromere 
17 probe was included for reference (green). All individuals show only one signal for RP11-6565O14 (arrow 
indicating aberrant chromosome 17). The de novo occurrence for the deletion was proven in all individuals. 
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Figure 5.1 
Examples of genome architecture and MLPA probe locations. (a), 17q12 (b) and 17q21.31. Note that for the 
17q21.31, a 900-kb inversion polymorphism including the NSF locus has been observed in the general 
population, represented by the H1 and H2 orientation (Stefansson et al. 2005). For all regions, Mb position, 
cytoband, BAC clones, genes located within the region, LCRs/ GAPs (if present) and the location of the MLPA 
probes are depicted. The BAC clones that were previously reported to show CNV are colored red (Genome 
Variation Database). The LCR structures, if present, are depicted in colors to better represent their positional 
orientation with respect to each other. The locations of the MLPA probes are indicated by vertical orange solid 
lines, whereas dotted orange lines indicate alternative MLPA locations, sharing high homology to the region the 
probe was originally designed for. 
a 
b 
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Figure 6.3 
Schematic representation of a normal 17p and der(17) (black & white) with translocated chromosome 21 
material (blue). The location of the FISH probes are shown on the left side of each figure panel; der(17) is 
indicated on FISH pictures by a white arrow. (a) Terminal deletion of 17pter was validated using BAC clones 
RP11-1260E13 (red) and CTD-2326F1 (green). (b) FISH with PMP22-specific PAC RP1-150M12 (red) and RAI1-
specific BAC RP11-525O11 (green) revealed direct duplication of the CMT1A and SMS regions in 17p12p11.2. 
(c) FISH with PAC RP1-95H6 (red) and BAC GS-202L17 (green) showed inverted insertion of the MDLS region 
into the SMS region. (d) Array CGH also identified a duplication of 21q22.3. Additional FISH analysis using BAC 
clones RP11-40L10 (green) and RP11-16B19 (red) revealed that the duplicated material of 21q22.3 was 
translocated onto der(17). Summary of FISH results is provided in Table 6.1. 
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Figure 6.4 
Schematic representation of the normal 17p and der(17). The locations of the FISH probes are shown on the 
left side of each figure panel. (a) Duplication I showed relatively simple fluorescence signal pattern with probes 
RP11-810M2 (green; normal) and RP11-597I9 (red; duplicated) for the distal breakpoint, and (b) RP11-222J21 
(green; duplicated) and RP11-98D15 (red; normal) for the proximal breakpoint. (c) Direct orientation of 
duplication III was shown using BAC clones RP11-601N13 (green) and RP11-726O12 (red). (d) For the distal 
breakpoint of duplication IV, BAC clones RP11-448D22 (green) and CTD-2145A24 (red) showed duplicated 
signals on der(17), indicating that both middle SMS-REP and LCR17pB are duplicated as a block. Note four red 
signals on der(17) representing two normal and two duplicated copies of LCR17pA/B (dupIII) and LCR17pB 
(dupIV) and four green signals depicting three normal copies of SMS-REPs and the duplicated middle SMS-REP. 
Summary of FISH results is provided in Table 6.2. 
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Figure 6.6 
Schematic representation of the proposed mechanism for CCR formation in patient 1 and patient 2. (a) The 
complex rearrangement observed in patient 1 includes ten breakpoints, with one insertion, two microdeletions 
and two microduplications. We propose that the breaks in chromosome 17, p13.3, p12 and p11.2 as well as the 
break in chromosome 21q22.3 arose simultaneously. This resulted in the insertion of the MDLS region into the 
middle SMS-REP/LCR17pB block, loss of telomeric 17p and part of 17p12 and duplication of the CMT1A region. 
Additionally, the duplicated 21q22.3 fragment was translocated to the 17p subtelomeric region. (b) The 
complex rearrangement in patient 2 included eight breaks. We suggest that breaks in chromosome 17, p13.2, 
p13.1, p12 and p11.2 occurred at the same time, resulting in four interspersed directly orientated 
microduplications. Note: arrows do not represent a chronological order of events. 
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